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Abstract 
 
The failure rates of drugs once they reach clinical trials are high, with estimates up to nearly 
90%. One reason is the lack of biologically relevant models in which potential drug candidates 
are screened, evaluated and selected during discovery and development phases. 
Leishmaniasis is a disease that suffers from this problem. Current therapies are weak, toxic 
and there is a growing problem of drug resistance. 
The aim of this thesis is to investigate different ways in which the current in vitro model 
systems could be made more predictive. Three methods of potentially improving reliability 
and predictability of in vitro models are investigated. 
Firstly, the differences between the media perfusion and static cell culture systems were 
studied. Using macrophages and L. major parasites, infections within the media perfusion 
system were optimised. The activities of standard drugs used for the treatment of 
leishmaniasis, were determined. A decrease in infection rates and in the activity of standard 
drugs was seen when using the media perfusion. 
Secondly, a 3D in vitro infection model was developed and used to determine the activity of 
standard drugs, compared with 2D cell culture. The model shows that 3D and 2D provide 
similar results for the activity of the standard drugs tested. 
Thirdly, a variety of macrophage cell types have been used as Leishmania host cells for 
intracellular amastigote assays. The use of macrophages differentiated from induced 
pluripotent stem cells was investigated as a viable and more predictive alternative. The 
option to use a cell type that is more biologically similar to the human in vivo situation, but 
can be maintained like cell lines, is a clear benefit to in in vitro assays. It was concluded that 
macrophages differentiated from induced pluripotent stem cells would be a suitable 
alternative to currently used cell types. 
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Chapter 1: Introduction 
The failure rates of drugs once they reach clinical trials is high, with estimates up to nearly 
90%. One reason for this is the lack of biologically relevant models in which potential drug 
candidates are screened, evaluated and selected during both discovery and development 
phases. Leishmaniasis is a disease that suffers from this problem. Current therapies are weak, 
toxic and there is a growing problem of drug resistance. Current approaches use both 2D cell 
assays and in vivo mouse models, both of which may not accurately reflect the infection in 
humans. 
The aim of this thesis is to investigate different ways in which the current in vitro model 
systems could be made more predictive.  
1.1 Leishmaniasis 
Leishmaniasis is a disease caused by protozoa of the Leishmania genus. Leishmania species 
are protozoan parasites with two distinct life cycle phases. One phase is the motile 
promastigote, which is found extracellularly in the sand-fly vector and can be grown in 
culture media. The other is the amastigote, an obligate intracellular stage found in the 
phagolysosomal compartment of macrophages, one of the most common host cells in 
mammals. There are over 15 species1 of Leishmania, usually separated into two categories: 
New World (Central and South-America) and Old World (Europe, Middle East, Central Asia 
and Africa) species, figure 1.1.1. These two categories are based on the geographical location 
where the species are found. Different species of Leishmania can cause different forms of 
the disease2: cutaneous (CL), mucocutaneous and visceral (VL).  
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Figure 1.1-1 Leishmania phylogeny tree and corresponding disease phenotypes343. 
 
In 1901, Leishman, a colonel serving in the British Royal army medical corps, identified 
certain organisms in smears taken from the spleen of a patient who had died from "dum-
dum fever" and proposed them to be trypanosomes; this was the first time Leishmania was 
identified in India3. A few months later, Captain Donovan confirmed the finding of what 
became known as Leishman-Donovan bodies in smears taken from people in Madras in 
southern India4. Later Ronald Ross proposed that Leishman-Donovan bodies were the 
intracellular stages of a new parasite, which he named Leishmania donovani5. 
1.1.1 Distribution and Epidemiology 
Leishmaniasis is endemic in 98 countries over 5 continents and 350 million people are at risk 
of infection6&7. It is estimated to cause 0.9-1.6 million new cases every year and affect 12 
million people worldwide8. The reported incidence of VL and CL patients is approximately 58 
000 and 220 000 cases a year respectively. The overall magnitude of the problem, however, 
is estimated to be much higher due to underreporting. The majority (90%) of VL cases are 
found in six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia. In 
contrast, CL is more widely distributed, with 70-75% of the estimated cases occurring in 
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Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru. 
CL affects an estimated 10 million people and 0.7-1.2 million new cases occur every year9. 
1.1.2 Life Cycle of the Leishmania Parasite  
The transmission of Leishmania species can either be zoonotic, when the parasites are 
transmitted from animal to man, or anthroponotic, when transmitted from man to man. L. 
tropica and L. donovani typically involve anthroponotic transmission9. 
The life cycle stages of the Leishmania parasites is summarised in figure 1.1-2. The parasites 
are transmitted by the bite of a female sandfly10, of the genus Phlebotomus (in the Old World) 
or Lutzomyia (in the New World) 11. Approximately 100-1000 promastigotes12 are injected in 
the skin and engulfed by neutrophils, which are rapidly recruited to the site of the bite13. 
Some of the parasites survive in the neutrophils and are internalized in their phagosomes9 
that then fuse with a lysosome to become a phagolysosome. This is where they transform 
into amastigotes and replicate14. Heterogeneity in the mechanism of phagocytic uptake of 
the parasite into the phagolysosome, coiling versus conventional zipper phagocytosis, has 
been reported for different types of macrophages in vitro9. Neutrophils have been proposed 
to act as a transient host15 for the amastigotes before they are taken up by either dermal 
macrophages or those attracted by inflammation caused by the sand-fly’s bite, where they 
replicate. Research suggested that the presence of the amastigotes in the phagolysosome 
(pH 5-5.5) of the macrophage inhibits apoptosis and necrosis of the host cell and hence, 
contributes to the survival of the parasites16. Usually the low pH and enzymes in the lysosome 
would degrade intracellular pathogens. However, in macrophages, it is generally accepted 
that parasite containing phagosomes undergo ‘maturation’ to acquire lysosomal properties, 
and the Leishmania inhibit this process17, potentially through the effect of a key surface 
lipophosphoglycan molecule. The acidic and hydrolase-rich environment of the 
phagolysosome is known to trigger the differentiation of the promastigote into the 
amastigote, and its subsequent proliferation18. Eventually the macrophage ruptures, 
releasing the pathogens which then  infect other macrophages19. The parasites can stay in 
the skin or migrate to internal organs (liver, spleen and bone marrow) leading to CL or VL 
respectively . In CL the Leishmania parasites can also infect skin fibroblasts20, it has been 
suggested that these cells provide a niche for survival in the face of immune attack21. 
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Figure 1.1-2 The life cycle of Leishmania parasites9. 
 
1.1.3 Visceral Leishmaniasis 
Visceral leishmaniasis (VL) is endemic in 62 countries, with a total of 200 million people at 
risk, an estimated 400 000 new cases each year worldwide, and 30 thousand recorded deaths 
annually6-8 &22. Both the number of recorded cases and the geographical areas affected have 
grown in the past two decades. Over 90% of cases of VL occur in five countries: India, 
Bangladesh, Nepal, Sudan, and Brazil. It is characterized by symptoms that typically present 
as fever, cough, abdominal pain, diarrhoea, epistaxis, splenomegaly, hepatomegaly, 
cachexia, and pancytopenia, but infection with the parasites can often be asymptomatic. 
Infection with Leishmania parasites that cause VL results in systemic infection of the liver, 
spleen, and bone marrow. The geographical locations of reported cases of VL are shown in 
figure 1.1.3. 
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Figure 1.1-3 World map with reported cases of visceral leishmaniasis 
(http://www.who.int/leishmaniasis/en/) 
 
1.1.4  Cutaneous Leishmaniasis  
Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis, its annual incidence 
is 1.1 to 1.5 million cases and it is endemic in 88 countries23. It is characterized by a variety 
of clinical symptoms ranging from defined nodular lesions to mucosal destruction. Most 
lesions tend to heal without treatment but this process can take 3 to 18 months24 and nearly 
always leave a disfiguring scar, which, depending on its size and location, may cause 
substantial disfigurement and stigmatisation25. The geographical locations of reported cases 
of CL are shown in figure 1.1.4.  
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Figure 1.1-4 World map with reported cases of cutaneous leishmaniasis 
(http://www.who.int/leishmaniasis/en/) 
 
1.1.5 Clinical Symptoms  
CL has a range of symptoms, although most patients with infections probably remain 
asymptomatic26. The clinical features of CL vary in severity and depend on host, parasite and 
vector. Old World CL is mainly caused by L. major, L. tropica and L. aethiopica, whereas New 
World species are L. mexicana, L. amazonensis, L. panamensis and L. braziliensis.  
In its simplest form, CL consists of a single localised lesion. The first sign of a localised 
infection is a small, itchy erythema at the site of the insect bite. Amastigotes continue to 
proliferate in the dermis causing the erythema to develop into a larger papule. The papule 
expands into a nodule that reaches its final form and size about two weeks to six months 
later26. At this point, the papule can ulcerate and a crust can form over any open wound. 
Sometimes the crust can fall off and an ulcer, typically with raised edges is exposed; this is 
particularly susceptible to further infection by bacteria27. Specific species might be 
associated with a typical clinical form but this can vary. For instance, infection with L. tropica 
can evolve to leishmaniasis recidivans, a chronic form of CL where satellite lesions appear in 
the edges of the initial healing lesion. This form is characterized by a sparsity of parasites and 
can last for years28-30.  L. aethiopica can cause diffuse cutaneous leishmaniasis (DCL), a form 
that is characterized by widely disseminated non-ulcerated papules, nodules, plaques on the 
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skin. In the New World, this form is caused by L. mexicana and L. amazonensis31. This disease 
does not heal spontaneously and relapses occur frequently after treatment32. 
1.2 Treatment Challenges 
It is widely accepted that all current CL treatments are unsatisfactory34&35. In the 1990’s 
concern was raised about the lack of new chemical entities registered for neglected diseases. 
The development of a new drug is a long process that takes 9-12 years on average and costs 
an estimated 802 million US dollars36&37, once the cost of all the failed attempts have been 
taken into account. The pharmaceutical industry is not keen to invest this amount of money 
in a neglected disease that only offers low return on their investment. A study published in 
the Lancet revealed that only 4 new chemical entities and 25 products were registered during 
2000-2011 for neglected diseases38. Neglected tropical diseases (NTDs) are defined by the 
WHO as a diverse group of communicable diseases that prevail in tropical and subtropical 
conditions in 149 countries and affect more than one billion people, costing developing 
economies billions of dollars every year. They mainly affect populations living in poverty, 
without adequate sanitation and in close contact with infectious vectors, domestic animals 
and livestock. 
Drug repurposing is one of the strategies to overcome the high development costs of a new 
drug or chemical entity39. This is where a known drug is tested against a different disease to 
its original target. This can save money and time, as the drug will already have been through 
toxicity testing, pharmacokinetic and pharmacodynamics studies to prove it is safe for use. 
Further to this, if information on the mode of action of the drug is known, then fewer studies 
are required. This can shorten the time it takes to get a drug to market. Another option is 
drug reformulation, a process that focusses on the reformulation of the active ingredient of 
existing drugs in order to optimise the formulation. From 2000 to 2011, all three drugs 
approved to treat leishmaniasis, of which one was for CL, were repurposed molecules that 
were initially indicated for a different disease. For example, miltefosine was first brought to  
the market as an anti-cancer drug40; amphotericin B was to treat fungal infections41 and 
paromomycin was an oral treatment for intestinal amoeba infections42.  
As previously mentioned, depending on host and parasite factors, CL shows a variety of 
clinical manifestations. One of the main problems of treatment development is finding a 
treatment that is active against all Leishmania species. Biochemical and molecular 
differences between Leishmania species lead to differences in drug susceptibility in vitro43. 
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This correlates with variability in clinical responses observed when the success rates of 
treatments are compared across  different geographical regions. 
 There are several logistic factors that complicate the development of a treatment for CL. 
Firstly, CL occurs in tropical climates in regions of high temperature and high humidity where 
cold chains are absent. Both high temperature and humidity are known to cause instability 
of drug formulations44. Storage of some drugs can also be a problem, as they may need 
refrigerated conditions to maintain activity, such as liposomal amphotericin B, and reliable 
electricity supplies can be difficult to find in some rural areas. Furthermore, primary health 
centres that offer treatment for CL patients can be difficult to reach for people living in rural 
areas and even when reached, medication availability is not guaranteed45.  
The price per CL treatment is estimated by the WHO to range between 12-40 US$31. In some 
cases, the drug can be given freely if donated by a company or charitable organisation. This 
is only the direct cost of the treatment and indirect costs such as inability to work are not 
included. Moreover, Alvar et al reported that the annual income per person in areas that are 
greatly affected by CL range from 82 to 200 US$. This means that the price of a treatment 
can exceed the monthly salary for some patients31. 
Patients often seek treatment late because they will only realise they have the disease after 
the appearance of the first symptoms. The erythema initially could be mistaken for other 
diseases that may not require treatment or even considered a bad reaction to the sand-fly 
bite. Sometimes patients do not seek treatment because effective and safe treatments are 
lacking or postpone seeking help by trying herbal or homemade remedies46. Only after 
multiple herbal treatment failures, will they visit primary health care centres. Research into 
the treatment seeking behaviour of CL patients report variable delays between the onset of 
the symptoms and seeking treatment. A study in Syria reported 2.4 months on average47, 
while in Paraguay this was 1-6 months48. By this time, the lesion might have progressed to 
an ulcer, which makes it more difficult to treat and increases the risk of scar formation. 
Resolution happens via the action of T cells, specifically of the T helper 1(TH1) subset33, which 
can stimulate host cells to kill intracellular parasites. Therefore, there is an advantage for a 
treatment that can kill the parasites, or encourage the immune system to clear the parasite, 
before extensive lesion ulceration and disfigurement can take place. 
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1.3 Currently Available Treatments  
1.3.1 Recommended Treatments 
The current first-line recommended drug treatments for CL are pentavalent antimonials.  
These include; 1–5 mL of 33.4 mg Sb/kg body weight per session every 3–7 days by 
intralesional administration, or a 15% paromomycin/12% methylbenzethonium chloride 
ointment applied topically twice daily for 20 days49 . Other recommended treatments are; 
amphotericin B deoxycholate at 0.7 mg/kg per day by intravenous infusion for 25–30 doses, 
and miltefosine at 2.5 mg/kg per day orally for 28 days or in  combination33. 
The available chemotherapeutics to treat CL can be divided in two groups; systemic 
treatments, where the drug is taken up in the blood and transported to the target tissue, or 
topical treatments, where the formulation is directly applied to the site of action. Systemic 
treatments come with a higher risk of adverse effects and is therefore typically reserved for 
patients with more severe or complex forms of CL. 
1.3.2 Pentavalent Antimonials  
The pentavalent antimonials (Sbv): sodium stibogluconate (Pentostam®, GlaxoSmithKline 
and generic products)(Figure 1.3.1), often referred to as SSG, by Albert David in India and 
meglumine antimoniate (MA) (Glucantime™, Sanofi) (figure 1.3.1) have been first-line 
treatment for CL since their discovery in the 1940s50. 
 
Figure 1.3-1 Chemical structure of sodium stibogluconate (Left) and Meglumine antimoniate 
(Right). 
 
The mechanism of action is still not completely understood. When administered the Sbv is 
converted to SbIII, which is an active secondary metabolite. The data suggests that the 
trivalent form, SbIII, disturbs the ability of the amastigotes to maintain the redox homeostasis 
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of the parasites, by interfering with the trypanothione reductase system that protects the 
parasite from oxidative damage and toxic heavy metals51&52. Other papers have reported 
DNA fragmentation and externalization of phosphatidylserine from the surface of the plasma 
membrane of amastigotes treated with SbIII, leading to parasite apoptosis53&54. However, 
other studies indicate an intrinsic anti-leishmanial activity for SbV as it forms a complex with 
adenine ribonucleoside. This complex indirectly inhibits type I DNA topoisomerase causing a 
depletion of intracellular ATP possibly via inhibition of the glycolysis and fatty acid β–
oxidation in the amastigotes55. This leads to inhibition of the biosynthesis of macromolecules 
in amastigotes56-58. 
Pentavalent antimonials can be administered locally or systemically depending on the 
severity of the disease. Local treatment consists of intralesional administration alone or in 
combination with cryotherapy31. During each session, 1-5 mL of pentavalent antimonials is 
injected in the edges of the lesion, followed by application of liquid nitrogen (-195 °C), if in 
combination. The injections can be repeated up to 5 times every 3 to 7 days. Local injections 
prevent or limit systemic adverse effects59; however, these injections are painful, causing 
burning, itching and inflammation at the injection site are amongst the reported adverse 
effects34. Antimonials can also be given systemically through intravenous or intramuscular 
administration (20 mg/kg per day for 10-20 consecutive days) when patients present with 
more complex CL31. Serious side effects such as hepatoxicity and cardiotoxicity are reported 
and require patient monitoring58. 
Randomised controlled trials to compare the efficacy of Sbv treatment against placebo are 
sparse, and evidence-based efficacy of Sbv against certain species is lacking34. In vitro studies 
confirmed species variation in drug sensitivity when tested in promastigotes60 and 
intracellular amastigotes61&62. Moreover, an in vivo study testing the efficacy of Pentostam® 
against L. braziliensis and L. mexicana showed a statistically significant higher cure rate 
against L. braziliensis63 compared to L. mexicana. It is hypothesised that this variability in 
drug susceptibility between different Leishmania species is responsible for sub-curative 
treatment in certain cases and consequently resistance development. 
1.3.3 Amphotericin B  
Amphotericin B (AmB) (figure 1.3.2) is a polyene antibiotic usually reserved for treatment of 
VL but is also effective against CL. It is a highly effective drug that consistently shows 
nanomolar EC50 values64, in most anti-leishmanial in vitro assays. 
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Figure 1.3-2 Chemical structure of amphotericin B. 
 
As a treatment for CL, AmB is reserved for complex forms such as post-kala-azar dermal 
(PKDL) and mucocutaneous leishmaniasis, and is typically administered through slow 
intravenous infusion. Amphotericin B deoxycholate is given at 0.7 mg/kg/day for 25-30 doses 
and liposomal amphotericin B at 2-3 mg/kg/day for a total dose of 20-40 mg/kg. The 
conventional amphotericin B deoxycholate formulation (Fungizone®) causes acute toxic 
reactions including renal toxicity, for which lipid formulations were developed to reduce. 
The main mechanism of action of AmB is that it alters the parasite's cell membrane 
permeability65, by creating transmembrane channels, causing a collapse of ion gradients in 
the parasite thereby causing the parasite to die66. It does so by preferentially binding to 
sterols, within the outer cell membrane, with a high affinity for ergosterol67. It has been 
shown to act in a dose-dependent manner. 
There is a lack of data from clinical trials that compare AmB treatment with placebo or Sbv 
treatments even though it has successfully been used to treat patients with mucocutaneous 
leishmaniasis68&69. In a recent study, 75% of patients dropped out due to the obligatory ‘20 
day’ admission in the hospital and no cure rate was reported for the patients that completed 
the study70. 
1.3.4 Miltefosine  
Miltefosine (MIL) (Figure 1.3.3) is recommended as a systemic treatment for both VL and CL. 
It is suitable for oral dosing, which makes it unique as an anti-leishmanial drug. It has been 
reported to show low micromolar EC50 values71 in most anti-leishmanial in vitro assays. This 
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drug has been shown to have a more time dependent activity, in pharmacokinetic and 
pharmacodynamics studies72. However, it has significantly different activities against 
different Leishmania species71. 
 
Figure 1.3-3 Chemical structure of Miltefosine. 
 
Miltefosine or hexadecylphosphocholine, is the only oral treatment currently available 
against CL and VL. Initially, phospholipid derivatives were developed as anti-cancer drugs 
because they were found to inhibit enzymes involved in cell proliferation and growth factor 
signal transduction73. In the 1980s, a number of research groups independently showed anti-
leishmanial activity of miltefosine and other phospholipid compounds74-76.  
The mechanism of action of miltefosine is not fully elucidated. Its leishmanicidal activities 
have been associated with perturbation of the alkyl-phospholipid metabolism and the 
biosynthesis of alkyl-anchored glycolipids and glycoproteins in the outer membrane of the 
parasite77. Miltefosine is a phospholipid derivative that is structurally similar to the 
phospholipid components of the cell membrane in both the host and parasite. Another 
hypothesised mechanism is the activation of the host cell mediated apoptosis of the infected 
macrophage via the phosphoinositide-3-kinase pathway78. 
Miltefosine is given orally at 2.5 mg/kg/day for 28 days. Gastro-intestinal problems such as 
vomiting and diarrhoea are the most common side effects. It is teratogenic, meaning women 
of childbearing age are required to take contraception whilst undergoing treatment. The long 
residence time of the drug in the organism (half-life:8-6 days) and the long treatment course 
lead to poor patient compliance and resistance development79&80.  
As with the pentavalent antimonials, a difference in intrinsic sensitivity of Leishmania species 
to miltefosine was observed in vitro81&82 and might explain the variability in clinical response 
seen in clinical trials conducted in different regions. For example, a trial conducted in 
Colombia where L. panamensis is most common, resulted in a cure rate of 91% compared to 
38% for placebo treatment. In contrast in Guatemala, where L. mexicana and L. braziliensis 
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were identified as CL causing species, the cure rate was only 53% compared to 32% in the 
placebo group83. 
1.3.5 Paromomycin Sulphate  
Paromomycin (PM) (monomycin or aminosidine) (Figure 1.3.4) is an aminoglycoside 
antibiotic that acts by binding on the small ribosomal unit leading to misreading of the mRNA 
and inhibition of protein synthesis in bacteria. In the 1960’s it was identified to have anti-
leishmanial activity84. 
 
Figure 1.3-4 Chemical structure of Paromomycin sulphate. 
 
The mechanism of action of PM against Leishmania parasites is not fully understood. 
Previous research comparing protein expression levels between PM-resistant and PM-
susceptible L. donovani promastigotes suggested that PM reduced the protein synthesis, by 
inhibiting the dissociation of the ribosomal subunits85. Other studies in L. mexicana 
promastigotes confirmed these results and suggested that it could also lead to induction of 
translation errors86 and thus altered the accuracy of protein synthesis in Leishmania. This 
increased level of misreading RNA results in defective proteins that affect parasite survival86. 
It has also been shown to change lipid metabolism, affect membrane fluidity, in the parasite, 
and alter uptake properties of the parasites, leading to growth arrest87. 
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Paromomycin is a hydrophilic molecule with a high molecular weight (714 g/mol) resulting 
in poor oral availability. Therefore, a parenteral formulation was developed and is mainly 
used to treat VL and occasionally CL. The majority of CL patients are treated topically with 
Leshcutan® ointment (Teva, Israel), the only currently available topical formulation.  
The topical formulation of paromomycin sulphate was first tested in vivo in mice by El-On et 
al in the early 1980’s88. A month after the treatment (two times a day for 10 days) all lesions 
caused by L. major in BALB/C and C/C3H mice were cured.  
Analyses of the subsequent clinical trials indicate a higher cure rate for paromomycin 
sulphate with methylbenzethonium treatment, compared to placebo, in patients infected 
with L. mexicana, L. braziliensis and L. major34&89. However, it is important to note that the 
ointment was applied after manually removing the scab of the wound and hence the drug 
had direct access to the affected tissues. In some studies, an occlusive dressing was used. An 
occlusive dressing is one that keeps water from moving either in or out of the wound but 
could be permeable to both water vapour and oxygen. PM has physicochemical properties 
that are unfavourable for skin permeation. These trial conditions do not reflect the cure rate 
in patients at onset of the disease where the lesions are still in the nodular stage.  
1.3.6 Local Treatments  
Systemic treatments for CL are often preferred for several reasons, including the fact that 
most new therapies for CL are derived from those used for VL. Topical or intralesional 
treatments are also more difficult to evaluate due to problems in standardizing the dose 
given during administration of a drug. Even when local treatments are known to be effective, 
there may be problems with crossing the skin barrier. 
Intralesional injection of SbV drugs is the most established form of local treatment for CL91. 
Numerous studies have been performed in comparison to parenteral SbV treatment or other 
experimental therapies. 
Topical paromomycin treatment for CL shows species and geographical variation. A meta-
analysis conducted in 2007 concluded that in placebo-controlled trials, topical paromomycin 
appeared to have therapeutic activity against Old World and New World CL, with increased 
local reactions, when combined with methylbenzethonium chloride. However, its efficacy 
was not significantly different to that of intralesional SbV treatment for Old World CL, and it 
was inferior to parenteral SbV treatment for New World CL91. 
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Many local treatments are preparations of compounds used for systemic treatment that 
have been formulated into topical creams/ointments. An example of this is the Amfoleish 
project where development of a topical formulation of amphotericin B92 was applied locally 
to the CL lesion, showing high anti-parasitic effect, but without the systemic toxicity 
associated with amphotericin B. A Phase Ib/II open-label, randomized, non-comparative, 
two-arm exploratory study conducted in Colombia has recently been completed93. Local 
treatments have been used less often for New World CL due to concerns about L. (Viannia) 
braziliensis complex infections leading to mucosal leishmaniasis91. 
1.3.7 Local Physical Treatments – Cryo-and Thermotherapy  
Cryotherapy and thermotherapy are the most frequently used physical therapies. Both 
cryotherapy and thermotherapy work by using extremes of temperature to kill the parasite, 
whilst only causing minimal damage to the host. The size of the host means that the body 
will be able to tolerate local applications of extremes of temperature, without too much 
damage. Once the parasites and infected cells have been killed, the body should be able to 
heal over any damage done to healthy skin. During cryotherapy, a cotton swab with liquid 
nitrogen is applied on the open wound and wound edges for about 10-25 seconds. Two 
studies in Iran were conducted to compare the effects of three different treatments for CL: 
cryotherapy alone, a combination of cryotherapy with intralesional meglumine antimoniate 
(MA) and intralesional MA alone94&95. The studies reported complete cure of patients in 52% 
and 67% for cryotherapy alone, 80% and 89% for a combination of cryotherapy with 
intralesional MA and 52% and 75% for intralesional MA alone. The researchers concluded 
that the combination therapy was significantly more effective than the two monotherapies. 
Based on these trials, it can be said that cryotherapy alone seems to be as effective as 
intralesional MA alone.  
Thermotherapy involves the induction of heat in the superficial layers of the skin. This can 
be done in several ways, for instance by using a radiofrequency generator, ultrasound or 
infrared radiation. In Iran, a randomized controlled study compared thermotherapy and 
intralesional MA for 4 weeks96. Temperatures of 50°C was achieved and maintained on the 
lesions for 30 seconds. This was done once a week for four weeks. Six months after the 
treatment, 80% of the participants in the thermotherapy group showed complete cure, 
compared with 56% in the intralesional MA group. These results were in agreement with 
previous studies conducted in Iran.  
Chapter 1: Introduction 
16 | P a g e  
 
A trial conducted in Afghanistan compared intralesional SSG for 29 days (2-5 mL every 5-7 
days), daily intramuscular sodium SSG (20 mg/kg/day) for 21 days, and thermotherapy based 
on radiofrequency (1 session with several repeats of 1 minute of 50°C), for the treatment of 
CL caused by L. tropica97. Two months after the treatment, the complete cure of patients in 
the three groups was 47%, 18% and 54% respectively. Treatment with thermotherapy was 
significantly more effective than intramuscular SSG therapy, however, no significant 
difference with intralesional SSG was observed. Some patients that had received 
thermotherapy experienced superficial second-degree burn wounds. 
Overall cryotherapy and thermotherapy seem to be good treatment options, as they are 
effective against all species. However, the main limiting factors are the requirement of 
expensive equipment, and availability of electricity in rural settings. The use of cyro or 
thermotherapy can be painful and can cause additional scars and damage to the skin. 
Additionally, thermotherapy requires experienced personnel to apply the treatment. 
1.3.8 Immunotherapy  
Research has suggested that immunotherapy can provide a useful adjuvant to chemotherapy 
in the treatment of CL. In contrast to chemotherapy, that aims to kill the parasite, 
immunotherapy stimulates the host’s own immune response in order to clear the parasite 
from its system7. 
Imiquimod is an imidazoquinoline and acts as a potent immunomodulator. It is the active 
ingredient in a topical cream Aldara™ (Meda Pharma, UK). In vitro studies have shown that 
imiquimod induces a leishmanicidal activity in macrophages98. In vivo mouse studies 
compared the Aldara™ cream with a placebo cream and found that the group treated with 
Aldara™ cream showed a significant reduction in footpad swelling, when compared to the 
placebo group. The compound is shown to induce nitric oxide (NO) production in 
macrophages, which allows them to better fight off the infection. Two trials, conducted in 
Peru, compared the activity of standard intravenous SSG or MA combined with topical 
imiquimod, to treatment with antimonials alone, in patients who had not responded to 
previous treatment with antimonials only. Both trials indicated that treatment with 
imiquimod is safe and significantly increased the cure rate, compared with antimonials alone 
in patients. However, due to the occurrence of local irritation, a routine of application on 
every other day is recommended. Furthermore, the action of imiquimod reduced the 
residual scarring315. 
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The immunomodulatory potential of simvastatin as a topical or systemic host-directed drug 
therapy, in controlling inflammatory responses, in an experimental mouse model of CL, 
caused by L. major has been investigated by Parihar et al99. In an ear infection model, direct 
topical application of simvastatin on established lesions significantly reduced severity of the 
disease, reflected by ear lesion size and ulceration. The host protective effect was further 
accompanied by decreased parasite burden in the ear, and draining lymph nodes, in both 
BALB/c and C57BL/6 mice. Reduced severity of disease by topical application of simvastatin 
in ear infection model, they found that systemic treatment with simvastatin, before L. 
major infection (prophylactic), was protective in both the resistant C57BL/6 as well as the 
susceptible BALB/c mice, during footpad infection99.  
Pentoxifylline is a tumour necrosis factor-α (TNF-α) inhibitor100 that also attenuates the 
immune response and decreases tissue inflammation. The association of pentoxifylline with 
antimony improves the cure rate of mucosal and cutaneous leishmaniasis. In a randomized, 
double-blind pilot trial against L. braziliensis, cure rate was higher, although not significant, 
in patients who received antimony plus pentoxifylline than in those patients receiving 
antimony plus placebo100. 
1.3.9 New Drugs 
There are currently a handful of potential new classes of drugs in the Drugs for Neglected 
Diseases initiative (DNDi) drug development pipeline; amongst these are oxaboroles, 
nitroimidazoles and aminopyrazoles.  
DNDi and Anacor have been working together over the last few years to identify oxaborole101 
compounds, initially for the human African trypanosomes (HAT) programme. This has 
expanded to include both leishmaniasis and Chagas disease. DNDI-6148 has emerged as a 
promising lead candidate for VL and CL, and by the end of 2016, studies including exploratory 
toxicology necessary for possible progression to preclinical development had been 
successfully completed. 
In June 2014, the first in vivo proof-of-concept for VL series 12, called the aminopyrazoles102, 
from Pfizer was achieved in the hamster early curative model of VL. An initial compound gave 
93% and 95% reductions in parasite number in the liver and spleen respectively after five 
days oral dosing at 50 mg/kg,. A subsequent compound showed even higher in vivo activity 
(>99% reduction in both the liver and spleen). The project moved into the lead optimization 
stage in January 2015, with further compounds being designed and tested. Profiling of 
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current and new leads in a panel of drug-sensitive and drug-resistant strains of Leishmania, 
exploration of the in vivo dose-response, rat pharmacokinetics, and initial in vitro safety 
assays are all underway. 
A project based on a series of nitroimidazole compounds was started and was terminated in 
early 2015103. The decision was taken to progress with lead compounds from two sub-series 
previously identified from the nitroimidazooxazine backup programme (DNDI-8219 and 
DNDI-0690), which had good efficacy in vivo, higher solubility, and lower potential for 
cardiotoxic effects. A 14-day toxicity evaluation carried out in 2015 led to DNDI-0690 
nomination as a pre-clinical candidate. In addition, with other potential lead compounds for 
VL, DNDI-0690 was profiled in vitro against CL-causing strains of Leishmania at the London 
School of Hygiene & Tropical Medicine and the Walter Reed Army Institute of Research, and 
showed good to excellent activity, consistent with their activity against L. donovani and L. 
infantum. 
As previously mentioned, repurposing is a possible strategy for the development of new 
drugs. Some examples of repurposing being used in the treatment of leishmaniasis are 
imipramine104, fexinidazole105, tamoxifen106 and tafenquine107, all of which showed in vivo 
activity. 
Another area in which new treatments are being explored for CL is the use of combination 
therapy108. A recent example of this is the clinical trial on the use of thermotherapy and a 
short course of miltefosine in combination. Local heat is applied using a localized current 
field radio frequency generating. The electrodes are applied to the skin heating one single 
lesion to 50°C. Depending on the size of the lesion, more than one application may be 
administered.  In addition to receiving one single session of thermotherapy as described 
above, subjects received oral miltefosine, two or three capsules a day, which is the 
equivalent of 100 to 150 mg respectively for 21 days. 
1.3.10 Drug Resistance 
Another issue with the treatment of CL and VL, is the increasing frequency at which drug 
resistant strains are encountered109-111. Clinical resistance to amphotericin B is rare110. 
Nevertheless, with the increasing use of amphotericin B, the possibility of emerging 
resistance cannot be ignored. 
Laboratory studies have shown that resistance to amphotericin B can be induced with 
minimal effort by changing their membrane chemistry65. One method by which the parasite 
Chapter 1: Introduction 
19 | P a g e  
 
can do this is, is to alter the expression of methyl transferases in the thiol metabolic 
pathways112. Miltefosine has such a long half-life that sub-therapeutic levels are maintained 
over long periods in the body, which could easily lead to the emergence of resistant 
strains110. The main route of resistance against miltefosine is the reduction of uptake into 
the parasites113. Finally, there is an issue with the fact that different species are affected to 
different degrees by each drug. In addition to this, within each species there are different 
strains that also show different responses when treated71. There is also the host cells to 
consider, as drug uptake and accumulation may be different in different cell types114. This 
leads to variation in the activity of drugs even between different strains in the same host cell 
type, depending on the source of the cell. 
1.4 Rationale for Improving the Drug Discovery Process 
1.4.1 Drug Discovery 
Recently there have been few advances for the treatment of simple or complex forms of CL. 
The main challenge for CL is to ensure that this disease is on the research and development 
agenda, so that new drugs are evaluated. There is a great need for the discovery and 
development of anti-leishmanial drugs, as those that are currently used for treatment, for 
either CL or VL, suffer from a wide array of side effects that can cause more discomfort than 
some pathologies of the disease. 
In a recent high-throughput screening (HTS) of 1.8 million compounds by GSK115 against L. 
donovani. 67,400 primary hits were identified; an overall hit rate of 4%. Confirmation of 
activity above the cut-off in at least one replicate was displayed for 32,200 compounds. The 
remaining compounds were tested in an intracellular assay of L. donovani infected THP1-
derived macrophages, resulting in 5,500 active compounds. Compound potency (EC50) as 
well as acute cytotoxicity of the compounds were assessed. Subsequently, 351 non-cytotoxic 
compounds were found. This screen shows a major problem with the development pipeline, 
which is the number of active compounds that are found unsafe due to high cytotoxic effects.  
Another screen of note is one conducted by Novartis116 who tested 1.5 million compounds 
in proliferation assays on three different parasites; L. donovani, T. cruzi and T. brucei. This 
was followed by triaging of active compounds, EC50 values of less than 10 μM with a clear 
window of selectivity with respect to growth inhibition of mammalian cells. An 
azabenzoxazole, GNF5343, was identified as a hit in the L. donovani and T. brucei screens. 
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Although GNF5343 was not identified in the T. cruzi screen, it has shown potent anti-T. 
cruzi activity in secondary assays. 
Optimization of GNF5343 involved the design and synthesis of ~3,000 compounds, and 
focused on improving bioavailability and potency on inhibition of L. donovani growth within 
macrophages. A lead candidate from this cycle of chemical improvements was named 
GNF6702. An in vivo footpad infection of BALB/c mice with the dermatotropic L. major strain, 
treated with GNF6702 at 10 mg kg−1 twice daily caused a fivefold decrease in footpad 
parasite burden and a reduction in footpad swelling. Both 3 mg kg−1 and 10 mg kg−1 twice-
daily regimens of GNF6702 were superior to 30 mg kg−1 once-daily miltefosine regimen 
(P < 0.01)116. 
1.4.2 Drug Discovery Pathway 
The drug discovery pathway is a long process that takes both a lot of time and money, with 
estimates at $1395 million dollars117 as an estimated average out-of-pocket cost per 
approved new compound. Despite the large investment, only a small number of compound 
will make it out of the pipeline118. The path to a marketed drug involves a long and exhaustive 
journey through basic research, discovery of the drug, preclinical development tests and 
formulation of the medicine and a series of complicated clinical trials with humans before 
regulatory approval. Usually 15 to 20 years36&119 of research and millions of pounds later, 
there is a possibility that a new drug will be approved for marketing. Drug discovery and 
development is widely recognized as one of the most financially risky endeavours in all of 
science and a major challenge for the industry. Much of this cost comes from failures, which 
is estimated to account for 75 percent of the total research and development cost. The 
failure rates of drugs once they reach clinical trials is very high, and is estimated at nearly 
90%120. One possible reason for this is the lack of biologically relevant models in which 
potential drug candidates are screened, evaluated and selected during both discovery and 
development phases. Key areas that are in particular need of better models are those that 
are used for pharmacodynamics and pharmacokinetic experiments as conditions that 
influence these factors are hard to recreate in vitro. Leishmaniasis is a disease that suffers 
from this problem, of having limited disease relevant models in many stages of its drug 
development pathway. 
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1.4.3 Need for Predictive Assays 
The common and persistent failures to translate promising preclinical drug candidates into 
clinical success highlight the limited effectiveness of disease models currently used in drug 
discovery. An apparent reluctance to explore and adopt alternative cell and tissue based 
model systems, coupled with a detachment from clinical practice, contributes to ineffective 
translational research121. 
Finally, a substantial proportion of clinical trial failures for novel medicines overall are due to 
safety issues such as cardiotoxicity and hepatotoxicity, and serious toxicity issues are often 
discovered only during clinical development has been completed. Thus, more predictive 
toxicology models would contribute substantially towards more successful clinical 
translation and improved patient care122. 
1.4.4 Improving In Vitro Models  
Despite advances in target and cell based screening technologies, the majority of drug 
discovery projects remain dependent on cell culture systems that were developed several 
decades ago, incorporating immortalized cell lines. Many researchers consider the use of 
such assay systems to be questionable owing to their poor disease relevance. Traditional cell 
culture methods typically rely on immortalized cells grown within artificial environments, 
and on non-physiological substrates such as functionalized plastic and glass. Although these 
methods have facilitated the discovery of many basic biological processes, they often fail to 
provide an adequate platform for drug discovery owing to their inadequate representation 
of key physiological characteristics121.  
Most cell-based assay screens are performed using cell lines, that have been cultured for 
many generations, resulting in a substantial drift in their genetic, epigenetic and physiological 
characteristics, which means they are not a good model of primary tissue cells123&124. The 
genetic and epigenetic abnormalities, characterized by multiple genetic rearrangements and 
amplified gene copy numbers, associated with long-term culture confound 
pharmacogenomics and functional genomic studies. Genetic adaptation resulting from long-
term in vitro cultures also contributes to heterogeneity in cultures of the same cell line 
between passages, batches and laboratories. One way to improve the cells used in assays is 
to use either freshly isolated primary cells or cells derived from stem cells125. Using cells that 
are more closely related to human biology can reduce the problems caused by genetic drift 
and long-term culture. The development of induced pluripotent stem cells (iPSCs) gives the 
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use of these stem cells other advantages such as, easy accessibility, expandability, ability to 
give rise to almost any cell types desired, avoidance of ethical concerns and the potential to 
develop personalized medicine. 
The media most commonly used for cell culture is designed for fast cell growth, incorporating 
large concentrations of fetal serum and nutrients, which may promote de-differentiation of 
primary cell types into more embryonic or fetal-like phenotypes126. Cells are often grown in 
standard incubators under high oxygen partial pressure, approximately 20%, which does not 
represent the steady-state conditions of human organs and tissues, fluctuating between 1% 
in the dermis, and 14% in arterial blood127-130. This has a profound impact on cell metabolism, 
reactive oxygen species production, mitochondrial functions and, ultimately, the 
differentiation and function of cells131&132. Additionally, conventional tissue culture systems 
do not readily permit the formation of short-range gradients of nutrients, hormones and 
oxygen that are often experienced by cells, depending on the distance to the nearest blood 
vessel. This can be mimicked with the adoption of microfluidic systems that can be adjusted 
to mimic physiological conditions and deliver nutrients, dissolved gases and remove waste 
products133.  
The two-dimensional (2D) planar substrates on which cells are typically grown are stiff, 
demonstrating high tensile strength and mechanical resistance to deformation, unlike most 
substrates found in the human body, with the exception of bone and cartilage134. Hence, the 
plastic or glass used in cell culture may not accurately represent the normal in vivo 
mechanical environment135&136. To avoid these problems a 3D environment could be used. 
Initially the use of collagen coating and other extracellular matrix substitutes can lead to a 
more natural environment for the cells. Further to this, 3D confirmations can be recreated 
using a scaffold for the cells, allowing complex cell behaviours to develop. Both solid scaffolds 
and hydrogels can be made with a variety of different tuneable properties. Stiffness, 
resistance to deformation and swelling behaviour can all be varied by changing either 
material or the concentration of polymers in hydrogels137&138. 
A further challenge in tissue modelling within current in vitro assays is the absence of a 
physiologically relevant extracellular matrix (ECM). For example, the popular use of Matrigel, 
a gelatinous protein mixture secreted by Engelbreth-Holm-Swarm mouse sarcoma cells with 
chief components of Matrigel being structural proteins such as laminin, entactin, collagen, 
heparan sulphate proteoglycans and growth factors, and collagen type I as an ECM substrate 
in hepatocyte cultures, does not represent the ECM proteins predominantly found in the 
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liver139. Many pathologies are associated with changes in ECM production. Some attempts 
to rectify this problem have been made; often to address this issue the solid scaffold used in 
cellular models is a decellularised section of tissue leaving only the ECM, which then can be 
seeded with new cells. In other models, the decellularised ECM is lyophilized and added to a 
hydrogel in order to restore the ECM proteins that would be missing from the hydrogel140. 
Cell-culture screening assays traditionally use a single cell type, whereas cells in vivo are in 
either direct contact or communicate over a long range with many different cell types. As 
most biological processes and pathologies involve the interaction of multiple cell types, these 
should ideally be incorporated into in vitro cellular assays whenever possible. For example, 
most toxicology assays use only hepatocytes, but although 80% of the liver volume consists 
of hepatocytes (60% of the cells); other important cell types within the liver include stellate 
cells, resident macrophages (Kupffer cells), sinusoidal endothelial cells and some non-
parenchymal cells. Both stellate cells and Kupffer cells are known to be important for some 
compound toxicities and should therefore be incorporated into in vitro toxicology 
assays141&142. Further development of co-culture methods, which incorporate disease cells 
with relevant immune sub compartments, is also urgently needed to help better understand 
and address the role of the host immune system in the pathology and therapeutic outcomes 
of diseases. These considerations are of particular importance for pathogen biology and 
infectious diseases, which operate at multiple cellular and tissue levels143.  
1.4.5 Improving In Vivo Models 
A model is a simple representation of a complex system. Consequently, an animal model for 
a human disease is by no means attempting to reproduce the human disease with all its 
complexities in an animal. Animals are instead used to model-specific aspects of a disease. 
Whenever an animal model is used, it is thus of utmost importance to define a specific 
question and to ensure that the chosen model is fit for purpose. Compounds fail for many 
reasons, but some are more avoidable than others. Poor oral bioavailability, pharmacokinetic 
properties or toxicity issues that are not predicted by animal pharmacology result in overlap 
of efficacious and toxic doses. These are often reasons for Phase I and Phase II attrition 
rates144. Indeed, animal studies seem to overestimate by about 30% the likelihood that a 
treatment will be effective because negative results are often unpublished145. Similarly, little 
more than a third of highly cited animal research is later tested in human trials.  
First, in vivo studies typically use high doses of compounds, which are orders of magnitude 
greater than those humans are exposed to. Whilst these higher values can be scaled with 
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allometric scaling146, dose-response relationships are complex, so extrapolation from these 
high doses to lower, human, exposure levels is difficult and results in many inaccuracies. 
Second, in vivo studies examine the response of a standard laboratory animal to a xenobiotic. 
This response may or may not occur in humans. Even more important is that the human 
population is very heterogeneous and a single strain of animal cannot accurately predict the 
variability in responses seen in the human population. Finally, in vivo exposures in toxicity 
testing are usually composed of a single compound. While this allows for close examination 
of the results of that single compound, humans are constantly exposed to mixtures of 
compounds daily, and the effects of these co-exposures need to be examined147.  
Many outcomes used in animal models are dependent upon subjective interpretation. While 
subjective evaluations are generally a very efficient way to score behavioural endpoints, it 
can create bias if the scorer is aware of the animals’ treatment148. One way to avoid this is to 
conduct blind studies. 
In animal models, treatment is frequently initiated either before or shortly after the disease 
pathology is initiated. This is in contrast to the clinical situation, in which treatment is 
normally started after onset of symptoms and clear diagnosis. Thus, a potential 
pharmacological effect could be overestimated in an animal model. 
While most experimental set-ups are very much standardized in a particular lab, slightly 
different parameters in another lab may yield different results. Repetition of experimental 
findings in slightly different models can give different results based on the biological 
differences between models148. Each result is from a separate entity and this means that 
variation is inherent and unavoidable. The animals will have different responses to both the 
treatment and the disease; this can cause large variation in results. If this happens, it is not 
hard to image that a valid response to the drug could be labelled as an outlier. 
The use of animal models can also be expensive. The more specific the animal strain, often 
allowing it to be more biologically similar, the more it can cost. Mouse strains can be inbred 
lines in order to maintain the specific phenotypes required by the end user. This, however, 
can lead to genetic issues, due to the nature of inbreeding. A well planned experiment can 
use many animals, as groups must be large enough to be statistically relevant despite the 
inherent variability in the animals. Often due to the high cost of animals, researchers will 
compromise on the number of groups and animals a study will consist of in order to save 
money. 
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Humanized mouse models in which immunodeficient mice are engrafted with human cells 
or tissues, are considered extremely useful. They allow human research studies in vivo and 
hence support clinical translation149. Dependent on the human disease, and question 
addressed, different humanized models and mouse strains are utilized. Most commonly used 
are the human tumour xenograft models for the study of cancer, and the humanized mouse 
models that mimic the human immune system. 
A humanized mouse model of HIV infection generated by CD34+ hematopoietic progenitor 
cell transplantation is used as the replication of HIV, is not supported in other murine in vivo 
models150. In these mice, CD34+ cells generate de novo human immune cells capable of 
supporting in vivo HIV replication. Due to the limited tropism of HIV, in vivo modelling of this 
virus has been almost exclusively limited; use of similar lentiviruses such as SIV that 
reproduce many important characteristics of HIV infection have been used as a substitute. 
However, there are significant genetic and biological differences among lentiviruses and 
some HIV-specific interventions in non-human hosts. Humanized mice are systemically 
reconstituted with human lymphoid cells offering rapid, reliable and reproducible 
experimental systems for HIV research. Advantages of this humanized mouse model include: 
their small size, relatively low cost, making them more accessible than primate models, and 
multiple humanized mice can be made from different human donors, permitting control of 
intragenetic variables. Both primary and laboratory HIV isolates can be used for experiments; 
and in addition to therapeutic interventions, rectal and vaginal HIV prevention approaches 
can be studied150.  
Plasmodium species infecting rodents and humans are highly divergent. While some critical 
factors for pre-erythrocytic infection are known in rodent-infecting P. berghei and P. yoelii, 
it remains largely unknown how relevant they are for P. falciparum and P. vivax pre-
erythrocytic infection151. Several humanized mouse models utilized to study human infective 
species at different stages of the malaria life cycle have been created. A better understanding 
of the receptors required for sporozoite invasion of host cells would uncover a remaining 
mystery about the malaria parasite and could facilitate the development of novel, 
immunocompetent, humanized mouse models. The first success in assessing P. falciparum 
liver stage development in liver-humanized mice used Alb-uPA on a SCID background152. The 
liver of these mice can be robustly repopulated with human hepatocytes soon after birth and 
these hepatocytes are susceptible to P. falciparum infection. More recently, it has been 
demonstrated that P. falciparum can infect fumarylacetoacetate hydrolase null mice (FRG 
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KO) mice. These mice lack FAH, Rag2 and IL2rγ and are efficiently transplanted with human 
hepatocytes (FRG KO huHep) 153. It has been shown that this model supports robust 
P. falciparum sporozoite infection and supports complete maturation of parasites. This 
model is now fully established in antimalarial drug development studies. A combined 
humanized mouse model that can harbour liver stages, allows transitions to blood stages 
and continuously supports blood stage infection, would constitute a major advance. 
The modelling of pharmacodynamics and pharmacokinetics is often done in animal models. 
Effective pharmacokinetics and pharmacodynamics (PK/PD) study design, analysis, and 
interpretation can help scientists elucidate the relationship between PK and PD, understand 
the mechanism of drug action, identify PK properties for further improvement and optimal 
compound design and dosing regimens. A large variety of animal models have been used to 
characterize the pharmacodynamics of antimicrobials154. Animal models have the advantage 
of determining antimicrobial efficacy at specific body sites such as the thigh in mice, the 
peritoneum in mice and rats, the lungs in mice, rats, and guinea pigs, endocarditis in rabbits 
and rats, and meningitis in rabbits. However, clearance of antimicrobials is more rapid in 
animals than in humans. Many factors, such as inoculum, media, growth-phase of the 
organism, site of infection, drug concentrations to measure correct drug exposure, presence 
of neutropenia, and measurement of outcome by colony-forming units (CFUs), 
survival/mortality, or another form of assessment, need to be considered to develop 
meaningful conclusions154. 
When adequately designed and conducted, animal models can contribute invaluable 
information to our knowledge of biology and medicine, including the discovery and 
development of new drugs. However, better design and conduct, as well as further 
development of animal models is warranted. 
1.5 Assays to Test the Activity of Drugs 
1.5.1 In Vitro Assays 
In vitro screening has many advantages over in vivo screening methods, such as a vast 
reduction in both time taken and cost. It also avoids ethical issues related to the use of 
animals. Today many cell lines are widely available, and it is possible to culture many 
different cell types. Immortalised cell lines are relatively easy to maintain in comparison with 
mice and can be maintained almost indefinitely. Large screens can be conducted using 
cultured cells rather than hundreds of mice, over a much shorter period. In vitro drug assays 
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can be completed within a week whereas, an in vivo experiment may take several weeks 
before the infection is seen and before a drug can be applied and evaluated. The amount of 
drug used in in vitro assays is also much less than in a standard in vivo experiment. When 
conducting an in vitro assay, more precise control over the conditions of the assay can be 
achieved and because of this, reproducibility is greater than in in vivo assays. In order to be 
relevant, in vitro screens must provide a good prediction of activity in vivo and be able to 
reflect cellular level changes that can be viewed with ease. However, this is often not the 
case as in vitro assays are usually lacking in biological complexity.  
1.5.2 In Vitro Assays for Testing Compounds against Leishmania  
In vitro assays for the testing of compounds against Leishmania parasites can be performed 
in a variety of ways. A number of aspects can be studied such as rate of kill, percentage 
infection, total burden or burden per cell after differing number of days. When choosing an 
assay there are a number of things to consider. In vitro assays have been conducted using a 
variety of cell types; these include a Sticker dog sarcoma fibroblasts cell line155, transformed 
rodent macrophage cell lines156, human monocytic cell line derived from an acute monocytic 
leukaemia patient, primary isolated mouse peritoneal or bone marrow macrophages and 
human monocyte-derived macrophages157. Another consideration is the stage of parasite 
that the drug will be tested against157 and whether the parasite will be actively dividing within 
the host cells. A further consideration with use of parasites is how long they have spent under 
in vitro culture conditions. It has been seen that after multiple passages the parasites adapt 
to in vitro culture, changing their biology and potentially altering the effect compounds 
would have on them158. 
1.5.3 Assay Endpoints 
The main method of evaluating intracellular infection of macrophages by Leishmania is to 
count the number of macrophages that have been infected. An in vitro assay involves 
infecting a population of cultured cells and then, after a 24 hour period, treating with a drug 
over a set period of time, usually for 72 hours, before determining their infection levels and 
elucidating the activity of the drug. Usually this requires the host cells to be fixed and stained 
before observation under an oil immersion microscope157. This allows the counting of the 
number of infected cells or the number of amastigotes within each infected cell; usually over 
a hundred cells are counted in total. Another method that involves counting is the limiting 
dilution assay159 where the number of viable intracellular pathogens can be determined by 
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creating a dilution series of the remaining parasites and measuring replication rates in each 
dilution in order to determine the number of viable parasites within the original sample.  
A variation on the above counting method is to use parasites that have been transfected with 
a fluorescent160&161 or bioluminescent163 marker. This allows the parasite to produce a signal 
that can be measured using different techniques. With these parasites, fluorescent 
microscopes or confocal imaging allow for easy counting of the infection. The imaging of 
fluorescent parasites can be detected and evaluated in many ways, such as total fluorescent 
signal, size of fluorescent area or simply the number of infected cells. One advantage that 
fluorescent or bioluminescent parasites have over a Giemsa stained slide is the difference in 
contrast between parasite and host cell. Automated systems such as Opera® (PerkinElmer, 
UK), can count the number of infected cells when used with these transfected parasites.  
A problem with using the counting method to determine infection is that it takes a long time 
for large data sets to be processed. A mechanised counting version as an end-point is flow 
cytometry, which allows cells infected with fluorescent or bioluminescent parasites to be 
counted135. Counting is also not easily compatible with 3D cell culture as the scaffolds or 
extracellular supports can easily stop cells from being viewed under light or fluorescent 
microscopes. The use of dyes, fluorescent or bioluminescent parasites and confocal 
microscopy would be needed. Another issue is that drug cytotoxicity can drastically change 
the number of cells available to count, which you would not be able to monitor until the 
sample is fixed and stained.  
There are many assays that do not give a microscopically read estimation of infection as a 
final readout, but give a value that can be scaled against specific controls to give a normalised 
readout based on the infection levels. These may become necessary as the complexity of in 
vitro systems increases and counting becomes impossible. Colorimetric assays are assays 
that use a colour change or development that can be detected by either absorbance or 
fluorescence. A simple example of this is the use of Alamar Blue, the oxidation–reduction 
indicator has been used for colorimetric determination of parasite cell viability and 
proliferation. Alamar Blue® is non-toxic for cells even during long incubation times. In the 
living cell, Alamar Blue® is reduced thereby changing its colour from blue to red allowing for 
detection of the number of viable parasites163. Another chemical that has been used along 
the same line is 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT). 
Surviving Leishmania parasites can be quantitated by their conversion of the chromophore 
MTT164. Reduction of the yellow MTT to an insoluble formazan, which has a purple colour, by 
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NADPH-dependent cellular oxidoreductase enzymes provides a measurable signal relating to 
cell viability. 
Another colorimetric method that has been developed uses a parasite-specific enzyme, 
trypanothione reductase, which reduces trypanothione disulphide leading to a colour 
change through the coupled reducing activity of 5,5′-dithiobis 2-nitrobenzoic acid, which can 
be detected by measuring its specific absorbance165. The assay measures the activity of an 
enzyme unique to the parasite so that host cells do not affect the colour change caused by 
the reaction catalysed by this enzyme.  
Along similar lines are assays that use reporter gene technology, where a gene has been 
transfected into the promastigote and produces a coloured or luminescent molecule or one 
that can react with an added chemical to create a measurable change in colour162 that can 
be detected and used as a measure of how many parasites are present. The use of such 
genes, like the firefly luciferase166 or the green fluorescent protein (GFP) gene167, could 
considerably facilitate the screening of antimicrobial agents by allowing direct read outs of 
the remaining fluorescent signal after drug treatment.  β-galactosidase168, chloramphenicol 
acetyltransferase167 and alkaline phosphatase167 are all genes that can be transfected into 
the parasite causing it to produce a specific enzyme that will then be used to catalyse a 
reaction that produces a coloured product, which is then detected by absorbance. 
Quantative polymerase chain reaction (qPCR) can be utilised as a method, which can be used 
to detect relative and absolute levels of parasite and host cell DNA when compared to a set 
of standards169. The results from this can show a decrease in DNA concentrations if the 
parasite has been cleared, whilst also giving a measure of the possible cytotoxic effects of 
the compound if it reduces the host cell DNA concentration. A further elaboration on this 
method is the use of reverse transcriptase qPCR, by adding the reverse transcriptase step 
you are only amplifying the RNA produced by actively viable parasites170. This is important, 
as it is possible for the DNA of parasites that have been killed to remain after the parasite 
has been killed. 
1.5.4 High-Content Screening for Anti-leishmanial Agents 
There is a strong trend towards high-content screening (HCS) of compound libraries as a tool 
for drug discovery171. High-content screening is a type of phenotypic screen, looking for 
changes in cells that may include increases or decreases in the production of cellular 
products such as proteins, changes in cell morphology or, for Leishmania, the presence of 
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parasites. High content screening includes any method that is used to analyse whole cells or 
components of cells with simultaneous readout of several parameters, such as parasite 
burden, percentage infection and number of live parasites all at the same time. Using the 
usual manual counting method would take a very long time for each data set to be fully 
evaluated, so automated image analysis is required. Even though an automated system is 
faster it requires greater time to set up and train the system to count as specified, even then 
images often have to be manually reviewed to check the results of the automated counting. 
A group from the Institut Pasteur Korea have used automated multidimensional analysis of 
macrophages infected with Leishmania parasites to determine drug sensitivities by studying 
a variety of factors172. Variables such as cell number, infected cell number, number of 
parasites per cell, cell dispersion and cell shape and texture have been analysed by an 
algorithm designed especially for the analysis of infection by Leishmania parasites. A group 
at the University of Dundee, conducted a similar assay, where images of fluorescent parasites 
in labelled macrophages were analysed and inhibition curves could be derived173. 
These high content screening methods can be used as a form of high throughput screening. 
Other methods, mentioned such as the colorimetric assay and reporter gene technology, 
also lend themselves to high-throughput screening as they can be quickly analysed and are 
cheap to complete120&165, but provide less information than the high content based image 
analysis. Most high-throughput screens have used a reporter gene transfected strain of 
Leishmania174. 
1.5.5 Ex Vivo Assays 
Ex vivo assays are conducted in or on tissue that is taken from an organism and moved to an 
external environment. Thus, there is minimal alteration of the physiological conditions within 
the tissue. Ex vivo conditions allow experimentation on an organism's cells or tissues under 
more controlled conditions than is possible in in vivo experiments; however, this is at the 
expense of altering the "natural" environment. A primary advantage of using ex vivo tissues 
is the ability to perform tests or measurements that would otherwise not be possible or 
ethical in living subjects. Tissues may be removed in many ways, including in part, or whole, 
organ removal. VL can be studied in splenic explants175 and samples of blood176 that, once 
removed from the body, can be cultured in a way that allows for the maintenance of the 
parasite. For cutaneous leishmaniasis, a skin explant model would be more relevant. 
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1.5.6 Standardisation among Laboratories 
A major problem with current in vitro assays is standardization of conditions among labs. 
Due to the large differences that can occur, not only through the use of different strains, but 
also the use of parasites at different stages of its lifecycle, it is almost impossible for different 
labs to be testing on the same parasite. This inherent variation is also seen between host cell 
sources. This can mean results are hard to replicate among labs and this can inhibit the 
development of new assays177. 
1.6 Cellular Models for the Study of Disease 
1.6.1 Why use Cellular Models 
Due to concerns about animal welfare, time and cost constraints, and the ever increasing 
number of chemicals that need testing, establishing more predictive in vitro culture systems 
has become a priority. In addition, the predictive accuracy of rodent in vivo testing for human 
adverse health effects has become a matter of dispute in recent years147, 178&179. In part due 
to poor concordance of animal study results to disease phenotypes observed in 
heterogeneous human populations. 
In vitro models to study disease are used for many of the same reasons mentioned in the in 
vitro assay section. There has been much development in models, over the past few years, 
to move from standard 2D in vitro static single-time point assays to model systems that are 
more biologically relevant.  
1.6.2 Increasing Complexity 
An easy first step to make a more biologically relevant system is to have a system where the 
cell culture medium constantly flows, transforming a 2D static system to a 2D flow system. 
In this way, you can mimic the fluidic conditions within the body180. Many tissues within the 
body have direct contact with moving bodies of fluid181, from the obvious circulatory system 
and digestive system to the slightly less considered spinal fluid and lymphatic system. The 
movement of the fluid is important for a number of functions, such as nutrient delivery and 
waste removal182. In addition to this, a media perfusion system can provide the cells with 
biologically relevant shear stress and oxygen gradients183, which are not reproducible in 
static systems. A further point to the fluid flow is that it allows for the creation of gradients, 
which are found in many biological environments and can be important for the function of 
that environment184&185. The flow of media through the cell culture system is especially 
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important as it allows for further complexity in the system to be maintained in conditions 
that would otherwise not easily support such complexity182.  
Along similar lines the use of bioreactors for the maintenance of cells have many of the same 
features as media perfusion systems. However, bioreactors can be scaled up for industrial 
uses producing many cells from the same growth conditions. In this method, cells can be 
harvested without passage and interruption of growth cycles182. 
Complexity can be increased by moving from 2D to 3D cell culture. The culture of cells in two 
dimensions is arguably primitive and does not reproduce the anatomy or physiology of a 
tissue for informative or useful study186. Creating a third dimension for cell culture is clearly 
more relevant. The 3D environment allows the cells to take a more physiologically relevant 
shape and volume187. This alters, not just the surface area to volume ratio, but fundamentally 
changes the availability of the cell surface for both cell-cell interactions188 and other 
important cell surface activities, such as receptor presentation188 and particle uptake189. 
Using primary cells instead of immortalized cell lines is another way to improve the 
predictiveness of a model. Immortalized cell lines are created by fusing a cell line with a 
cancer cell line which can lead to the resulting cell line taking on some of the properties of 
the cancer cells. For example as well as the intended immortalisation they also can take on 
other phenotypes190, for example, Hepa1– 6 cells were found to be deficient in 
mitochondria190. Using primary cells can avoid this issue and also has the added benefit that 
the cells are much closer to the cells that are found in the body, increasing biological 
relevance. The choice between human or animal primary cell should depend on the purpose 
of the model. 
Another option for cell choice, that may be more biologically relevant is the use of either 
stem cells or more readily available iPSCs. For the same reasons of being closer to the cells 
found within the body these cells could be more predictive in cellular assays191. The use of 
iPSCs has the added advantage that the cells can be donor specific and has been shown to 
react in the same way as the patient they are taken from. This way genetic variation is taken 
into account192. 
Using a cell culture system containing more than one type of cell is another way to increase 
the predictive strength of the model. It is obviously an understood fact that within the body, 
cell types do not function in isolation, and therefore, are always under the effects of 
surrounding cells in the tissue, some of which will be completely different cell types193. 
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Knowing this it seems incredible that we still grow cells in isolation and maintain that this 
can provide us with enough information. Co-culture models with multiple cell types in the 
same culture allow for cell-cell signalling, which is important as different cells will have 
different functions and convey different messages though their signalling. Many examples of 
cells having organisational roles within tissues have been elucidated194. The one issue with 
this is that in vitro conditions often lack the complexities to keep the different tissue types in 
balance, whether this be due to nutrient needs or the ability to stop one cell type outgrowing 
the other. 
Another important addition, that could be made to improve the realistic behaviour of the 
body, especially in disease models, is the incorporation of an immune response element195. 
As a minimum, a model should consider the amount and type of immune signalling molecules 
that can be found in the disease state environment. This aspect is missing from most 
currently used models. 
However, the size and complexity of models can cause problems if the models are to ever be 
used for high throughput purposes. Considerations in the design of the model are important 
when high throughput is the goal. The time a model takes to construct and reach equilibrium 
should be considered, as high throughput requires large numbers of models and using model 
that takes over a month to produce is not feasible. Also important here is the price that the 
model costs to produce, both in resources and an expert’s time. 
However, for Leishmania there is not yet an established model that bridges the gap between 
static 2D cell culture and in vivo models. 
1.6.3 Examples of Currently Used Models 
The most common model used is the cancer spheroid model. First described in the early 
1970s and obtained by culture of cancer cell lines under non-adherent conditions, spheroids 
have rapidly been accepted as a very useful model for the study of cancer196. Solid tumours 
grow in a three-dimensional spatial conformation, resulting in a heterogeneous exposure to 
oxygen and nutrients as well as to other physical and chemical stresses. Proliferation and 
hypoxia are found both at the same time in different areas of the same tumour197. This 
diffusion-limited distribution of oxygen, nutrients, metabolites, and signalling molecules is 
not mimicked in 2D monolayer cultures. However, it is possible to induce chemical gradients 
in 3D structures. In particular, the spheroid forms a necrotic core in very much the same way 
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as a solid tumour would and usually for the exact same reasons198. These similarities make 
the spheroid a useful model in the study of cancer199. 
Another important model of note is the model of the epidermis used for cosmetic testing200. 
The gold standard model used in the cosmetic industry is EpiDermtm, which is also known 
generically as a Reconstructed Human Epidermis201. EpiDerm is a ready-to-use, highly 
differentiated 3D tissue model consisting of normal, human-derived epidermal keratinocytes 
cultured on specially prepared tissue culture inserts. The process of creating the model is by 
the removal of all the cells from a human dermis and then re-seeding with mature 
keratinocytes. The model has multiple industry validations and accepted test guidelines, 
making it a proven in vitro model system for chemical, pharmaceutical and skin care product 
testing201. The model is used to study whether or not a compound is an irritant202, 
corrosive203, genotoxic204 or affects either hydration205 or epidermal differentiation206, and is 
a suitable alternative to animal testing. 
1.7 Media Perfusion Systems 
1.7.1 Why use Media Perfusion 
The importance of flow in physiology has been recognized for more than half a century, 
whether it be blood flow, media flow or interstitial flow. Since that time the understanding 
of fluid flow, and its effects on solute transport in biological tissues, including effects on cell-
cell signalling and morphogenesis, has increased substantially. The perfusion of media in a 
cell culture system allows for increased nourishment and sustainability of 2D and 3D cultures, 
which could otherwise lead to necrotic cores in the latter case. Flow however, affects more 
than just cell nourishment. It can, for example, induce blood and lymphatic capillary 
morphogenesis in vitro207-210, maintain the functional activity of chondrocytes and 
osteocytes211-214, drive fibroblast differentiation215&216 and induce cytokine production by 
smooth muscle cells217.  
Static systems do not offer any form of dynamic chemical or physical stimulus to cells, such 
as concentration gradients, flow, pressure, or mechanical stress caused by movement of 
fluids around them. This is a major limitation in experiments investigating cellular responses 
in vitro since the complex interplay of mechanical and biochemical factors is absent. 
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1.7.2 Types of Systems Available 
Generally, there are two types of media perfusion systems; microfluidic and macrofluidics 
systems. It could be argued that large scale industrial bioreactors could be considered a third 
type. The first two are used mostly to conduct assays, whereas industrial bioreactors are 
generally considered to be for cell maintenance and growth. Simple definitions of the two 
main types of media perfusion system are that microfluidic systems use microliters of liquid 
and macrofluidics systems use millilitres of liquid and above.  
Another way to categorise systems is whether the fluid is continuously circulated or has just 
a single pass through the system. This depends on the aim of the experiment, time duration, 
type of pump used and whether the system can be constructed to do either type of flow. 
1.7.3 Comparison of Micro vs Macro Flow Culture Systems  
Micro- (Figure 1.7.1) and Macro- (Figure 1.7.2) systems have their advantages and 
disadvantages, the correct decision of which system to use is largely dependent on the aims 
of the experiment. An obvious place to start the comparison is the volumes of liquid used. 
Micro fluidic systems use microliters of liquid, the benefits of this are that overall less 
reagents are used and this will help lower the cost of the experiment218. This also means 
experiments can be carried out on reagents that have only been produced in low quantities. 
A further point to the use of small volumes is that any signalling molecules produced by the 
cells within the system will not be diluted, which is important not only for the effects they 
may cause to other cells but also for measurement purposes. A disadvantage of the 
microfluidic systems is their difficulty of use, they are very small and therefore so are their 
connections and any handling must be done with care. Many microsystems have pre-
attached connections to help users manipulate them more easily. Advantages of using higher 
volumes of liquid, in macrofluidic systems, are low concentration compounds are easier to 
make without potentially wasting compound in an intermediate dilution and higher 
confidence in dilutions.  
Directly related to the different volumes of each system are the various surface area to 
volume ratios found between fluidic devices. A micro system will have a high surface area to 
volume ratio218, this can mean that a compound that is found to stick to, or be absorbed by, 
the material that either the system or the connecting tubes are composed of, will represent 
a much higher percentage of the total concentration of compound in the system. Also in 
microfluidic circuits, surface adsorption can lead to nutrient or ligand depletion, so giving rise 
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to experimental artefacts such as increased metabolic consumption rates219. This effect is 
minimised in macro systems due to both the low surface area to volume ratio and the high 
amount of compound used. 
It is not just the volume of liquid that is important. The size of the system also has profound 
effects on the behaviour of the liquid within it. Macro systems are known for their ability to 
re-create the low shear stress conditions found in the majority of biological environments. 
Conversely, micro systems can often have un-realistic levels of shear stress220. In addition to 
this issue, micro systems can be subject to air bubbles, which will cause both turbulence in 
the flow and increased shear stress, which is already high221. 
A larger system can support extensive cellular growth and this means that in theory macro 
systems can be run for longer time periods than microfluidic systems. Microfluidic systems 
will have a limit on the number of cells used and the size of the structures that can form 
within them. They will also have a maximum amount of nutrients available to absorb from 
the media and this could be used up near the beginning of the system, causing the cells at 
the end of the system to have less nutrients affecting the outcome of any assay. However, 
this can sometime be useful, such as when a hypoxic condition is the purpose of the model222. 
A further consideration related to the size of the systems is their ability to control the oxygen 
tension inside the system. A majority of micro fluidic systems are produced using 
polydimethylsiloxane (PDMS) a material chosen due to its property of gas permeability223. 
Additionally, PDMS has disadvantageous characteristics in terms of adsorption of small 
hydrophobic species224. Other materials are now being used but little is known about the 
oxygen levels within the systems. In macro systems, there is usually a reservoir 
compartment, which has an available air supply for re-oxygenation of the circulating media. 
In addition to this, they can be constructed from a variety of materials with differing 
properties. 
The next few points can be viewed as either advantages or disadvantages, depending on the 
purpose of the experiment and what is hoped to be achieved by using a media perfusion 
system. Many micro systems, figure 1.7.1, have built-in scaffolds for 3D cell culture placed in 
the system during production, and whilst this is often a good thing, these scaffolds cannot 
be removed and may inhibit downstream analysis. Many micro systems are available 
custom-designed and cannot be easily modified. In contrast, macro systems are often 
adaptable to a range of removable scaffolds, which allows for greater manipulation and use 
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of existing techniques. Macro systems, figure 1.7.2, are often designed to fit with already 
established laboratory equipment and this can be a major bonus in both reduced cost and 
optimal data analysis118. However, the recovery of cells from the system can be essential for 
further analysis, and the removal of scaffolds or other inserts can be difficult and require 
expertise. To top this off, the ability to open the system can lead to increased chances of 
contamination. 
 
Figure 1.7-1. Multilayer microfluidic Poly (ethylene glycol) diacrylate (PEGDA) hydrogel225. 
(A) Isometric view of PDMS/PEGDA microchannel device perfused with toluidine blue, (B) 
Diffusion of toluidine blue into PEGDA diffusion chamber (10 × 10 mm) from a single 50 μm 
channel. 
 
Figure 1.7-2. Kirkstall LTD. Quasi Vivo 900 media perfusion system in use circulating RPMI 
1640 media in an incubator. 
6cm 
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Microfluidics is a very popular technique and as mentioned, its inability to be used with 
existing techniques in some cases has led to the development of many new protocols and 
experimental guidance on how to get the most from microfluidic devices. In contrast, 
macrofluidic systems have seen fewer new techniques introduced, as they can be used with 
existing technology. 
The physical size of macro fluidic systems is also important as, if the desired result is a large 
piece of tissue, then the system that the tissue is grown in must also be large. Another 
advantage to size is the ability to have enough cells in order to be able to use less sensitive 
assays. 
1.7.4 Static Cell Culture Vs Flow Cell Culture 
All cells are sensitive to their microenvironment, which is rich with chemical signals from 
other cells, and from mechanical stimuli due to flow, perfusion, and movement. A major 
limitation in experiments investigating cellular responses in static in vitro systems since the 
complex interplay of mechanical and biochemical factors is absent219.  
The ability to perfuse a chemical, whether it be drug or signal, allows for the creation of a 
gradient. Gradients are found all over the body and in many cases are essential for the 
correct physiology and behaviour. Gradients of oxygen183&226 and pH227&228, which are 
common features of tissues within the biology of the body, can also be created. 
In several cases, the application of media perfusion has been shown to extend the life of 
spheroids229 and help reduce the incidence of necrotic cores230. It also provides a means by 
which to remove harmful waste products that might otherwise accumulate. This could lead 
to chemical entities that are considered toxic to cells because of metabolites that have been 
shown to be less toxic than previously thought231. It is true that the waste removal systems 
of the body are efficient and do not mirror the metabolites remaining in culture and in 
contact with the cells that have expelled them. 
The final thing that media perfusion provides is physical signals to the cell. The force of the 
fluid on the cells creates both mechanical and shear stress and these two factors can be 
interpreted by the cell as signals at the start of signalling pathways232. Flow alone has to be 
shown to aid fibroblast alignment in culture215. 
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1.7.5 Interstitial Flow in vivo 
Interstitial fluid is the fluid that is found among cells in a multicellular organism. The 
composition of the fluid that occupies the interstitial space also varies by location within the 
body. In most soft tissues, the source of fluid is the normal leakage of plasma from blood 
vessels, so the interstitial fluid has a composition similar to that of blood plasma. It is 
estimated that up to 20% of the body’s mass is made up of interstitial fluid233, and much of 
this fluid is in constant motion, albeit slowly. The constant movement of interstitial flow 
means that every cell in the body is under flow conditions to some degree. Most of this 
movement is a result of lymph drainage. Although the exact velocity ranges of the flow are 
unknown, measurements have suggested that they are of the order of 0.1–2 μms−1 233-235. 
1.7.6 Flow and Drugs 
Another effect of fluid flow is that it could be very important to the delivery of drugs to cells. 
The fluid flow can be used to model the permeation of drugs to a tissue, even utilising 
chemical gradients or pulsatile drug delivery. A static system cannot accurately reflect the 
delivery of drugs to the cells or the removal of the metabolites of the drug and surrounding 
cells. It has been shown that the addition of flow can extend the lifetime of cells kept in 
culture229&236, one way this could be possible is by the removal of toxic products. 
A relevant example of the use of a media perfusion system is demonstrated in a paper by 
R.Bakshi237, in which an in vitro system was made using a glass case and hollow fibres made 
by perforated dialysis tubing. The model was used for the study of P. falciparum and was 
capable of mimicking the dynamic fluctuations of a drug in vivo. The millimetre-sized 
perforations allowed free movement of drug and macromolecules between the 
compartments, thus providing rapid equilibration. The study was designed to use the same 
total dose of drug, deployed in two extremely different regimens: a short-lived high 
concentration bolus, where the drug is rapidly perfused followed by untreated media to 
remove the drug, versus a constant low concentration infusion. Using this method, they 
found that the activity of chloroquine is dependent on the time the drug concentration 
remains above the minimum inhibitory concentration, while the efficacy of artemisinin is 
driven by the maximum concentration achieved in the culture. The latter was confirmed in a 
mouse model of malaria. These characteristics can explain the clinical success of two 
antimalarial drugs with widely different kinetics in humans. Chloroquine, which persists for 
weeks, is ideally suited for its Time above the minimum inhibitory concentration (TMIC) 
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driven mechanism, whereas great efficacy despite short exposure is attained by CMAX 
(Concentration maximum) driven artemisinins.  
Another example of media perfusion system use is in cytotoxicity testing. Toh et al 238 
developed a microfluidic 3D hepatocyte chip for in vitro drug toxicity testing to predict in vivo 
drug hepatotoxicity. The chip is formed of microfluidic channels where a 3D 
microenvironment is engineered in each channel to maintain the hepatocytes’ synthetic and 
metabolic functions. The multiplexed channels allow for simultaneous administration of 
multiple drug doses to functional primary hepatocytes, while an incorporated concentration 
gradient enables the in vitro dose-dependent drug responses to predict in vivo 
hepatotoxicity. The IC50 values of 5 model drugs they tested correlated well with the 
reported in vivo LD50 values. 
A further use of media perfusion systems is to test drug delivery vehicles such as 
nanoparticles. A paper by O. Farokzad et al239 used a microfluidic system to study the 
interaction between cells and nanoparticles. Using a model system, they evaluated the 
interaction of polymeric nanoparticles and microparticles conjugated to aptamers that 
recognize the transmembrane prostate specific membrane antigen (PSMA). The binding of 
particles to cells that expressed or did not express the PSMA were evaluated with respect to 
changes in fluid shear stress and particle size. Nanoparticle-aptamer bioconjugates 
selectively adhered to the LNCaP cell line produced from lymph node carcinoma of the 
prostate, but not the prostate cancer cell line (PC3). The particles adhered to cells at static 
and low shear, but not higher shear conditions. Control nanoparticles and microparticles 
lacking aptamers and microparticle-aptamer bioconjugates did not adhere to LNCaP cells, 
even under very low shear conditions.  
1.8 3D Cell Culture 
1.8.1 Why use 3D 
Cells cultured as 3D models exhibit features that are closer to the complex in vivo 
conditions240. The 3D culture models have proven to be more realistic for translating the 
study ﬁndings for in vivo applications. While cell lines provide us with excellent homogenous 
study material, culturing them as 3D models induces them to behave in a manner that is a 
step closer to the natural conditions. To date, the 3D culture approach has been utilized to 
study more than 380 cell lines. It is also known that the optimal 3D condition requirements 
Chapter 1: Introduction 
41 | P a g e  
 
vary between cell types and the characteristic features of cells in 3D cultures differ in 
accordance to their types241. 
1.8.2 Types of 3D Systems Available 
There are many ways in which to categorise the different types of 3D cell culture systems 
available. The simplest way to start the categorisation is whether the culture relies on an 
external support or scaffold system.  
Common matrix-free methods employed for generating spheroids maintain the cells as 
suspension cultures in media. This can be done by hanging drop technology242-244, where the 
cells aggregate at the bottom of a droplet of media held upside down in special plates and 
drawn together by gravity, figure 1.8.1. Another method uses rotary cultures or rotary 
bioreactors245, the rotation of the culture stops the cells from forming attachments to the 
surface of the flask and means the only aggregation is between the cells forming spheroids. 
A further method is the use of low adhesion plates240, which again forces adherent cells to 
aggregate into spheroids. The overall size of spheroids is limited to a few hundred 
micrometres, beyond which, necrosis ensues within the core of the spheroids246&247. 
Spheroids represent an especially good physiological 3D model for studying solid 
tumorigenesis and stem cell differentiation. In addition, spheroids can be readily analysed 
by imaging using light, fluorescence, and confocal microscopy, which is an advantage over 
more complex 3D cell culture models. Furthermore, it is relatively simple to mass-produce 
uniformly sized 3D spheroids making them highly amenable for many in vitro high 
throughput and toxicity screening applications248. 
 
Figure 1.8-1. Generation of spheroids in a low adhesion plate (Left) and image of a spheroid 
formed in a single well (Right) 240. 
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A further development in the field of spheroids is the improvement of the model by the 
addition of other cell types to better simulate the situation within the body. When more than 
one cell type is involved, and primary cells or iPSCs, are used to allow the model to take on 
features of the tissue that cannot be produced in standard culture, then this is referred to as 
an organoid249. An organoid model is just the next step towards making the spheroid model 
“more realistic”, or in vivo like. An organoid uses different cell types, differentiation states or 
sometimes includes resident immune cells, to make a structure that resembles the 
heterogeneous tissues found in in vivo.  
Another type of 3D culture that does not rely on a support scaffold is explant culture250. This 
is where a section of tissue is excised from the body and kept in culture. Being taken from 
the body the cells can maintain their natural 3D confirmation. 
With emerging technologies, it is now possible to bio-print tissues and cellular models251&252. 
This often involves the placement of cell without the need for a scaffold. Bio-printed tissues 
are useful for numerous reasons and can be so close to natural human tissue that they can 
be used for implants253, where sourcing a tissue type may be problematic and difficult254. 
Hydrogels are comprised of networks of cross-linked polymer chains or complex protein 
molecules of natural or synthetic origin255. Due to their significant water content, hydrogels 
possess biophysical characteristics very similar to natural tissue, and serve as highly effective 
matrices for 3D cell culture. Several cell types also form spheroids in 3D hydrogels256, and to 
a limited extent, in some solid scaffolds depending on the structural and physical properties 
of the material.  
Solid scaffolds for 3D cell culture are fabricated with a broad range of materials including 
metal257, ceramics258, glass258, and polymers259. In particular, polymers are a common choice 
for generating solid scaffolds of diverse size, varying structure, stiffness, porosity, and 
permeability260. A multitude of fabrication techniques are being utilized to generate solid 
scaffolds for 3D cell culture, including soft-lithography260, electrospinning261, 
micropatterning262, printing263, and many others. The major drawbacks of using solid 
scaffolds are problems with cell imaging264 and difficulties that are encountered when 
recovering cells from the matrix265. 
Hollow fibre bioreactors are a 3D culture system that consist of fixed position fibres with cells 
typically seeded on the outside of the porous fibres and media delivered through the fibre 
lumen186. Hollow fibre type culture systems offer an in vivo-like environment with the fibres 
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mimicking blood capillaries and shielding the cells from the shear stresses associated with 
dynamic media delivery, while allowing defined shear stress to be applied to cells the via 
fluid flow outside the fibres if needed266. This creates a versatile culture system with superior 
mass transport in which high cell densities can be reached. This is a design that works 
particularly well with transporter267 or drug penetration studies268&269 as the transfer across 
the fibre and cells can be easily measured. 
1.8.3 2D vs 3D Comparison 
Main advantages of 2D cell cultures are easier environmental control, cell observation, 
measurement and eventual manipulation in comparison to 3D cultures. Furthermore, a rich 
body of literature exists to which outcome measures can be compared186-168. 
The main advantage of 3D is the conformation that the cell is able to take. Cells plated in 2D 
lose the natural shape that they can be found in within the body. Much of the cells surface 
area is lost to the culture plastic and the cell itself flattens and elongates, figure 1.8.2. 3D 
allows the cell to maintain a more accurate representation of its cytoarchitecture270, which 
in turn can affect cell function. 
 
Figure 1.8-2. Diagram showing the different cellular conformation cells take in either 2D or 
3D cell culture271. 
 
3D cell culture allows the cells to interact with other cells on all sides. This is important as it 
allows for more realistic interactions and the formation of important tissue components such 
as tight junctions272. Behaviour of 3D cultures is more similar to in vivo than 2D cultures. Cells 
in 3D culture have been shown to have better growth and survival than that shown by their 
counterparts in 2D273. 
3D cultures have been shown to take on full in vivo characteristics such as the production of 
extracellular matrix274 and the development of bile ducts275 in gut tissues. Another function 
that is essential for the study of some diseases is the ability for a culture to achieve full 
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polarization, such as apical-basal polarity meaning the cell has distinct microenvironments 
within it 242&276. In 3D, the cells can behave more biologically in migration assays277, through 
contacts with relevant cells instead of culture plastic.  
Limitations of 3D culture such as, diffusional transport limitations for oxygen and other 
essential nutrients can cause necrotic cores198&230 and limit the size of culture grown. 
Furthermore, some 3D cultures created from tissues can sometimes contain undesirable 
components like viruses or growth factors. 
1.8.4 3D Culture and Drugs 
In vitro tissue models have been developed to provide a means for systematic, repetitive, 
and quantitative investigation of drugs. By eliminating or reducing the need for animal 
subjects, these models can serve as platforms for more tightly controlled, high-throughput 
screening of drugs and for pharmacokinetic and pharmacodynamics analyses of drugs278. The 
results produced from 3D in vitro drug based assays could be more predictive than animals 
in certain situations as they allow for the use of human cells in a biologically relevant 
situation. 
Culturing cells in 3D could have large effects on drug efficacies. The change in confirmation 
allows more of the surface to be accessible to drug molecules. In addition to this, having a 
working cytostructure270 could affect how the drugs are processed. Further effects such as 
oxygen gradients183 and cell cell signalling194 could also affect drug processing. One study279 
on anticancer drug sensitivity testing on A431.H9 cells showed that cytotoxicity could be 
drastically different in the physiological 3D spheroids formed in the 384 hanging drop array 
plates compared to 2D monolayer cultures in conventional multiwell plates. Specifically, the 
anticancer drug 5-fluorouracil has higher anti-proliferative effects on 2D cultures whereas 
the hypoxia activated drug, commonly referred to as tirapazamine, is more effective against 
3D cultures. 
1.9 Aim and Objectives of this Research 
The aim of the project is to assist the discovery and development of drugs against 
Leishmania, by developing in vitro tissue culture infection models that are more predictive 
of the in vivo infection in humans. 
The objectives of the project are to: 
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I. Establish and compare 2D static and 2D flow cell culture models, in terms of the 
influence of flow on host cell infection and on drug activity. 
II. Develop a 3D tissue culture model of infection. 
III. Use iPSC derived macrophages to determine whether they are a valid alternative to 
currently used cell types. 
These are detailed below: 
Part 1: Establishment of 2D flow models and comparative 2D static systems. Including 
experiments concerning the effect of flow on infection and drug activity.  
The progression of infection and treatment with control drugs was compared, using specially 
developed and adapted methods, in the two conditions of static and flow. Different rates of 
flow were used to demonstrate not only the effect of flow on the model but also the effect 
of the speed of the flow within the system. Then the flow was specifically tuned to match 
the rate of interstitial fluid flow within the skin. Measurements of macrophage status and 
drug accumulation were acquired to help explain the differences. 
 
Part 2: Development of a 3D in vitro model. 
Macrophages were grown using two scaffolds. The models were evaluated for infection and 
response to drugs using fluorescent parasites and confocal imaging. Comparisons of the 3D 
model against 2D controls will elucidate any differences between the systems. 
 
Part 3: Utilization of iPSC derived Macrophages 
Macrophages derived from iPSCs were be used for infection to show their response to drugs. 
The results of infection studies with a variety of parasite strains were compared against the 
infection rates in a panel of other widely used cell types in Leishmania in vitro models. 
Further to this, the efficacies of standard drugs used for the treatment of leishmaniasis were 
measured across the same range of parasites in each of the different cell types used. The 
results of this determined whether iPSCs are a valid alternative to these other cell types and, 
which widely used cell type they behave most similarly to. 
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Chapter 2 Materials and Methods 
2.1 Materials 
Table 2.1-1 Materials used throughout  
Item Company Cat No. 
Roswell Park Memorial Institute 
(RPMI-1640) medium 
Sigma, Gillingham, UK R0883 
L-glutamine Sigma, Gillingham, UK 59202C 
Heat inactivated Fetal Calf Serum 
(HiFCS) 
Harlan, Bicester, UK 
 
Human Macrophage Colony 
Stimulating Factor (hM-CSF) 
Sigma, Gillingham, UK M6518 
Phosphate buffered saline (PBS) Sigma, Gillingham, UK P4417 
Phorbol 12-myristate 13-acetate 
(PMA) 
Sigma, Gillingham, UK P1585 
Schneider’s insect medium Sigma, Gillingham, UKb S0146 
M199 medium Sigma, Gillingham, UK M5017 
Dulbecco's Modified Eagle's medium 
(DMEM) 
Gibco - Thermofisher, 
Paisley, UK 
31966-021 
Penicillin and Streptomycin Sigma, Gillingham, UK P4333 
Giemsa stain Sigma, Gillingham, UK G5637 
miltefosine Nycomed, Aldwych, UK 
 
amphotericin B VWR international E437 
paromomycin sulphate salt Sigma, Gillingham, UK P9297 
sodium stibogluconate Sigma, Gillingham, UK S5319 
Dimethyl sulfoxide (DMSO) Sigma, Gillingham, UK D8418 
Ethylenediaminetetraacetic acid 
(EDTA 
Sigma, Gillingham, UK E6758 
Methanol Sigma, Gillingham, UK 322415 
Fatty acid free Bovine Serum Albumin 
(BSA) 
Sigma, Gillingham, UK A2153 
Formic acid in water Fisher, Loughborough, UK 13484269 
Acetonitrile Sigma, Gillingham, UK 360457 
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Item Company Cat No. 
Tolbutamide Sigma, Gillingham, UK T0891 
Phalloidin Cruz fluor 488 Santa Cruz Biotechnology, 
Heidelberg, DE 
SC-363791 
4',6-Diamidino-2-Phenylindole (Dapi) Sigma, Gillingham, UK D9542 
Synthemax (Plate coating) Corning, Wiesbaden, DE 
 
Gelatine Sigma, Gillingham, UK G1393 
2-mecaptoethanol Sigma, Gillingham, UK M6250 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
(HEPES) 
Fisher, Loughborough, UK BP310-1 
hIL-3 RnD, Abingdon, UK 203-IL-010 
TrypLE™ what is this? Thermofisher, Paisley, UK 12604013 
Starch Sigma, Gillingham, UK 33615 
Alamar Blue   Sigma, Gillingham, UK R7017 
Triton x-100 Sigma, Gillingham, UK X-100 
Paraformaldehyde (PFA) Sigma, Gillingham, UK P6148 
Fluoromount Sigma, Gillingham, UK F4680 
Trisma base Sigma, Gillingham, UK T1503 
Triton X-100 Sigma, Gillingham, UK X100 
phenylmethanesulfonyl fluoride 
(PMSF)  
AppliChem, Stockport, UK A0999 
Nicotinamide adenine dinucleotide 
phosphate (NADPH) 
Sigma, Gillingham, UK NADPH-RO 
Trypanothione disulphide (T[S]2) BAChem, St Helens, UK H-7510 
5,5-dithio- bis 2-nitrobenzoic acid 
(DTNB) 
Sigma, Gillingham, UK D218200 
Ethanol Sigma, Gillingham, UK 652261 
BCA protein assay kit Thermofisher, Paisley, UK 23227 
Edu assay kit Thermofisher, Paisley, UK C10337 
NO detection kit Thermofisher, Paisley, UK G7921 
Lipopolysaccharides E. coli 026:B6  Sigma, Gillingham, UK L8274 
Chapter 2 Materials and Methods 
48 | P a g e  
 
Item  Company Cat No. 
TESR-E8 medium StemCell Technologies, 
Cambridge, UK 
TeSR 05940 
Knockout replacement serum (KSR) Invitrogen - Thermofisher, 
Paisley, UK 
10828-028 
Dispase:Collagenase Sigma, Gillingham, UK COLLDISP-RO 
X-Vivo 15 plus gentamycin Lonza, Slough, UK 04-418Q 
 
Table 2.1-2 Equipment used throughout 
Item Company Cat No. 
Glass coverslips Bellco, New Jersey, US 1943-100 12A 
Peristaltic pumps Parker, Warwick, UK PF22x0204 
96 well low adhesion 
round bottomed plate 
Corning, Wiesbaden, DE CLS7007 
Cryovials Greiner Bio-One, Stonehouse, UK 121263 
T75 Flasks Greiner Bio-One, Stonehouse, UK 658940 
T175 Flasks Greiner Bio-One, Stonehouse, UK 661940 
Spectramax M2 Molecular Devices, Wokingham, UK  
QV500 media perfusions 
system 
Kirkstall Ltd, Rotherham, UK  
QV900 media perfusion 
system 
Kirkstall Ltd, Rotherham, UK  
3D printed insert for 
QV900 
Kirkstall Ltd, Rotherham, UK  
16 well Lab-Tek™ plates VWR International, Leicester, UK 62407-350 
70 μM cell strainer Corning, Wiesbaden, DE CLS431751 
10 cm2 dish Thermofisher, Paisley, UK 150318 
24 well plates Corning, Wiesbaden, DE 353226 
96 well plates Corning, Wiesbaden, DE 353072 
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Table 2.1-3. Cells used 
Cells Company Cat No. 
THP-1 ATCC, Teddington, UK TIB-202 
3T3 Fibroblasts ATCC, Teddington, UK CRL-1658 
MEF CF-1 cells (mouse 
embryonic feeder) 
Amsbio, Abingdon, UK  GSC-6001 
Human bone marrow 
mononuclear cells  
ATCC, Teddington, UK PCS-800_013 
 
Table 2.1-4 Parasites used 
   
Table 2.1-5. Animals used 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 THP-1 cells 
THP-1 cells were maintained in RPMI-1640 medium supplemented with L-glutamine and 10% 
Heat inactivated Fetal Calf Serum (HiFCS). The THP-1 cell line was maintained in an incubator 
at 37°C and 5% CO2 and passaged to new medium once a week (1/10 ratio). 
Parasite Strain Source 
Leishmania major JISH MHOM/SA/85/JISH118  
Leishmania amazonensis DSRed IFLA/BR/1967/PH8 Eric Prina, Institut Pasteur 
Leishmania mexicana MNYC/ BZ/62/M379  
Leishmania major mCherry LV39c5 (RHO/SU/59/P Rosa Reguera, University of 
Leon 
Animal Source Purpose 
CD-1 Charles River, Margate, UK Peritoneal and bone 
marrow macrophages 
BALB/c Charles River, Margate, UK Parasite maintenance 
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2.2.1.2 3T3 Fibroblasts 
3T3 Fibroblasts were maintained in DMEM medium supplemented with L-glutamine and 10% 
HiFCS. The fibroblast cell line was kept in an incubator at 37°C and 5% CO2 and passaged to 
new medium once a week (1/10 ratio) using TrypLE to detach adherent cells. 
2.2.1.3 Peritoneal Macrophage Isolation 
Mouse peritoneal macrophages (PEM) were isolated from CD-1 mice upon peritoneal 
injection with 0.5 mL of 2% starch solution in sterile water. Macrophages were collected by 
abdominal lavage with RPMI-1640 medium containing 1% penicillin and streptomycin. The 
collected cells were centrifuged for 15 minutes at 500 g and 4°C, washed in RPMI-1640 
medium and re-suspended in RPMI-1640 medium containing 10% HiFCS. 
2.2.1.4 Leishmania Culture 
L. major JISH and L. mexicana promastigotes were maintained in Schneider’s insect medium 
(Sigma Aldrich, UK) supplemented with 10% HiFCS at 26°C. 
L. amazonensis DSRed and L. major mCherry were maintained in M199 medium 
supplemented with 10% HiFCS at 26°C. 
Parasites were maintained in a 26°C incubator and passaged to new medium once a week 
(1/20 ratio). 
2.2.1.5 Parasite Maintenance 
Female BALB/c mice of about 6-8 weeks old were purchased and housed in a controlled 
environment of 55% relative humidity and 26°C. They were provided with tap water and a 
standard laboratory diet. All in vivo experiments were carried out under license (PPL 70/6997 
and X20014A54) at the London School of Hygiene and Tropical Medicine (LSHTM) after 
discussion with the veterinarian and according to UK Home Office regulations. 
Female BALB/c mice had their rump shaved and injected with 2x107 stationary phase 
promastigotes (in 200 μl of RPMI 1640 media) subcutaneously on the rump above the tail. 
The mice were inspected daily for the presence of a nodule. After about 7 days, a small 
papule at the site of injection was visible in the infected mice. When an average lesion 
diameter of 5 mm was reached, the mice were sacrificed and the papule was excised. The 
excised papule was inverted and the lesion mass in the dermis was removed from the 
epidermis. The dermis was cut into smaller pieces and placed in 4 mL of RPMI-1640 medium 
containing 10% HiFCS and 1% penicillin and streptomycin for 3-7 days. During this period 
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parasites transformed to promastigotes and then passaged into Schneider’s insect medium 
supplemented with 10% HiFCS kept at 26°C 
2.2.1.6 Cell and Parasite Cryo-storage 
Mid exponential phase parasites were counted using a haemocytometer, then centrifuged 
at 700 g for 10 min (4°C) and re-suspended in RPMI-1640 medium supplemented with 20% 
HiFCS and 10% DMSO to a 2 x 108 cells/mL density. Parasites were aliquoted in 1 mL volumes 
into cryovials.  
Cells were counted using a haemocytometer, then centrifuged at 500 g for 10 min (4°C) and 
re-suspended in RPMI-1640 medium supplemented with 20% HiFCS and 10% DMSO to a 2 x 
107 cells/mL density. Cells were aliquoted in 1 mL volumes into cryovials.  
Cryovials were placed in a Thermo Scientific™ Mr. Frosty™ Freezing Container, and placed in 
a -80°C freezer overnight. The next day cryovials were transferred into liquid nitrogen for 
storage.  
2.3 Static vs Media Perfusion Methods 
2.3.1 Kirkstall Media Perfusion Systems 
Kirkstall Ltd was founded in November 2006 by Dr J Malcolm Wilkinson and is now based in 
Rotherham, UK. The company has an exclusive worldwide licence to patented cell culture 
technology from the University of Pisa, patent number EP2710110. The technology is the 
outcome of over 10 years of research by an interdisciplinary research team in Pisa. Kirkstall 
has developed this research into a commercially available inter-connected cell culture 
system, known as Quasi Vivo®, which can be set up to mimic some aspects of human 
metabolism, resulting in high quality, rather than just high throughput studies. 
2.3.1.1 QuasiVivo 500 Media Perfusion System 
The QV500 cell culture chamber (shown in Figure 2.3.1) is a highly flexible research tool, and 
consists of individual chambers, which allow for maximum flexibility in assay design. 
Produced from medical-grade silicone, the chamber provides a leak proof seal, allowing flow 
of cell culture media across cells. The modular design allows the flow system to be set up in 
a wide range of configurations to best replicate the in vivo environment. The internal 
diameter of the chamber is equal to the well diameter of a 24 well plate, table 2.3-1. 
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Figure 2.3-1. QuasiVivo 500 system 
 
Table 2.3-1. Details of QuasiVivo 500 media perfusion system333.  
Chamber width 15 mm internal 
Chamber depth 10 mm from culture surface to top of chamber 
base 
Materials Chamber: Polydimethylsiloxane (PDMS) 
 
Tubing: Tygon 
 
Luers and reservoir bottle: Polypropylene 
Overall 
dimensions 
23 mm height x 37 mm diameter 
Diameter of 
tubing 
Inlet: 1/16” ID 
 
Outlet: 3/32” ID 
Volume of 
chamber 
2 mL 
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2.3.1.1.1 Construction of QV500 Media Perfusion System 
The QV500 system was arranged as shown in the schematic diagram below, figure 2.3.2. The 
various parts of the system were connected with silicon tubing joined using a luer lock 
system.
 
Figure 2.3-2. Schematic diagram of the QuasiVivo 500 media perfusion systems 
arrangement and construction 
 
2.3.1.1.2 Evaluation of Flow Rates in the QV500 Media Perfusion System 
Once the system was constructed and filled with media, the luer lock between the reservoir 
and the last chamber was opened. The end of the tube coming from the chamber was placed 
in a pre-weighed small container. The system was then run at different speed settings for 
different periods of time until about 1-2 mL of media had been deposited in the container. 
The container was then weighed and the mass of the media was calculated. From this, the 
rate of bulk media transfer was calculated in µL/mL, and are shown in table 2.3-2. 
 
 
 
 
 
Reservoir 
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Table 2.3-2. Details of bulk media transport in the QuasiVivo 500 media perfusion system at 
different pump settings. 
Pump 
Setting 
Bulk media transfer rate µL/min 
1 62 
2 174 
3 281 
4 385 
5 477 
6 580 
7 686 
8 788 
9 888 
10 902 
 
2.3.1.2 QuasiVivo 900 Media Perfusion System 
The QV900 (shown in Figure 2.3.3) is a 6-chamber optical tray providing the same advantages 
of the QV500 but in a compact format. Each tray contains six chambers within the same 
footprint as a standard well plate, all of which have optically clear floors and ceilings to allow 
imaging of cultures in situ, table 2.3-3. Each tray is single use and this helps stop the spread 
of any possible contamination. The nature of the six well plates allows for a much higher 
throughput than the individual chambers with greater ease. A disadvantage of the system is 
that an error in the design before manufacturing means that the dimensions of the QV900 
system does not match those of the QV500. Therefore, the bulk of the modelling conducted 
with QV500 was not applicable to QV900. To rectify this error, Kirkstall have produced a 3D 
printed insert, which will change the depth of the chambers so they match the depth of the 
QV500. Another disadvantage is that due to the stiffness of the material used to make the 
plates, leaks occur far more frequently. A recent effort to stop the plates from leaking is to 
use lids for the wells that have been autoclaved separately. By doing this, the lids are not 
deformed by the autoclave. 
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Figure 2.3-3. Photograph of the QV900 media perfusion system 
 
Table 2.3-3. Details of QuasiVivo 900 media perfusion system334. 
Chamber width 15 mm internal 
Chamber depth 22 mm 
Materials Chamber: 
 
Base: Altuglas SG7 – Acrylic Resin 
 
Lids: Melifex  M8706 – Styrene TEP 
 
Tubing: PTFE & FEP 
 
Luers and reservoir bottle: 
Polypropylene 
Overall 
dimensions 
23 mm height x 37 mm diameter 
Diameter of 
tubing 
Inlet: 1/16” ID 
 
Outlet: 3/32” ID 
Volume of 
chamber 
4 mL 
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2.3.1.2.1 Construction of QV900 Media Perfusion System 
The QV900 system was arranged as in the schematic below, figure 2.3.4. The various parts 
of the system were connected with Teflon tubing joined using a luer lock system. 3D printed 
inserts (Kirkstall Ltd) were produced using Nylon-12 and were shaped to fit the interior of 
the chambers. The depth of the insert was 9 mm and this reduced the depth of the well to 
12 mm, including the pins at the bottom of the well previously used to hold up the glass 
coverslips. When 3D printed inserts were used, they were placed in the final three wells of 
the system, so conditions between cells with or without an insert were identical. 
 
Figure 2.3-4. Schematic of the QuasiVivo 900 media perfusion systems arrangement and 
construction. 
 
2.3.1.2.2 Evaluation of Flow Rates in the QV900 Media Perfusion System 
Measurement of the bulk transfer rate of the QV900 system was measured using the 
protocol in 2.1.1.2. Results of the experiment are in table 2.3-4. 
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Table 2.3-4. Details of the bulk media transport in the QuasiVivo 900 media perfusion system 
at different pump settings. 
Pump 
Setting 
Bulk media transfer rate µL/min 
0.5 36 
1 107 
2 220 
2.5 280 
3 360 
3.5 400 
4 460 
5 584 
6 682 
7 811 
8 947 
9 1074 
10 1169 
 
2.3.2 Differences between Kirkstall Ltd QV500 and QV900 
There are several differences between the two systems such as in the materials used in the 
manufacture of the systems.  
 The QV500 system (Figure 3.3.1) is silicone based and liable to contamination as it 
was a re-useable system, whereas the QV900 system’s (Figure 3.3.1) base is made 
from Altuglas SG7 – Acrylic Resin and the lids from Melifex M8706 – Styrene TEP.  
 Another problem with the silicone is that it is known to adsorb small molecules such 
as drugs. The QV900 shows less drug absorption and release than the QV500 making 
it more suitable for drug studies.  
 The QV900 system has also been equipped with Teflon tubing instead of the silicone 
tubing that the QV500 system uses. This again reduces the drug absorption by the 
system. The layout of the QV900 system allows for a higher throughput assay whilst 
saving time with easier handling.  
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 However, the main difference between these two systems is the well depth, caused 
by a manufacturing error. The QV500 system is 10 mm deep whereas the QV900 
system is 22 mm deep. Originally, the company did not mention this difference 
suggesting that the two systems would behave similarly. It eventually became clear 
that this is not the case. After months of experimentation trying to replicate previous 
results, the schematics were made available and the difference in depth was 
discovered.  
 The extra depth causes a large reduction in both media velocity across the surface 
of the cells and shear stress felt by the cells in the system. 
 The extra depth also affects the chamber volume increasing the volume from 2 ml 
up to 4.4 ml. 
 
 In order to set this problem right, Kirkstall have produced 3D printed inserts that fit 
within the well of the QV900 reducing its depth back to 10 mm and back to the 
original flow velocities and stresses. The insert is a specially designed cylinder made 
from Nylon-12 with a raised cross to support the glass slide on top of it.   
 
2.3.3 Measurement of Cell Viability 
2.3.3.1 Plating of cells 
Cells, either THP1 or peritoneal macropahges were seeded on sterile 12 mm glass cover slips, 
in 24 well plates, in RPMI-1640 supplemented with 10% HiFCS at a density of 4x104 per well. 
If the cells were THP1 cells an additional 20 ng/mL PMA was added to the media. The glass 
coverslips had been sterilised using an autoclave. The glass coverslips were placed in a 37°C 
and 5% CO2 incubator. 
2.3.3.2 Measurement of Cell Viability in Static System 
THP1 cells plated as in 2.3.2.1. After 72 hours incubation at 37°C and 5% CO2, the glass 
coverslips and adhered cells were transferred to a new well. 500 µL of RPMI media containing 
10% Alamar blue was added to each well. An initial fluorescence reading was taken using a 
Spectramax M2 at 530 nm excitation and 580 nm emission, with a 550 nm cut off. The plate 
was incubated in the dark at 37°C and readings were taken every hour. 
2.3.3.3 Measurement of Cell Viability in Kirkstall QV500 Media 
Perfusion System 
THP1 cells plated as in 2.3.3.1. Adherent cells on the glass coverslips were transferred to the 
chamber of the QV500 media perfusion system, which was then placed in the 37°C and 5% 
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CO2 incubator. The media transfer rate was selected and the system was run for 72 hours. 
Subsequently, the glass coverslips and adhered cells were transferred into a 24 well plate. 
Viability readings were taken as in 2.3.3.2. 
2.3.4 Evaluation of L. major Infection Rates 
2.3.4.1 Evaluation of L. major Infection - Static System 
Mouse peritoneal macrophages (PEM) or THP1 cells were as in 2.3.3.1. After 24 hours 
incubation at 37°C and 5% CO2, stationary phase promastigotes were added to the adhered 
cells at several promastigote : host cell ratios (1:1 to 25:1), and maintained at 34°C in a 5% 
CO2 incubator. After 24h, the cell cultures were washed to remove extracellular 
promastigotes and one slide was fixed with methanol and stained with Giemsa to determine 
the initial level of infection. After a further 72 hours incubation, all slides were methanol-
fixed and Giemsa-stained. The percentage infection was determined microscopically (400x 
magnification) by counting the number of infected macrophages in a population size of at 
least 100, then comparing with untreated controls. 
2.3.4.2 Evaluation of Infection - Media Perfusion System 
Infection under Low Flow 
Protocol as in 2.3.4.1 except slides were maintained inside the media perfusion system, for 
72 hours incubating at 34°C and 5% CO2. The peristaltic pump was set to setting one (107 µL 
per minute), table 2.3-4. 
Infection under High Flow 
Experiments were carried out as above except the speed of the peristaltic pump was set to 
setting ten (1169 µL per minute), table 2.3-4.  
Infection with Parasites in Media 
Experiments were carried out as in the infection under low flow section, except the media 
contained stationary phase promastigotes at a variety of ratios. 
Infection with and without 3D Printed Inserts 
Experiments were carried out as the infection under low flow section, except the speed of 
the peristaltic pump was set to setting three (360 µL per minute), table 2.3-4. In addition, a 
3D printed insert were placed in half of the wells of the media perfusion system. 
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2.3.5 Colorimetric Assay For Trypanothione 
Host cells and parasites were chemically lysed by a 15 minute incubation with lysis buffer 
(200 μL/well), consisting of EDTA (1 mM), HEPES (40 mM), Tris (50 mM;pH 7.5), and Triton X-
100 (2% vol/vol). Immediately prior to use, the buffer was supplemented with the protease 
inhibitor phenylmethanesulfonyl fluoride (PMSF) at a final concentration of 1 mM. TryR 
activity was measured in 75 μL of sample lysate. NADPH (25 μL/well), trypanothione 
disulphide (T[S] 2) (75 μL/well) and 5, 5-dithio- bis 2-nitrobenzoic acid (DTNB) (25 μL/well) 
were sequentially added to the sample lysate to yield final concentrations of 200, 75, and 
100 μM, respectively. A blank for each sample, consisting of sample lysate supplemented 
with the reaction mixture described above, in which the substrate T[S] 2 had been replaced 
by Tris (0.05 M) buffer, pH7.5, was included on every plate. Samples were incubated at 26°C 
for three to six hours. After incubation, absorbance was measured at a wavelength of 412 nm 
using a plate reader, Spectramax M2.  Data was compiled in Excel and then analysed in Prism. 
2.3.6 Evaluation of Anti-leishmanial Activity of Compounds 
2.3.6.1 Evaluation of Anti-leishmanial Activity in the Static System 
THP1 cells or PEMs were plated as in 2.3.3.1. After 24 hours incubation at 37°C and 5% CO2, 
the adhered PEMs were infected with stationary phase promastigotes at a ratio of 5 (for 
THP1 cells) or 3 (for PEMs) L. major JISH promastigotes to 1 macrophage and maintained at 
34°C in a 5% CO2 incubator. After 24h, the cultures were washed to remove extracellular 
promastigotes and one slide was fixed with methanol and stained with Giemsa stain to 
determine the initial level of infection. If a sufficient level of infection, (i.e. > 50%) was 
obtained after 24 hours, drugs were added over a pre-determined range of concentrations. 
Miltefosine solutions at concentrations of 20, 5 and 1.25 μM, amphotericin B solutions at 
concentrations of 200, 50 and 12.5 nM, sodium stibogluconate at concentrations of 600, 200 
and 60 ug of SbV/mL or paromomycin sulphate salt at concentrations of 300, 100 and 30 μM 
were added in triplicate at each concentration, on the same plate. After 72 hours incubation, 
all slides were methanol-fixed and Giemsa stained. The percentage reduction of inhibition 
was determined microscopically (400x magnification) by counting the number of infected 
macrophages following drug treatment. Non-linear sigmoidal curve fitting (variable slope) 
was conducted using Prism Software (GraphPad, Surrey, UK).  
2.3.6.2 Evaluation of Anti-leishmanial Activity in the QV900 Media 
Perfusion System 
Experiments were carried out as in 2.3.4.2 (Infection with and without 3D printed insets) 
except cells were infected at a 25:1 (for THP1 cells) or 6:1 (for PEMs) ratio before being 
maintained inside the media perfusion system for 72 hours incubating at 34°C and 5% CO2. 
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The peristaltic pump was set to setting three (360 µL/ min), table 2.3-4. In addition, a 3D 
printed insert were placed in half of the wells of the media perfusion system. 
2.3.7 Measurement of Drug Accumulation in Cells 
2.3.7.1 Drug Accumulation Studies in a Static System 
Experiment was conducted as in 2.3.6.1 except MIL at 20 μM or AmB at 1 µM were added to 
each well. Cultures were maintained for either 4, 8, 12 or 24 hours at 34°C and 5% CO2.  
Slides were transferred to a new 24 well plate and washed three times with PBS. If 
miltefosine was used a back-exchange step to remove membrane-bound miltefosine was 
completed by adding 3% (w/v) fatty acid-free BSA in PBS. Then the cells are washed again in 
PBS. To lyse the cells, 0.1% (v/v) formic acid in water was added and vigorously mixed by 
pipetting up and down every five minutes during a 30 minute incubation at room 
temperature. Lysates were transferred to a microcentrifuge tube with 250 µL acetonitrile, if 
miltefosine was used, or 250 µL of 16% DMSO in methanol, if amphotericin B was used. 200 
ng/mL tolbutamide was used as an internal standard for both drugs. Tubes were then placed 
on a shaker for 10 minutes before being centrifuged 15 min at 4150 g at 4oC. Supernatant 
was transferred into 96 well plates and stored at -80°C. 
A calibration curve was created using untreated cell lysates spiked with known miltefosine 
or amphotericin B concentrations. A further set of blanks were prepared using acetonitrile 
without tolbutamide. 
Frozen plates were taken to Pharmidex Ltd (Stevenage UK), a company specialising in ADMET 
assays with experience in miltefosine and amphotericin B drug accumulation in cells studies. 
Plates were analysed for drug concentration using HPLC-MSMS using an electro-spray 
ionisation on an Agilent 1200 HPLC/Agilent 6410 triple quad under positive ion MSMS mode. 
Data was extracted into Excel files and analysed in both Excel and Prism. 
The remaining lysate was used to measure protein concentration as a measure of cell 
number using a Pierce™ BCA protein assay kit. 
2.3.7.2 Drug Accumulation in the Kirkstall QV900 Media Perfusion 
System 
Experiment conducted as in 2.3.6.2 except PEMs were infected with stationary phase 
promastigotes at a ratio of 6 L. major promastigotes to 1 macrophage and maintained inside 
the QV900 media perfusion system, either at the chamber base or on top of the 3D printed 
inserts.  
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2.3.7.3 Protein Determination Assay 
A working reagent was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA 
reagent B. A standard curve between 0 and 2 mg/mL BSA was constructed. 25 µL of lysate or 
standard curve was added to 200 µL of the working reagent, in a 96 well plate. The plate was 
covered in tin foil and incubated at 37°C for 30 minutes. Absorbance was measured at 562 
nm using the Spectramax M2 plate reader. A standard curve was created in Graphpad Prism 
and values for the samples were interpolated. 
2.3.8 Cell Proliferation - Edu Incorporation Assay 
Invitrogen Click-iT® EdU Imaging Kit was used to measure 5-ethynyl-2´-deoxyuridine (Edu) 
incorporation as a measure of cell proliferation. The kit supplies a labelled DNA base that is 
incorporated only into the cell’s DNA as they synthesise new DNA for cellular division, this 
can then be detected by attaching a fluorescent marker to the label. Experiment conducted 
as in 2.3.3.1 and 2.3.3.2, using the section infection with and without 3D printed inserts, 
except PEMs were infected with a ratio of 3 L. major promastigotes to 1 macrophage and 
maintained at 34°C in a 5% CO2 for 24 hours. Media used contained 50 µM Edu. After 24 
hours, cells were placed in a new 24 well plate and were fixed in 4% PFA for 15 minutes at 
room temperature. The samples were treated with 0.2% Triton X-100 in PBS for 20 minutes 
and then 1% BSA in PBS for 10 minutes. Click-iT® reaction cocktail was prepared according 
to instructions in Invitrogen Click-iT® EdU Imaging Kit. 0.5 mL of Click-iT® reaction cocktail 
was added to each well containing a coverslip. Cells were incubated for 30 minutes at room 
temperature, protected from light. Cells were then washed with 1 mL of 3% BSA in PBS. Cells 
were incubated with 300 mM DAPI stain for 10 minutes. Coverslips were mounted onto slides 
and imaged using a confocal microscope (Zeiss LSM510 Axiovert). Images taken were 40x 
magnification. The lasers used were Laser Diode: 405 nm for DAPI excitation and Argon laser: 
458, 488, 514 nm for Edu excitation. Images captured were analysed using Volocity software 
(PerkinElmer) to automatically count nuclei for total cell number and then the images were 
manually viewed to count number of fluorescent and non-fluorescent parasites within each 
cell. The results were exported and analysed with Graphpad Prism. 
2.3.9 Nitrite Ion Detection using the Griess Assay 
The Griess test detects the presence of nitrite ion in solution, in this case detecting nitrites 
released by the cells as a defence mechanism. The purpose of this experiment is to determine 
if the media perfusion increases the cells response to parasites. PEMs were plated as in 
2.3.3.1 and maintained for 24 hours at 34°C 5% CO2 in either the QV900 media perfusion 
system set to 360 µL/min, using depth reducing inserts in half the wells or in a static plate. 
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All cells were then transferred to a new well in a static 24 well plate and treated with 
10ng/mL lipopolysaccharides, which has been shown to stimulate nitrite release326, for 24 
hours at 34°C 5% CO2. Then 250 µL of media was removed from the wells and an equal 
volume of Griess reagent, made as specified in NO detection kit, was added in a new plate. 
The plate was incubated for 1 hour in the dark at 37°C and then the absorbance at 548 nm 
was found using a plate reader. Values were determined by comparing to a standard curve 
made using sodium nitrite, provided in the NO detection kit. 
2.3.10 Modelling of the Kirkstall QV900 System 
The following section was provided by Lauren Hyndman and Dr Sean McGinty of the 
University of Glasgow who developed a mathematical model of the fluid flow and oxygen 
transport within the QV900 media perfusion system. The purpose of the model was to aid in 
the configuration of the experiments and to quantify the oxygen concentrations and shear 
stresses found within the system. COMSOL Multiphysics, a commercially available finite 
element analysis software, was used to perform simulations for six chambers connected in 
series with cells placed (i) at the base of each chamber, and (ii) on a solid 9 mm insert placed 
at the base of each chamber. Figure 2.3.5 illustrates the computational geometry (of a single 
chamber) which was used in each case. Note that the geometry on the right is shorter 
because the computational domain only includes the parts of the chamber that contain fluid, 
and since the 9 mm insert is solid it is assumed that there is no fluid flow within this region. 
 
 
 
Figure 2.3-5. Idealised 3D geometry of a single QV900 chamber. Note that length scales are 
in m. Left: Geometry for cells placed at the base of the chamber. Right: Geometry for cells 
place on the insert. 
 
Chapter 2 Materials and Methods 
64 | P a g e  
 
The fluid flow was modelled using the Navier-Stokes equations, assuming that the medium 
is an incompressible Newtonian fluid. The transport of oxygen throughout the fluid was 
modelled by convection and diffusion, and within the cells, the oxygen consumption was 
modelled according to Michaelis-Menten kinetics. For simplicity, the values of the 
parameters in these equations were chosen under the assumption that the fluid is water. 
table 2.3-5 lists all the parameter values that were used in the simulations. As the exact value 
of Vmax was unknown for macrophages, the minimum and maximum values of an accepted 
range were chosen in order to demonstrate the effect of varying this parameter. The 
thickness of the cell layer was calculated by dividing the total cell volume by the area covered 
by the cells. 
Table 2.3-5 Parameter values used in the simulations. 
Parameter Description Value Unit 
ρ Fluid density 1 x 103 kg m-3 
μ Fluid dynamic viscosity 1 x 10-3 Pa s 
p Pressure 1 x 103 Pa 
D Oxygen diffusion coefficient in water 3 x 10-9 m2 s-1 
Dc Oxygen diffusion coefficient in cells 1 x 10-9 m2 s-1 
hc Thickness of cell layer 5 x 10-6 m 
Vmax Maximum oxygen consumption rate 1 x 10-2 or 1 x 10-3 mol m-3 s-1 
Km Michaelis-Menten constant 6.3 x 10-3 mol m-3 
ci Inlet oxygen concentration (20% O2) 0.2 mol m-3 
Q Volumetric flow rate 360 μ L min-1 
 
2.4 3D vs 2D methods  
2.4.1 3D Scaffold Selection 
2.4.1.1 Alvetex (UK) 
Reinnervate Ltd was founded in 2002 by Professor Stefan Przyborski as a spinout 
biotechnology company from Durham University, UK. Reinnervate was acquired by 
ReproCELL in 2014 and was merged with Biopta to form ReproCELL Europe Ltd in July 2016.  
Reinnervate’s core strength was in its Alvetex® family of 3D cell culture products, providing 
a flexible platform that allows scientists in any life science laboratory to easily establish 
improved in vitro assays and tissue models that better mimic the in vivo growth of cells. 
Alvetex® is a highly porous polystyrene scaffold designed for 3D cell culture. Each disc of 
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spun polystyrene is engineered to a thickness of just 200 microns with pore sizes of 36-40 
microns. No cell is ever further than 100 microns from the nutrient source enabling easy 
exchange of nutrients, gases and waste products by passive diffusion across short distances. 
Alvetex is completely inert so there is no chance of contaminating biological material that 
can sometimes be found in animal derived scaffolds.  
Alvetex has been designed for simple and routine use. It uses conventional cell culture 
plasticware. It requires no specialist equipment, changes to media or optimized cell feeding 
protocols and is compatible with the majority of downstream analytical techniques. Alvetex 
3D cell culture enables cells to maintain their in vivo morphology, behaviour and 
responsiveness within an in vitro model system. 
2.4.1.2 Invitrocue (Singapore) 
Invitrocue Ltd Singapore is a leading provider of bio-analytic solutions including in vitro cell-
based testing technologies and image analytics software for use in digital pathology. 
Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and 
Research (A*STAR). Invitrocue have been developed and validated in partnerships with 
leading biopharmaceutical companies and scientific collaborators. 
The 3D CelluSponge254 is an innovative in vitro platform for 3D cell culture. It is fabricated 
from inert hydroxypropyl cellulose, has a uniform macroporosity of 80 – 150 μm and each 
disk is 1 mm thick. The controlled macroporosity allows the formation of uniformly sized 
spheroids. This thereby prevents necrosis in the spheroid core by allowing access to nutrients 
without mass transfer limitations. The constrained spheroids have shown excellent 
maintenance of 3D cell morphology, viability, cell-cell interaction, cell polarity, synthetic and 
metabolic functions335. The 3D CelluSponge exhibits minimal drug absorption and offers new 
possibilities for in vitro drug safety testing. 
2.4.2 Cell Seeding Protocols 
2.4.2.1 Alvetex  
Alvetex scaffolds were submerged in 70% ethanol for 10 seconds, then washed in RPMI-
1640. Scaffolds were then placed in a 24 well plate. Cells were washed, centrifuged and re-
suspended at 2x107 per mL in RPMI-1640 supplemented with 10% HiFCS. Cells were seeded 
by pipetting 50 µL directly on to the scaffold. Scaffolds were left at 37°C and 5% CO2 for 45 
minutes then wells were topped up with in RPMI-1640 supplemented with 10% HiFCS and 
replaced in the incubator. 
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2.4.2.2 InvitroCue 
Cells were washed, centrifuged and re-suspended at 4x107 per mL in RPMI-1640 
supplemented with 10% HiFCS. Sponges were placed in the centre of a well in a 24 well plate. 
Cells were seeded by pipetting 25 µL directly on top of the sponge. Sponges were left at 37°C 
and 5% CO2 for 45 minutes then wells were topped up with in RPMI-1640 supplemented with 
10% HiFCS and replaced in the incubator. 
2.4.3 Measurement of Cell Viability 
2.4.3.1 Measurement of Cell Viability in 2D Cultures 
Peritoneal macrophages were seeded in 96 well plates at 1x106 cells/well per mL in RPMI-
1640 supplemented with 10% HiFCS. Cells were incubated in a 37°C and 5% CO2 incubator. 
To take a reading, the media was removed and 100 µL of media containing 10% Alamar blue 
was added to each well. The plate was incubated in the dark at 37°C for an hour. After an 
hour, samples of media were taken and fluorescence was read using a Spectramax M2 at 530 
nm excitation and 580 nm emission with a 550 nm cut off. The media was replaced with 100 
µL of fresh media before cells were replaced in the incubator. 
2.4.3.2 Measurement of Cell Viability in 3D 
Peritoneal macrophages were seeded as in 2.4.2.2 and viability was measured as in 2.4.3.1. 
2.4.4 Evaluation of Leishmania Infection in 3D Cell Culture 
Peritoneal macrophages were plated as in 2.4.2.1 and 2.4.2.2. After 24 hours incubation at 
37°C and 5% CO2, the adhered PEMs in both scaffolds were infected with stationary phase 
promastigotes, by removing the media in the well and replacing with fresh media containing 
promastigotes, at a variety of ratios (0.5:1 to 6:1). Cells were maintained at 34°C and 5% CO2 
for a further 72 hours. The scaffolds were then fixed in 4% PFA overnight at 4°C. The next 
day the scaffolds were treated with 0.2% Triton X-100 in PBS for 10 minutes and then 1% BSA 
in PBS for 10 minutes. Scaffolds were then stained with phalloidin Cruz fluor Actin labelling 
antibody overnight at 4°C on a plate shaker. The next day scaffolds were washed and treated 
with 300 mM DAPI stain for 10 minutes. The percentage infection was determined 
microscopically using Zeiss LSM510 confocal (40x magnification) by counting the number of 
infected macrophages. 
2.4.5 Evaluation of Anti-leishmanial Activity in 3D Cell Culture 
Peritoneal macrophages were plated as in 2.4.2.2. After 24 hours, the adhered PEMs in the 
Invitrocue scaffold were infected with stationary phase promastigotes at a ratio of 5 L. major 
(mCherry) promastigotes or 7 L. amazonensis (DSred2) to 1 macrophage and maintained at 
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34°C in a 5% CO2 for 24 hours. After 24 hours, media was removed from all wells and 
miltefosine at concentrations of 20, 5 and 1.25 μM or amphotericin B at concentrations of 
200, 50 and 12.5 nM were added in triplicate at each concentration. A set of un-drugged 
controls were included in triplicate, by adding just fresh media. After 72 hours, percentage 
infection was assessed as in 2.4.4. 
2.4.6 Confocal Microscopy 
The confocal microscope used was a Zeiss LSM510 Axiovert (Zeiss, Germany) contained 
within an incubation chamber, which can be temperature and CO2 regulated, it uses Zeiss 510 
software for image acquisition.  Images taken with the microscope were usually 40x but it is 
also equipped with x10, x20, x63 and x100 lenses. The following lasers were used Laser 
Diode: 405 nm for DAPI excitation, Argon laser: 458, 488, 514 nm for phalliodin excitation 
and HeNe1 laser: 543 nm for parasite mCherry and RFP excitation. The optical slice was set 
to 1 μm for all lasers, scan speed was set to 8 and image size was set to 512 pixels. Cells were 
found visually using the laser that excites the DAPI stain and then intensities of the lasers 
were adjusted using the software to provide equal intensities for each colour detected. The 
total depth of the z-stack was selected to capture the complete 3D structure of the cells. 
Images captured were analysed either completely automatically by Invitrocue or semi-
automatically at the LSHTM using Volocity software (PerkinElmer) to automatically count 
nuclei for total cell number and then the images were manually viewed to count number of 
infected cells. The results were exported and analysed using Microsoft Excel and Graphpad 
Prism. 
2.5 Cell Choice Methods 
2.5.1 Cell Culture 
2.5.1.1 Induced Pluripotent Stem Cells 
Induced pluripotent stem cells are reprogrammed adult, specialized cells320. The 
reprogramming turns them into pluripotent stem cells meaning they can make any type of 
cell in the body. IPS cells and embryonic stem cells are similar321. They are self-renewing, 
meaning they can divide and produce copies of themselves indefinitely. Both types of stem 
cell can be used to derive nearly any kind of specialized cell under precisely controlled 
conditions in the laboratory. For our purposes, the iPSCs were differentiated to make iPSC 
derived macrophages322 & 323. 
Dr Christine Hale provided training on the culture, differentiation and use of iPSCs at the 
Wellcome Trust Sanger Institute, Genome Research Limited.  
Chapter 2 Materials and Methods 
68 | P a g e  
 
2.5.1.1.1 iPSC Culture 
iPSCs were removed from cyrostorage and thawed. Cells were washed once with TESR-E8 
medium and plated on Synthemax coated 6 well plates and maintained at 37 ˚C 5% CO2 in 
TESR-E8. Once the cells reach about 80% confluence they were harvested with TrypLE and 
divided onto four Synthemax coated 10cm2 dishes. When the cells reached 80% confluence 
they were transferred to a second Synthemax coated 10 cm2 dish. During the culture on 
Synthemax coated plates media was changed daily.  
A vial of MEF CF-1 cells (mouse embryonic feeder) was defrosted and cultured in 2 x 10 cm2 
round tissue culture dishes coated in 0.1% gelatine in MEF media, Advanced DMEM F12 with 
10% HiFCS, L-glutamate and 3.5 μl 2-mecaptoethanol. 
After the cells reached 80% confluence on Synthemax they were harvested with TrypLE, 
washed twice with huiPS base medium (Advanced DMEM/F12, 20% Knockout replacement 
serum (KSR), 1x L-glutamine, 3.5 µL B-mercaptoethanol containing fibroblast growth factor 
(FGF) (7.5 µL per 50 mL) and transferred to 16 MEF CF-1 containing 10 cm2 dishes. This 
process was repeated again after a couple days. After the second passage, the cells were 
isolated with a 1:1 Dispase: Collagenase solution and centrifuged. The pellet after 
resuspension in huiPS base medium at 4 x 105 cells/mL and was then plated at 100 µL per 
well between the well in a 96 well low adhesion round bottomed plate. The plate was then 
centrifuged to stimulate embryo body formation. The plate was then left for 3-4 days in a 
humidified CO2 incubator. 
After 3-4 days, the embryoid bodies were harvested and 16 bodies were placed in each 10 
cm2 dish.  
2.5.1.1.2 iPSC Differentiation 
Embryoid bodies were plated onto 10 cm2 round dishes in monocyte differentiation media, 
X-Vivo 15 plus gentamycin with L-glutamine, B-mercapto-ethanol, hM-CSF (50 ng/mL) and 
hIL-3(25 ng/mL). Media was changed every 7 days and the resulting floating monocytes were 
ready to be harvested after day 21. Harvesting was repeated once a week for up to 100 days. 
Monocytes were harvested and contaminating clumps of stem cells were removed by 
collecting the media and straining through a 70 μM cell strainer (Corning CLS431751). 
Monocytes were centrifuged, re-suspended in macrophage differentiation media, RPMI with 
10% FCS, l-glutamine and hM-CSF (100 ng/mL), prior to re-plating in 10 cm2 round dishes. 
Differentiated macrophages were isolated between day 7-14, TrypLE (5 minutes at 37 oC), to 
remove them from the surface of the dish. 
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2.5.1.2 Mouse Bone Marrow Monocytes 
2.5.1.2.1 Mouse Bone Marrow Monocyte Isolation 
Mice were euthanized by schedule 1 killing, then using aseptic technique, the femurs were 
removed and placed in a plastic dish containing sterile PBS. Femurs were stripped of further 
skin and muscle from legs by holding the end of the bone with forceps and using scissors to 
push muscle downward away from forceps. Leg bones were severed proximal to each joint. 
A 25G needle was used to flush the bone cavity with 5mL of ice cold DMEM, until the bone 
cavity appeared white. Flushed RPMI was collected and then centrifuged before re-
suspending the bone marrow progenitor cells in RPMI 1640 + 10% FCS and 
penicillin/streptomycin. 
2.5.1.2.2 Mouse Bone Marrow Monocyte Differentiation 
The mouse bone marrow monocytes were plated at a concentration of 25 million cells per 
T175 flask. Then extra DMEM + 10% FCS and pen/strep containing macrophage colony 
stimulating factor (m-CSF) was added to give a final concentration of 50 ng/mL of m-CSF. The 
cells were incubated for 7 days in a 37°C incubator before mature macrophages were 
harvested.   
2.5.1.3 Human Bone Marrow Monocytes 
Human bone marrow mononuclear cells were purchased from ATCC (PCS-800_013). 25 
million cells were delivered cryopreserved, these were defrosted and plated. The ATCC have 
characterised these cells to be CD45, CD3, CD8, CD58, CD14, CD19 and CD34 positive 
immediately before freezing. 
2.5.1.3.1 Human Bone Marrow Monocyte Differentiation 
The human bone marrow monocytes were plated at a concentration of 8.3 million cell per 
T175 flask in RPMI 1640 + 10% FCS, pen/strep and 50ng/mL macrophage colony stimulating 
factor m-CSF. The cells were incubated for 7 days in a 37°C incubator before mature 
macrophages were harvested.   
2.5.2 Evaluation of Infection Potential of Cells 
Cells (THP1, Human and mouse bone marrow macrophages and iPSC derived macrophages) 
were seeded in 16 well Lab-Tek™ plates in RPMI-1640 supplemented with 10% HiFCS at a 
density of 2x104 per well. After 24 hours incubation at 37°C and 5% CO2, cells were infected 
with stationary phase promastigotes. A variety of ratios (0.5:1 to 10:1) of L. major JISH 118, 
L. major mCherry, L. mexicana M379 and L. amazonensis DSred2 were used and maintained 
at 34°C in a 5% CO2. After 24h, the cultures had the media replaced to remove extracellular 
promastigotes and one slide was fixed with methanol and stained with Giemsa to determine 
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the initial level of infection. After a further 72 hours incubation, all slides were methanol-
fixed and either Giemsa-stained or stained for use with the confocal microscope. The 
percentage inhibition was determined microscopically (400x magnification) by counting the 
infected macrophages. 
2.5.3 Evaluation of anti-leishmanial drug activity 
Experiment conducted as in 2.5.2. Except, after 24 hours incubation at 37°C and 5% CO2, cells 
were infected with stationary phase promastigotes at a ratio of promastigotes to 
macrophage, pre-selected using the results of the 2.5.2. Parasite strains L. major JISH 118, L. 
major mCherry, L. mexicana M379 and L. amazonensis DSred2 were used. In addition, drugs 
were added for the 72 hours incubation at a variety of concentrations. Miltefosine solutions 
at concentrations of 30, 10, 5 and 1.25 μM, amphotericin B solutions at concentrations of 
300, 100, 50 and 10 nM or sodium stibogluconate at concentrations of 600, 300, 100 and 50 
ug of Sb/mL were added in triplicate at each concentration. 
2.6 Statistical Analysis and Computer Packages 
2.6.1 General Statistics 
Data was first formatted and normalised in Microsoft excel and then transferred into Prism 
Software. The Hill coefficient, EC50 and EC90 values were determined by non-linear sigmoidal 
curve fitting (variable slope) and statistics carried out using the built in functions.   
2.6.2 3D Imaging Software 
As previously mentioned, images were taken using Zeiss 510 software. The images were then 
processed in either Zeiss image browser or Volocity. Zeiss image browser was used to view 
images, add scale bars, make videos and publish images in other file formats. The Volocity 
software was used to analyse the images to quantify infection. 
2.7 Ethical Clearance 
All animal experiments were conducted under license (project license 70/6997 or 
X20014A54) in accordance with UK Home Office approval, EU regulations, EU directive 
2010/63/EU and the ethics committee at the LSHTM. At all stages the 3Rs (replacement, 
reduction and refinement) were taken into consideration. The overall aim of the project was 
to help develop models that could be used as a replacement for some animal experiments. 
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Chapter 3 Development of a Media Perfusion System 
Model for Leishmaniasis 
3.1 Introduction 
The aim of this thesis is to investigate different ways in which the current in vitro model 
systems could be more predictive of in vivo results. Current approaches are based upon both 
2D cell assays and in vivo mouse models, both of which may not accurately reflect the 
infection in humans. Three methods of potentially improving reliability and predictability in 
models are investigated in this thesis. In this first results chapter the development of a 
dynamic media perfusion system for in vitro assays is addressed. 
Static systems have been the most commonly used in vitro assay to measure the infection 
rates and drug activities against Leishmania parasites in most laboratories. A variety of plates 
with different well numbers, from 2 wells per plate up to 6144 wells, are widely available for 
purchase and have been used in Leishmaniasis assays173. This form of in vitro assay is based 
upon continuous exposure of infected cells for 48/72 hours. However, it does not offer any 
form of dynamic chemical or physical stimulus to cells. This is a major limitation in 
experiments investigating cellular responses in vitro since the complex interplay of 
mechanical and biochemical factors is absent. 
 
The use of a dynamic media perfusion system can stimulate cells by creating: concentration 
gradients, flow, pressure and mechanical stress caused by movement of fluids around 
them133. The media can be set to a single pass or used in a re-circulating system depending 
on the purpose of the assay. With enough knowledge of the system, the exact conditions can 
be carefully controlled to simulate several aspects of an in vivo system. 
 
For the introduction of fluid flow into the in vitro model, a macro fluidic system was chosen 
over microfluidic systems, as this would allow easier manipulation of the parameters of the 
system. One important factor for the choice of a macro system is that it would allow for the 
eventual creation and sustainment of a reconstituted skin model that was large enough for 
use in the testing of topical medicines. Another important consideration was the retrieval of 
cells post experiment, this is critical for the study of Leishmania parasites in vitro, as the main 
method of evaluation is microscopic counting of infected cells157. 
 
The Quasi Vivo system from Kirkstall Ltd was selected as not only is it a macro fluidic system, 
but also because it can provide a variety of fluid flow rates which includes the range of 
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interstitial fluid flow rates in the skin and at the same time a low shear stress environment. 
For CL, the interstitial fluid flow rate in the skin is the condition that the system aims to 
replicate. Interstitial fluid is the fluid that is found between the cells in a multicellular 
organism, the movement of the fluid in the skin is caused by the normal leakage of plasma 
from blood vessels and drainage into the lymphatic system. Although the exact velocity of 
this flow may vary, measurements have suggested that the interstitial fluid flow rates in 
human skin are of the order of 0.1–2 μms−1 233-235. The Quasi vivo systems are able to produce 
this rate of fluid flow consistently and were designed specially with easy inter-changeable 
layouts and the ability to remove cells after the completion of the experiment.  
 
The work covered in this section for Leishmania has almost no precedence in the literature 
and almost all of the experiments conducted have never been previously reported to the 
best of my knowledge. Notable work in the area of Leishmania by Miller and Twohy280, 
involved using a perfusion model for the infection of mouse peritoneal macrophages with L. 
donovani. They used a media perfusion system to observe the infection of the macrophages 
by leptomonads, however they did not, include the rate of media perfusion, the reasons 
behind the experiment, or comment on any differences between their experiment and the 
static alternative.  
 
Other examples of media perfusion systems used in other infectious disease areas are also 
rare, although the use of microfluidics in this area is growing. The malaria and Leishmania 
parasites are both vector-borne protozoan parasites with different life cycle stages. The 
malaria parasite has a specific blood stage to its life cycle and this environment is highly 
dynamic. Microfluidic devices have been used to model this dynamic environment to study 
the maturation of P. falciparum and its effect on the deformability of infected red blood 
cells281&282. One study showed that P. falciparum decreases the deformability of infected red 
blood cells, increasing their clearance as they attempt to pass through endothelial slits of the 
splenic sinus281. Another previous study on P. vivax infected erythrocytes reached different 
conclusion with respect to cellular deformability282. A variety of bacterial models, such as 
ones simulating the dynamic environments in the gut exist. One such model is used to model 
bacterial attachment283 and another colonisation284 of E. coli. Media perfusion is used in 
these models to simulate gut movements and demonstrate the strength of binding between 
bacteria and the gut wall. In some cases, a media perfusion system is used for the 
maintenance and production of cells before the testing of infectious disease285.  One example 
Chapter 3 Development of a Media Perfusion System Model for Leishmaniasis 
73 | P a g e  
 
where the media perfusion is just as important for the function of the host cells is in the liver 
and in models of hepatitis C286. A direct modelling of hepatitis replication was studied using 
a microfluidic device and showed that it is an adequate system for virus infection286. Other 
infections by viruses have been studied with microfluidic devices, one such example is the 
infection of cells from Spodoptera frugiperda by baculovirus287. 
 
The objectives of this study were: 
I. To set up an in vitro media perfused model of macrophages in the skin. 
II. To determine viability of host cells in the Quasi Vivo macrofluidic system. 
III. To establish methods to detect the infection within the system. 
IV. To establish an infection and determine the infection potential within the system.  
 
3.2 Investigation of Cell Viability Differences between Cells 
Maintained under Static or Media Perfusion Conditions 
Media perfusion systems have been reported288&289 to maintain cell viability for longer in 
both 2D and 3D cell culture systems. To investigate if the same effect was seen using the 
Kirkstall QV500 system THP1 macrophages were plated and maintained either under media 
perfusion or static conditions. The system was then left to run for 72 hours, which is the same 
period used in a standard three day drug assay. The viability of the cells was assessed using 
an Alamar blue assay, which is a measure of mitochondrial metabolism290. The Alamar blue 
assay is based upon the compound resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) 
which is weakly fluorescent. The conversion of resazurin to resorufin (7-Hydroxyphenoxazin-
3-one) by the cells is an irreversible reduction giving a red fluorescent molecule. 
Mitochondrial metabolism is a good measure of cell viability as non-viable cells will not be 
able to process and metabolise the dye. Resazurin based assays show excellent correlation332 
to other viability assays such as formazan-based assays, whilst being easier and safer to use. 
If the media perfusion maintains the cell viability better than the static system then the 
fluorescent signal produced by the resorufin will be higher. 
3.2.1 Cell Viability Differences between Cells Maintained 
under Static or Media Perfusion Conditions 
In the first experiment, shown in figure 3.2-1, after four hours of incubation with Alamar 
blue, the fluorescent reading of the cells maintained under media perfusion conditions had 
increased to an average of 1210 RFU. Whereas, the fluorescence reading of cells maintained 
in static conditions, had increased to an average of 390 RFU. Using a student T-test, to 
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compare viability between the static system and media perfusion, set to 50 µL/min, viability 
in the media perfusion system is statistically higher (p<0.0001).  
In the second experiment (0-7 hours), figure 3.2-1, cells maintained under media perfusion 
conditions and a bulk transfer rate of 50 µl/min had increased this fluorescent read out to 
an average of 5308 RFU after 7 hours, whereas the cells maintained in a static system had 
only increased the read out to an average of 3273 RFU. The cells maintained under media 
perfusion conditions with a bulk transfer rate of 100 µL/min had increased this fluorescent 
read out to an average of 8115 RFU after 7 hours. Using a student T-test viability was 
compared between the static system and the QV500 media perfusion system, set to 50 
µL/min, viability in the media perfusion system was statistically higher (p<0.0001). When the 
perfusion system was set to 100 µL/min, viability in the media perfusion system was again 
statistically higher, p<0.0001. If the two speeds of the media perfusion system were 
compared viability at 100 µL/min was statistically higher than the 50 µL/min, p<0.0001. A 
linear relationship between fluorescent signal and time for each of the three conditions can 
be seen in figure 3.2-1. This shows that the assay is in the linear stage of the reaction and has 
not reached the limit of detection of the plate reader after 7 hours.  
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Figure 3.2-1. Turnover of Alamar blue by cells maintained under either static or media 
perfusion conditions (50 µL/min or 100 µL/min) measured over a period of 0-7 hours. N =3 
Error bars show SD 
 
3.2.2 Discussion of Cell Viability Differences between Cells 
Maintained under Static or Media Perfusion Conditions 
The data shows that even at a speed of 50 µL/min the media perfusion system better 
maintains the viability of the cells when compared to the static condition. This is further 
evident when increasing the flow speed. A reason for this difference in viability could be an 
increased availability of nutrients in the media or the increased rate of potentially harmful 
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waste products removal. From the literature, it is clear that different types of cells have 
different responses to media perfusion and are comfortable over a particular range of 
speeds. Thus, it can be expected that whilst increasing the speed of media perfusion better 
maintains the viability of these macrophages, the increase will not continue exponentially 
and eventually the increased media perfusion speed will cause damage to the cells and a 
decrease in cell viability291&292.   
3.3 Change of Media Perfusion Systems from Kirkstall Ltd 
QV500 to QV900 
3.3.1 Rationale behind Change of Media Perfusion System 
The QV media perfusion system is a complex system with many interchangeable parts; one 
challenge when using this system is maintaining sterility. The QV500 media perfusion system 
is a multi-use system, which can be re-used if cleaned correctly between uses. Cleaning the 
system before and after each experiment is meant to maintain sterility but the 
deconstruction and re-construction of the system each time allows contaminants an 
opportunity to enter the system. The problem of bacterial contamination caused a series of 
failed and aborted experiments, this problem was then investigated. Despite the QV500 
system being regularly flushed with both 70% and 100% ethanol and autoclaved between 
uses, the bacterial contamination was still present. A test of the system, using nothing but 
filtered RPMI-1640, still yielded a contaminated system. The result of the experiments was 
realisation the bacterial contamination was coming from the system itself. After contact with 
the Kirkstall Ltd, who produce the system, it was concluded that the bacteria had grown into 
the systems silicone pores and autoclaving would not be effective to remove the colonies.  
Due to the contamination issues, it was decided to switch to the QV900 system, relying on 
single use disposable plates, which would avoid any recurrence of contamination between 
assays. 
3.4 In Silico Modelling of Media Perfusion Systems 
3.4.1 Modelling of the Kirkstall Ltd QV500 Media Perfusion 
System 
The modelling of the fluid flow rates and the stresses that this causes for cells within the 
QV500 system was first reported in two publications: Ahluwalia (2010)219: A low shear 
stress modular bioreactor for connected cell culture under high flow rates and Ahluwalia 
(2014)360: Design Criteria for Generating Physiologically Relevant In Vitro Models in 
Bioreactors. Authors of these papers were part of the original team who designed the 
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QV500 system before Kirkstall Ltd spun out from the project. The modelling in these 
papers was used to choose a bulk flow speed that matched the flow velocity at the cell 
surface to the interstitial fluid flow rate. The selected value from the papers was 360 
µL/min bulk flow. This translates to 1 µm/s in flow velocity across the cell surface, which 
is the value for interstitial fluid flow rate in human skin233-235. 
3.4.2 Modelling of the Kirkstall Ltd QV900 Media Perfusion 
System  
3.4.2.1 Modelling of Cells Maintained at the Base of the Well when 
the Maximum Rate of Oxygen Consumption (Vmax) = 1e-3 mol/m3/s 
 Visual representations of the results of the modelling conducted in COMSOL, which is 
a modelling software, are shown in figure 3.4-1. The figure shows the modelling of the 
first chamber, of six chambers, each containing cells connected in series with the 
maximum oxygen consumption rate of the cells set to 1 x 10-3mol/m3/s. The top left 
image of figure 3.4-1 shows the oxygen concentrations throughout the first chamber in 
the series, showing a decrease in the oxygen concentration moving from the inlet of the 
chamber to the bottom of the chamber. This is partially due to the oxygen diffusion and 
convection within the system. In addition, the cells at the bottom of the well are using 
the oxygen for metabolism and this further reduces the oxygen concentration within 
the media at the bottom of the chamber. The middle left image of figure 3.4-1 is a 2D 
representation of the oxygen concentrations at the bottom of the well. Oxygen 
concentrations reduce from left to right across the bottom of the well due to this being 
the direction of travel of the media, and the oxygen being used up by the cells. This 
reduction in oxygen concentration is graphically displayed in the bottom left image of 
figure 3.4-1. The oxygen concentrations range from 0.1898 mol/m3 down to 0.1864 
mol/m3 across the base of the chamber. Values showing the oxygen concentrations for 
each of the six chambers connected in series are shown on the bottom right of figure 
3.4-1. The oxygen concentrations are lower in each consecutive chamber but the 
pattern of the spread of oxygen concentrations across the base of the chamber is the 
same in each chamber. By the time the final chamber is measured, the maximum oxygen 
concentration has fallen to 0.1889 mol/m3 and the minimum to 0.1855 mol/m3. 
The top right image of figure 3.4-1 shows a representation of the streamlines, showing 
how the media travels through the chamber. It also shows the flow velocity of the media 
throughout the chamber. The depth of the well allows flow recirculation zones at the 
bottom of the well. In this area, the media is recirculated and this could result in oxygen 
or drug molecules being trapped. The image shows that the media velocity is fastest at 
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the inlet and outlet. The flow velocity of the media at the base of the well where the 
cells are is 1.74 x 10-9 m/s. The flow velocity across all six chambers is consistent and is, 
on average, 1.75 ± 0.01 x 10-9 m/s. 
The middle right image of figure 3.4-1 shows a 2D representation of the magnitude of 
shear stress the cells are under at the bottom of the well. The shear stress is highest in 
the centre of the well and was reduced nearer the edges. The shear stress values range 
from 3.52 x 10-7 Pa, at the centre of the chamber, down to 1.51 x 10-11 Pa, at the edges 
of the chamber. The shear stress across all six chambers is consistent and is on average 
3.53 ± 0.03 x 10-7 Pa, at its maximum value, and the minimum value is identical across 
all wells at 1.51 x 10-11 Pa. 
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Figure 3.4-1. COMSOL results for cells at the base of the chamber and Vmax = 1 x 10-3 
mol/m3/s. Upper left: Oxygen concentration in chamber 1. Upper right: Flow profile in 
chamber 1. Middle left: Cell surface oxygen concentration in chamber 1. Middle right: 
Magnitude of the cell surface shear stress in chamber 1. Bottom left: Cell surface oxygen 
concentration profile in chamber 1. Bottom right: Cell surface oxygen concentration profiles 
for all 6 chambers. 
 
3.4.2.2 Modelling of Cells Maintained at the Base of the Well when 
the Maximum Rate of Oxygen Consumption (Vmax) = 1e-2 mol/m3/s 
Visual representations of the results of the modelling are shown in figure 3.4-2. The 
figure shows the modelling of the first chamber of six chambers each containing cells 
connected in series with the maximum oxygen consumption rate of the cells set to 1 x 
10-2 mol/m3/s. The images show the same results as before. The pattern of results is 
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identical; however, the values produced by this simulation are different. Oxygen 
concentrations range from 0.1009 mol/m3 down to 0.0703 mol/m3 across the bottom of 
the chamber. The oxygen concentrations are lower in each consecutive chamber but 
the pattern of the spread of oxygen concentrations across the base of the chamber is 
the same in each chamber. By the time the final chamber is measured, the maximum 
oxygen concentration has fallen to 0.0925 mol/m3 and the minimum to 0.0623 mol/m3. 
The flow velocity of the media at the base of the well where the cells are is 1.74 x 10-9 
m/s. This is identical to the previous (figure 3.4-1) above with a lower maximum oxygen 
consumption. The shear stress values range from 3.52 x 10-7 Pa at the centre of the 
chamber down to 1.51 x 10-11 Pa at the edges of the chamber. This is also identical and 
follows directly from the fact that the flow velocities are identical as in the previous 
simulation. The flow velocity and shear stress values in each of the six chambers are 
identical to the values produced in the previous simulation. 
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Figure 3.4-2. COMSOL results for cells at the base of the chamber and Vmax = 1 x 10-2 
mol/m3/s. Upper left: Oxygen concentration in chamber 1. Upper right: Flow profile in 
chamber 1. Middle left: Cell surface oxygen concentration in chamber 1. Middle right: 
Magnitude of the cell surface shear stress in chamber 1. Lower left: Cell surface oxygen 
concentration profile in chamber 1. Lower right: Cell surface oxygen concentration profiles 
for all 6 chambers. 
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3.4.2.3 Modelling of Cells Maintained on Top of the 9mm Insert 
when the Maximum Rate of Oxygen Consumption (Vmax) = 1e-3 
mol/m3/s 
Visual representations of the results of the modelling, conducted in COMSOL, on the 
first chamber of six chambers connected in series, each with a 9 mm insert placed inside 
the chamber to reduce its depth, are shown in figure 3.4-3.  The maximum oxygen 
consumption rate was set to 1 x 10-3 mol/m3/s, the accepted value for HEPG2 cells, as 
the value for macrophages is unknown. The images shown represent the same 
parameters as before, oxygen concentration, flow velocity and shear stress. When the 
9 mm insert was placed inside the chambers, the insert changed both the pattern of 
results observed and the values produced in the simulation. The top left image of figure 
3.4-3 showing the oxygen concentrations throughout the chamber. The reduction in the 
height of the well means that the oxygen concentration seen is higher throughout the 
whole chamber. There is reduced oxygen concentrations at the edges of the chamber 
caused by recirculation of the media, leading to maximum oxygen concentrations being 
found closer to the centre of the chamber. The oxygen concentrations range from 
0.1979 mol/m3 at the centre of the well down to 0.1937 mol/m3 at the far right hand 
side of the chamber. Values showing the oxygen concentrations for each of the six 
chambers connected in series are shown in the bottom right of figure 3.4-3. The oxygen 
in the final chamber ranges from 0.1969 mol/m3  to 0.1927 mol/m3. 
The top right image of figure 3.4-3 shows a representation of the streamlines of the 
movement of the media in the chamber. The streamlines in the reduced depth well 
(figure 3.4-3) are clearly more horizontal to the base of the chamber than in the deeper 
well (figure 3.4-1). The flow velocity of the media at the base of the well where the cells 
are is 1.46 x 10-7 m/s. The flow velocity across all six chambers is consistent and, is on 
average, 1.46 ± 0.01 x 10-7 m/s. 
The middle right image of figure 3.4-3 shows a 2D representation of the magnitude of 
the shear stress the cells are under across the bottom of the well. This variation in shear 
stress is graphically displayed in the bottom right image of figure 3.4-3. The shear stress 
values range from 2.95 x 10-5 Pa at the centre of the chamber down to 4.42 x 10-11 Pa at 
the edges of the chamber. The shear stress across all six chambers is consistent, and is 
on average 2.96 ± 0.02 x 10-5 Pa at its maximum value and the minimum value is on 
average 4.35 ± 0.92 x 10-11 Pa, across all wells. 
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Figure 3.4-3. COMSOL results for cells on top of the 9mm insert and Vmax = 1 x 10-3 
mol/m3/s. Upper left: Oxygen concentration in chamber 1. Upper right: Flow profile in 
chamber 1. Middle left: Cell surface oxygen concentration in chamber 1. Middle right: 
Magnitude of the cell surface shear stress in chamber 1. Lower left: Cell surface oxygen 
concentration profile in chamber 1. Lower right: Cell surface oxygen concentration profiles 
for all 6 chambers. 
 
3.4.2.4 Modelling of Cells Maintained on Top of the 9mm Insert 
when the Maximum Rate of Oxygen Consumption (Vmax) = 1e-2 
mol/m3/s 
 Visual representations of the results of the modelling conducted are shown in figure 
3.4-4. The maximum oxygen consumption rate set to 1 x 10-2 mol/m3/s. The images show 
the same results as before. The pattern of results is identical; however, the values 
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produced by this simulation are different. The oxygen concentrations range from 0.1797 
mol/m3 at the centre of the chamber down to 0.1382 mol/m3 at the far right hand side 
of the chamber. Values showing the oxygen concentrations for each of the six chambers 
connected in series are shown in the bottom right of figure 3.4-4. By the time the final 
chamber is measured, the maximum oxygen concentration has fallen to 0.1696 mol/m3 
and the minimum to 0.1285 mol/m3. 
The top right image of figure 3.4-4 shows the flow velocity of the media at the base of 
the well where the cells are is 1.46 x 10-7 m/s. The shear stress values range from 2.95 x 
10-5 Pa down to 4.42 x 10-11 Pa. The flow velocity and shear stress values in each of the 
six chambers are identical to the values produced in the previous simulation. 
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Figure 3.4-4. COMSOL results for cells on top of the 9mm insert and Vmax = 1 x 10-3 
mol/m3/s. Upper left: Oxygen concentration in chamber 1. Upper right: Flow profile in 
chamber 1. Middle left: Cell surface oxygen concentration in chamber 1. Middle right: 
Magnitude of the cell surface shear stress in chamber 1. Lower left: Cell surface oxygen 
concentration profile in chamber 1. Lower right: Cell surface oxygen concentration profiles 
for all 6 chambers. 
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3.4.3 Comparisons between the Kirkstall Ltd QV500 and 
QV900 Media Perfusion Systems 
A range of values are quoted in the literature for the speed of interstitial fluid flow in the skin 
under normal conditions. These values are between 0.1 and 2 µm/s233-235, this is the range 
that the velocity of media in the system should aim to be within. As stated, the value selected 
for bulk media transfer based from the equations, in the papers that modelled the QV500 
system, was 360 µL/min. According to the equations in the papers, this translates to a media 
velocity of 1 µm/s across the surface of the cell in the QV500 media perfusion system. This 
was chosen to be in the middle of the range using a pump set to setting three on the controls. 
It was assumed that the systems would have the same chamber size and depth. Therefore, 
a bulk media transfer rate of 360 µL/min was also chosen, as the bulk media transfer rate in 
the QV900 system. However, the results from the modelling of the QV900 show that the 
velocity of the media at the surface of the cells is actually 1.75±0.01 nm/s. This is 1000 times 
less than the media velocity that the system was expected to produce. This explains why the 
results of the earlier viability studies in the QV500 system could not be repeated in the 
QV900 system. 
When comparing the QV500 system to the QV900 system with the depth correcting insert 
the maximum velocity of the media again does not match that of the original system. Using 
the same 360 µL/min bulk media transfer rate gives a media velocity across the surface of 
the cells of 0.15 µm/s. This value is about seven times less than what was expected. Despite 
this, the value for media velocity across the cell surface produced by the QV900 system with 
an insert included in each chamber still fits within the reported range of interstitial fluid flow 
rates within human skin. 
3.4.4 Comparisons between the Kirkstall Ltd QV900 Media 
Perfusion System with or without an Insert 
The results from the modelling analysis of the QV900 shows that when the cells are placed 
on the bottom of the chamber, the velocity of the media at the surface of the cells is 
1.75±0.01 nm/s and the sheer stress is 36.4±0.2 nPa. When a 3D printed insert is included in 
the well, in order to reduce the depth back to matching the QV500 depth, the results from 
the modelling show the velocity of the media at the cell surface to be 146±1 nm/s, and the 
sheer stress is on average 3.76±0.02 µPa. The values from the system with the inserts 
included are about 100 times higher than without the insert. When the oxygen concentration 
values are compared, the values are very similar when the maximum oxygen consumption is 
set to 1 x 10-2 mol/m3/s. Although, when the maximum oxygen consumption rate is set to 1 
x 10-3 mol/m3/s the oxygen concentration in the chambers with an insert is nearly twice as 
Chapter 3 Development of a Media Perfusion System Model for Leishmaniasis 
86 | P a g e  
 
high. In chambers without an insert, the maximum oxygen concentration is 0.1 mol/m3 and 
the minimum is 0.07 mol/m3. When comparing to the values of oxygen concentration in 
chambers with an insert, 0.1797 mol/m3 at maximum and 0.1382 mol/m3 as a minimum 
value, a difference is seen that is dependent on both chamber depth and maximum oxygen 
consumption rate. 
3.4.5 Limitations of the Model 
Whilst the modelling provides us with a calculated estimation of the system, it is only as good 
as the parameters used in its construction. All models require an iterative process of 
improvement to become closer to the in vivo situation. The parameters concerning the 
behaviour of the media is modelled using parameters from water, a change which is widely 
used in fluidic models. We have also set the maximum oxygen consumptions to the accepted 
value for HEPG2 cells, and then raised the value by one order of magnitude in order to assess 
the effect that an increased oxygen consumption may have on the model. The Michaelis-
Menten constant, a constraint of a well-characterised kinetic model used in this case for 
measuring the rate of oxygen consumption, is set to a value accepted for many cell types. 
However, these are all estimates of the true values hence the data produced by the model is 
also an estimate of how the system functions with regards to oxygen consumption. 
3.5 Development of a Colorimetric Assay to Measure the 
Influence of Drugs on the Infection of Cells by 
Leishmania 
3.5.1 Introduction 
Colorimetric assays are assays that use a colour change or colour development that can be 
detected either by absorbance or fluorescence. Advantages of a colorimetric screening 
method are a reduction in both time taken and cost. Results can be produced in a much 
shorter time allowing a much larger number of compounds to be tested in each experiment. 
They are also compatible with the development of in vitro 3D cell culture methods, where 
conventional microscopy is more difficult. 
A trypanothione reductase (TryR) based assay was carried out as detailed in Van den Bogaart 
et al (2014)165.  The assay is based on the fact that TryR is only found in kinetoplasts, such as 
Leishmania, and has a specific substrate allowing a measurement of substrate turnover to be 
directly relatable to number of parasites in a culture. Trypanothione reductase is an essential 
component of the unique kinetoplast thiol-redox metabolism, and was used to assess the 
viability of the Leishmania parasites by monitoring the colour change of 5,5-dithio- bis 2-
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nitrobenzoic acid (DTNB) as it is reduced. This reaction combines the TryR-catalysed 
reduction of trypanothione disulphide (T[S] 2) with its in situ regeneration through DTNB, as 
shown in figure 3.5-1.  
 
Figure 3.5-1. Schematic of the DTNB-coupled reaction165. 
 
The optical density of the blank, which consisted of all the reaction components except the 
DNTB, was subtracted from the corresponding sample signal, yielding the TryR activity, which 
correlated to the number of parasites present in each sample. As only the parasite contains 
TryR, the assay directly measures the number of parasites in the culture with no interference 
from the host cells. 
3.5.2 Method Development for the Colorimetric Assay 
Initially we were unable to reproduce the assay reported by van den Bogart et al (2014). 
Therefore, the assay was tested using different concentrations of promastigotes (2 x 105 – 1.2 
x 106 per mL), different durations of incubation (1 hour to 48 hours) and different species of 
parasite. To start with, no signal was produced at any concentration of promastigote, after 
any duration of incubation with the reagents. Eventually a signal was detected using a high 
concentration of promastigotes (8 x 107), which was being used as a positive control and this 
enabled validation of the assay and the data recording sensitivity of the plate reader.  
The first goal was to determine whether there was a correlation between parasite number 
and the colorimetric titre. Initial experiments yielded little data, as only very high 
concentrations of parasite (1-8 x 107 cells) gave a signal. This meant our assay had a problem 
with sensitivity. The results from high concentrations of parasites allowed us to confirm the 
linearity of the signal over a concentration range of parasites and the use of a cell-only 
negative control. 
A visit to the group who developed the assay gave a better understanding of the assay. The 
sensitivity problem had been caused by the degradation of the trypanothine reductase as 
the protease inhibitor; phenylmethanesulfonyl fluoride (PMSF) was insoluble in water and 
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therefore not available in solution. This was not mentioned in the paper and an alternative 
solvent, isopropanol was subsequently selected.  
As the final step in the development of the assay, the results from the colorimetric assay were 
matched to the results from an identical experiment where percentage infection was 
determined by microscopic counting. An assay measuring the activity of amphotericin B on 
L. major infected THP1 cells was conducted, using both the colorimetric assay and the 
established counting assay; results were compared allowing validation of the colorimetric 
assay for the measurement of drug activity. There was a difference between the two 
methods, with the counting method consistently giving lower EC50 values.  The difference 
between the results from the colorimetric assay and the counting was caused by the 
measurement of extracellular parasites during the colorimetric assay. To overcome this 
problem, the cells were incubated with media containing horse serum, which is known to 
remove the extracellular parasites as horse serum is less rich in nutrients and growth factors 
than fetal calf serum. Another difference between the detection methods is that the 
colorimetric method measures parasite burden i.e. total number of parasites. Whereas, the 
microscopic counting shows percentage infection i.e. number of cells that are infected. 
Burden could be counted, but in certain cells the quality of the dye, overlapping of parasites 
and cells make this difficult and time consuming. 
3.5.3 Development Results for the Colorimetric Assay 
3.5.3.1 Determination of the Correlation between Parasite Number 
and the Colorimetric Titre 
L. major JISH 118 parasites at different concentrations (1 x 105 – 7 x 105 per mL) were lysed 
and tested for signal using the colorimetric assay. Correlation between parasite number and 
colorimetric result can be seen in figure 3.5-2. A linear increase was seen showing that the 
signal produced was directly proportional to the number of parasites within the sample. 
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Figure 3.5-2. Graph showing a linear increase in signal with increasing concentration of 
parasite. Graph shows A412 reading after 6 hours of incubation. N =3 Error bars show SD, 
error bars are excluded if smaller then symbols. 
 
3.5.3.2 Validation of the Colorimetric Assay against Microscopic 
Counting 
To validate the use of the trypanothione reductase based assay for assessing viability of the 
intracellular Leishmania amastigote, the activity of the two reference drugs, figure 3.5-3, was 
measured against L. major. Light microscopy was used in comparison, as it is the 
conventional method to measure drug efficacies in Leishmania dose-response assays. 
Table 3.5-1 EC50 determined by Graphpad Prism 
 
EC50 values seen, table 3.5-1, are similar to previously reported values in the literature330. A 
one-way repeated measure ANOVA shows that there were significant differences between 
the curves (figure 3.5-2) for the treatment of THP-1 cells with amphotericin B. Statistically 
significant differences were seen between both colorimetric assays and the counting method 
(p<0.01). 
EC50 values for the activity of miltefosine, seen in table 3.5-1, given in this assay are lower 
than what is often reported in the literature72 &331, but does still fit with previously produced 
EC50 Colorimetric assay 1 Colorimetric assay 2 Counting 
amphotericin B (95% 
CI) (nM) 
34.54 (28.74 to 
41.51) 
28.42 (23.21 to 
34.79) 
22.15 (21.29 to 
23.04) 
Miltefosine (95% CI) 
(µM) 
8.49 (6.25 to 11.54) 8.56 (6.37 to 11.49) 2.98 (2.64 to 3.36) 
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values. Significant differences are seen between the results of the counting method and the 
colorimetric assay (p<0.0001, one-way repeated measure ANOVA). 
 The results from the colorimetric assay show a lower reduction in the percentage infection 
than the counting analysis suggests. The reason for this was the resulting signal from 
extracellular parasites still attached to the cells. When microscopically counting these 
extracellular parasites are not counted. In the colorimetric assay, the extracellular parasites 
contribute to overall signal, which would make it appear higher than it should be and less of 
a reduction would be seen. To improve the assay extracellular promastigotes need to be 
removed, this can be done with horse serum treatment post drugging as part of the 
experiment296. 
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Figure 3.5-3. Dose-response curves showing the reduction in infection of THP-1 cells 
produced by treatment with amphotericin B (Left) or miltefosine (right). Curves were fitted 
by Prism with a variable slope and maximum and minimum set to 0 and 100%. The 
reduction in infection was measured either by the colorimetric assay or by microscopic 
counting and scaled to a reduction in total infection seen in the untreated control. N =3 
Error bars show SD 
 
3.5.4 Colorimetric Assay with Horse Serum Treatment to 
Remove Extracellular Promastigotes 
The activity of the two reference drugs, figure 3.5-4, was measured against L. major; horse 
serum was used to reduce extracellular promastigotes. The process by which the horse 
serum reduces the number of extracellular promastigotes is not known, however, it is known 
that horse serum is less rich in nutrients and growth factors than fetal bovine serum, and this 
could contribute to the observed effect296. 
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Table 3.5-2 EC50 by Graphpad Prism 
 
The EC50 value for the activity of amphotericin B, seen in table 3.5-2 and figure 3.5-4, using 
the colorimetric assay closely matches the EC50 value when the reduction in infection was 
measured by microscopic counting. These values are both similar to what is reported in the 
literature330.  The EC50 values produced after the addition of horse serum show a stronger 
similarity than in the previous experiment. EC50 values of the counting method were not 
affected by the horse serum treatment. The horse serum treatment, however, does produce 
a difference in the colorimetric assay, giving a more comparable result to the counting 
method. A student t-test shows that there was still significant differences (p<0.01), between 
the colorimetric assay and the counting method. 
The EC50 value for the activity of miltefosine, seen in figure 3.5-4 and table 3.5-2, are closer 
in value than in previous assays. The EC50 values produced by this experiment are much closer 
to what is seen in the literature72. The horse serum treatment has reduced the signal 
generated by extracellular promastigotes and this has reduced the EC50 value produced by 
the colorimetric assay, reducing the differences between the two assays. A two-way student 
t-test shows that there was still a significant difference (p<0.0001), between the two 
methods of analysis, but to a much lower degree than in the previous experiments without 
a horse serum treatment post experiment. There may still some extracellular promastigotes 
detected by the colorimetric assay interfering with the results of the experiment. 
EC50 Colorimetric Counting 
amphotericin B (95% CI) 
(nM) 
29.93 (23.79 to 37.64) 23.44 (22.48 to 24.45) 
Miltefosine (95% CI)  (µM) 5.96 (4.33 to 8.20) 3.81 (3.48 to 4.17) 
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Figure 3.5-4. Dose response curves showing the reduction in L. major infection of THP-1 
cells produced by treatment with amphotericin B or miltefosine. Curves were fitted by 
Prism with a variable slope and maximum and minimum set to 0 and 100%. The reduction 
in infection was measured either by the colorimetric assay or by microscopic counting and 
scaled to a reduction in total infection seen in the untreated control. N =3 Error bars show 
SD 
 
To prove that the colorimetric assay would also work when mouse peritoneal macrophages 
were used instead of THP1 cells, an experiment to determine the efficacy of amphotericin B 
was conducted using peritoneal macrophages, shown in figure 3.5-5. An EC50 value of 29.6 
nM (95% CI = 22.17 to 39.42 nM) was seen using the colorimetric assay without horse serum 
treatment and 74.1 nM (95% CI = 46.6 to 117.7 nM) with a horse serum treatment. The EC50 
value when the reduction in infection was measured by microscopic counting was 55.2 nM 
(95% CI = 52.9 to 57.5 nM). The EC50 values produced by this experiment are similar to what 
is seen in the literature72. Significant differences are seen when comparing the counting 
method to both of the colorimetric assays, (p<0.0001).  
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Figure 3.5-5. Dose-response curves showing the reduction of L. major infection of mouse 
peritoneal macrophages produced by treatment using amphotericin B. Curves were fitted 
by Prism with a variable slope and maximum and minimum set to 0 and 100%. The 
reduction in infection was measured either by the colorimetric assay or by microscopic 
counting and scaled to a reduction in total infection seen in the untreated control. N =3 
Error bars show SD 
 
Despite wash steps, it can be seen under the microscope that promastigotes are still present 
in the culture around the host cells. If the number of wash steps are increased then this could 
lead to the cells being damaged. The horse serum treatment has been shown to reduce the 
number of extracellular promastigotes296 whilst having no effect on the host cells. When the 
horse serum was used, the signal produced by the colorimetric assay was more closely 
related to the values achieved by microscopic counting. The use of horse serum to remove 
extracellular parasites is both important to the assay and better than alternatives such as 
repeated wash steps. 
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3.5.5 Evaluation of the Colorimetric Assay for Determining 
Drug Efficacies 
This colorimetric assay works, the signal produced by the assay was proportional to the 
number of parasites in the system. It has also been used to produce results in a drug efficacy 
determination assay, which can be matched to microscopic counting. This validated the assay 
for use with this specific strain of L. major. This assay is useful and reduces the time taken 
from the start of analysis to results. 
The results produced in this section do both match and reinforce the data shown in the paper 
describing the use of this trypanothione reductase based assay165. Both have shown the 
relationship between the numbers of Leishmania parasites and the signal produced by the 
colorimetric assay. Both have also used the assay to assess drug efficacies and produced 
values that match microscopic counting methods and figures seen in literature 72&165. 
However, the colorimetric assay is a continuous recording method that measures total 
parasite burden, whereas microscopic counting is a discrete method that measures the 
number of infected cells. Whilst these two measures should show the same trend, they will 
never perfectly line up due to the differences in what the assays measure. 
3.5.6 Using the Colorimetric Assay for Screening of 
Compounds 
This colorimetric assay was used to screen eleven unknown compounds from the pathogen 
box, produced by the Medicines for Malaria Venture. The pathogen box contains 400 diverse, 
drug-like molecules active against neglected diseases of interest and is available free of 
charge. The compounds had previously had their EC50 values determined by microscopic 
counting, table 3.5-3, and were used in order to measure the ability of the colorimetric assay 
to rank compounds in potency order and further validate its ability to produce results table 
3.5-3, that match those produced using the conventional counting method. 
Determination of the EC50 values for some compounds displaying weak anti-leishmanial 
activities and poorly fitted dose-response curves, were not always feasible, and hence were 
classified as >30 µM. The level of correlation and agreement between the trypanothione 
reductase based assay, and the microscopic assessments was analysed with a scatter plot 
and the Bland-Altman plot. The scatter plot showed a significantly high level of correlation 
between the results from the two assays giving an R squared value of 0.9492 and a p<0.0001 
in a Spearman’s rank correlation test.  In the Bland-Altman plot (Figure 3.5-6), all points were 
scattered around a mean difference of 0.097, and all but one point fell within one standard 
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deviation of this mean. This mean difference was the average difference seen between the 
two methods of drug efficacy determination. If the values fall between one standard 
deviation then this is considered noise. The Bland-Altman plot allows assay bias to be taken 
into account and results can be scaled between assays to give more representative values. 
Overall, the correlation between the colorimetric assay and the counting method, 
considered the gold standard for in vitro assays, was strong. This validates its use in screening 
assays as a quicker and more efficient way to rank the strength of compounds against 
Leishmania. Doing the colorimetric assay first would allow compounds that were weak, or 
showed no anti-leishmanial activity, to be removed before time is wasted on the compounds 
used in other (more time-consuming) assays. 
 
Table 3.5-3  EC50 values (95% confidence interval) for 11 compounds from the pathogen box 
and standard drug controls of amphotericin B and miltefosine. N =3 
  L. major JISH 118 
  Trypanothione assay (µM) Microscopic assay (µM) 
Standard drugs     
amphotericin B 0.04 (0.02-0.08) 0.03 (0.03-0.04) 
miltefosine 8.00 (3.25-20.90) 19.59 (17.45-21.99) 
Pathogen box compounds     
MMV676158 >30 >30 
MMV676057 7.25 (3.71-13.49) 13.02 (11.46-14.79) 
MMV676005 >30 >30 
MMV676001 2.95 (2.10-3.81) 9.00 (wide) 
MMV676169 >30 >30 
S2621 3.46 (1.70-5.70) 3.15 (wide) 
MMV688263 23.65 (19.59-27.70) >30 
MMV688274 8.66 (6.51-12.07) 12.37 (9.88-15.49) 
MMV688273 9.52 (4.45-14.22) 10.43 (wide) 
MMV688283 7.13 (4.17-12.98) 8.51 (wide) 
MMV688272 >30 >30 
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Figure 3.5-6. A Bland-Altman plot of the EC50 values of 11 selected compounds of the 
pathogen box between the TryR-based assay and the microscopic assessments. The mean 
difference of the Bland-Altman plot was 0.097. The upper and lower limits of agreement 
(mean ± SD) are 0.25 and -0.06, respectively.  
 
3.6 Evaluation of Infection 
3.6.1 Rationale 
The first step in exploring how the media perfusion system affects the treatment of a 
Leishmania infection was to establish an infection within the system. To demonstrate the 
direct effect of flow on the process of infection with L. major parasites, a variety of flow rates 
have been studied. Initial conditions have been varied to try to establish a high infection that 
will reflect and match the infection seen in the static system. It is important that the overall 
levels of infection match, as they will need to be the same to avoid dose inoculum effects 
when testing drug efficacy. 
3.6.2 Evaluation of Infection in a Static System 
3.6.2.1 Evaluation of L. major Infection of THP1 Cells 
Increasing the initial ratio of parasite to host cell increases the percentage infection after 72 
hours of co-incubation, shown in figure 3.6-1. At the lowest ratio of parasites to THP1 cells, 
the 1:1 infection ratio, the infection after 72 hours is, on average, 37%. The overall 
percentage infection using initial infection ratios from 6:1 up to 15:1 are all very similar and 
have essentially reached the maximum infection possible. The ideal percentage infection is 
between 80-90% hence the best infection ratio for THP-1 cells is a 4:1 ratio of parasites to 
THP-1 cells. 
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A one-way ANOVA showed a significant difference between ratio 1:1 and all other results, 
p<0.0001. There are also significant differences between ratio 3:1 and 4:1, p<0.05 and all 
other data sets p<0.0001. The data set from infection using an initial ratio of 4:1 shows a 
significant difference from 6:1, p<0.01, 10:1 and 12:1, p<0.001 and 15:1, p<0.05. The other 
data sets show no significant differences. 
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Figure 3.6-1. Box and whisker diagram showing the percentage of THP-1 cells infected after 
72 hours co-incubation with different ratios of L. major promastigotes. N =9 
 
3.6.2.2 Evaluation of L. major Infection in Mouse Peritoneal 
Macrophages 
The trend of an increase in initial infection ratio giving an increase in percentage infection 
after 72 hours was also found for mouse peritoneal macrophages (table 3.6-1). When the 
initial infection ratio was 1:1 the average percentage infection was 86%, which is the 
optimum level of infection and therefore 1:1 is the optimum infection ratio. When the data 
was analysed, using a one-way ANOVA, all ratios are significantly different from each other, 
p<0.0001, apart from ratio 3:1 when compared to ratio 6:1. 
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Table 3.6-1 Percentage infection of mouse peritoneal macrophage when exposed to L. major 
promastigotes at different ratios. N =9 
 
0.5:1 
Static 
1:1 
Static 
3:1 
Static 
6:1 
Static 
Minimum 53.00 82.00 100.00 100.00 
Maximum 67.00 86.00 100.00 100.00 
     
Mean 58.50 84.17 100.00 100.00 
Std. 
Deviation 
5.96 1.47 0.00 0.00 
 
3.6.3 Evaluation of L. major Infection in THP1 Cells in the 
QV900 Media Perfusion System using a Media Flow Rate of 50 
µl/min 
THP-1 cells were infected with different ratios of a mixed population of stationary phase L. 
major promastigotes then maintained in static culture for 24 hours. This was to allow the 
establishment of infection.  Subsequently, the QV900 media perfusion system was set to a 
bulk media transfer rate of 50µL/min, which was the minimum reproducible rate of bulk 
media transfer possible using the peristaltic pumps available at this time. 
Once again, increasing the initial ratio of parasite to host cell increases the percentage 
infection after 72 hours in both the static, conducted in parallel to test the influence of flow, 
and the media perfusion system, shown in figure 3.6-2. Although, the percentage infection 
increases as the initial infection ratio increases, the percentage infection seen in the cells 
maintained under media perfusions conditions was consistently lower. At a 1:1 infection 
ratio, the infection after 72 hours was on average 37% in the static system; however, it was 
only 16% in the media perfusion system. This pattern of a higher infection in the static system 
compared to the media perfusion system continues with each different initial ratio used. At 
a 3:1 infection ratio, the infection after 72 hours was on average 74% in the static system 
whereas; it was only 29% in the media perfusion system. Similarly, at a 4:1 infection ratio, 
the infection after 72 hours was on average 83% in the static system; however, it was 32% in 
the media perfusion system. The overall percentage infection using initial infection ratios of 
6:1 up to 15:1 are all very similar, around 100% infection for the static system, having 
essentially reached the maximum infection possible. However, the media perfusion system, 
even at the highest initial infection ratio of 15:1, only reaches an infection percentage of 81% 
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after 72 hours of incubation. A ratio of 15:1, in the media perfusion system, the percentage 
infection in the media perfusion system was still rather lower than optimum.  
When comparing the same initial infection ratio between the two conditions of static or 
media perfusion, significant differences, p<0.0001, are seen in a one-way ANOVA. An 
interesting example where there was no significant difference was seen between 1:1 ratio in 
the static system and the 3:1, 4:1 and 6:1 infection ratios under media perfusion conditions. 
This shows that the percentage infection after 72 hours when using a 1:1 infection ratio in 
the static system was equivalent to the percentage infection seen when infecting with an 
initial ratio of either 3:1, 4:1 or 6:1 in the media perfusion system. Similarly, a 3:1 ratio of 
infection in the static system was not significantly different from 10:1, 12:1 and 15:1 infection 
ratios under media perfusion conditions. 
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Figure 3.6-2. Percentage of THP-1 cells infected after 72 hours co-incubation with different 
ratios of L. major promastigotes in static or flow conditions. * = p<0.05 **** = p<0.0001 
Error bars = maximum and minimum values N =9 
 
3.6.4 Evaluation of L. major Infection in THP1 Cells in the 
QV900 Media Perfusion System under a Flow Rate of 1000 
µl/min 
The results of the previous experiment showed that media perfusion decreased the overall 
percentage infection after 72 hours. In this set of experiments using a higher rate of bulk 
media transfer (1000 vs 50 µL/min), higher initial infection ratios were used. Once again, the 
percentage infection seen in the cells, which have been maintained in the media perfusion 
Chapter 3 Development of a Media Perfusion System Model for Leishmaniasis 
100 | P a g e  
 
system, was consistently lower than the infection seen in the static system, using the same 
initial infection ratios, as seen in figure 3.6-3. At an 8:1 infection ratio, the infection after 72 
hours was on average 89% in the static system; however, it was only 30% in the media 
perfusion system. This pattern of a higher infection in the static system compared to the 
media perfusion system continues with each different initial ratio used. At a 10:1 infection 
ratio, the infection after 72 hours was on average 94% in the static system whereas; it was 
only 44% in the media perfusion system. Similarly, at a 12:1 infection ratio, the infection after 
72 hours was on average 94% in the static system; however, it was 70% in the media 
perfusion system. At 15:1 in the static system 92% after 72 hours of incubation compared to 
the media perfusion system where the overall average infection was 77%. All matching ratio 
data sets are significantly different from each other when static and flow are compared, 
using a one-way ANOVA, p<0.0001.  
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Figure 3.6-3. Box and whisker diagram showing the percentage of THP-1 cells infected after 
72 hours co-incubation with different ratios of L. major promastigotes either in static or 
flow conditions. **** = p<0.0001 Error bars = maximum and minimum values N =9 
 
3.6.5 Evaluation of L. major Infection of THP1 Cells with 
Leishmania Parasites in the Perfusion Media 
The QV900 media perfusion system was set to a bulk media transfer rate of 50 µL/min. 
Increasing the initial ratio of parasite to host cell increases the percentage infection after 72 
hours in both the static and the media perfusion system, shown in figure 3.6-4. However, the 
cells maintained for 72 hours in the QV900 media perfusion system with parasites in the 
media have achieved a higher percentage infection when compared to the static system. The 
percentage infection of the cells maintained in the static system was on average 23%. When 
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compared to the 55% infection seen in the cells maintained under the media perfusion 
system, it was clear that there was a much higher overall percentage infection after 72 hours 
in the media perfusion system. This result was repeated using an initial infection ratio of 3:1, 
when the static system shows 49% infection compared to the media perfusions systems 84%. 
All matching ratio data sets are significantly different from each other when static and flow 
are compared, using a one-way ANOVA,  p<0.0001.  
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Figure 3.6-4. Box and whisker diagram showing the percentage of THP-1 cells infected after 
72 hours co-incubation with different ratios of L. major promastigotes either in static or 
flow conditions. **** = p<0.0001 Error bars = maximum and minimum values N =9 
 
In the experiment where parasites are in the circulating media, the infection percentage after 
72 hours was higher in the media perfusion system than in the static system, seen in figure 
3.6-4. In this model, the circulating media has a constant ratio of parasites per mL: number 
of host cells per mL in the initial plating media. This method leads to a good infection rate in 
the media perfusion system, however, there would be a vast difference between total 
number of parasites used between flow and static systems. What appears to happen is the 
parasites are carried in the perfusion media, pushed into the wells and then, as flow velocity 
reduces a number of parasites remain at the bottom of the well, trapped in recirculation 
zones. This causes a local increase of parasite number in the bottom of the wells and 
increases the effective parasite to host cell ratio. This could be why the infection in flow 
conditions were much higher than in the static conditions. However, using this method 
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meant that there was many extracellular promastigotes in the media. Drug used to treat 
infected cells in this system will also have an effect on the extracellular promastigotes. 
Another problem would be with so many promastigotes around the cells, the possibility for 
re-infection would be high. For this reason, it was concluded that, this model of the system 
using promastigotes in the perfusion media would not be the model that would be used in 
future experiments. 
3.6.6 Evaluation of L. major Infection with and without 3D 
Printed Inserts Included in the QV900 Media Perfusion System 
3.6.6.1 Evaluation of L. major Infection in THP1 Cells with and 
without 3D Printed Inserts Included in the QV900 Media Perfusion 
System 
The QV900 media perfusion system was set to a bulk media transfer rate of 50µL/min. Depth 
reducing inserts were included in the QV900 system’s chambers to increase the flow velocity 
by reducing the depth, providing additional conditions for the experiment. Previous 
observations can be seen again in figure 3.6-5; showing increasing the initial ratio of parasite 
to host cell increases the percentage infection after 72 hours and that the application of flow 
reduces the overall percentage infection after 72 hours. In addition to this, the inclusion of a 
depth-reducing insert further reduces the overall percentage infection seen in the cells after 
72 hours. At a 15:1 infection ratio, the infection after 72 hours was on average 100% in the 
static system, 81% in the media perfusion system without insert and 67% in the media 
perfusion system when an insert was included. This pattern of a higher infection in the static 
system compared to the media perfusion system was seen again at a 25:1 infection ratio. 
Here the infection after 72 hours was on average 100% in the static system; 86% in the media 
perfusion system and 75% when the chamber contains an insert. The optimal percentage 
infection is between 80-90% hence the best infection ratio for THP-1 cells in the media 
perfusion system is an initial infection of a 25:1 parasite to host cell ratio, with no insert and 
a bulk transfer speed of 50µL/min.  The optimum percentage infection, using an insert and a 
bulk media transfer rate of 50µL/min, was not achieved in the range of infection ratios 
tested.  
All matching ratio data sets are significantly different from each other when static and flow, 
with or without an insert, are compared, using a one-way ANOVA. Achieving the required 
percentage infection level after 72 hours, under media perfusion conditions with an insert, 
would involve a higher parasite to host cell ratio, which would not be representative of the 
situation in the body360.  
Chapter 3 Development of a Media Perfusion System Model for Leishmaniasis 
103 | P a g e  
 
 
In fe c t io n  in  T H P 1  c e lls  u n d e r  th re e  c o n d it io n s
1
5
:1
 S
t
a
t
ic
1
5
:1
 F
lo
w
1
5
:1
 I
n
s
e
r
t
2
5
:1
 S
t
a
t
ic
2
5
:1
 F
lo
w
2
5
:1
 I
n
s
e
r
t
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
P a ra s ite  to   H o s t  C e ll  R a t io  a n d  C o n d itio n
%
  
In
fe
c
ti
o
n
* * *
* *
* *
*
* * * *
* * * *
 
Figure 3.6-5. Percentage of THP-1 cells infected after 72 hours co-incubation with different 
ratios of L. major promastigotes either in static or flow conditions, with or without an 
insert. * = p<0.05 ** = p<0.01 *** = p<0.01 **** = p<0.0001 Error bars = maximum and 
minimum values N =9 
 
3.6.6.2 Evaluation of L. major Infection in Mouse Peritoneal 
Macrophages with and without 3D Printed Inserts Included in the QV900 
Media Perfusion System 
Mouse peritoneal macrophages were chosen, to test if suitable overall percentage infection 
after 72 hours can be reached. The QV900 media perfusion system was kept at a bulk media 
transfer rate of 360 µL/min. As before, depth reducing inserts were placed in the QV900 
system’s chambers to increase the flow velocity and provide additional conditions for the 
experiment.  Peritoneal macrophages show the exact same trend as the THP-1 cells but with 
lower initial infection ratios, figure 3.6-6. At a 0.5:1 infection ratio, the infection after 72 
hours was on average 59% in the static system, 40% in the media perfusion system without 
insert and 24% in the media perfusion system with an insert. At a 1:1 infection ratio the 
infection after 72 hours was on average 85% in the static system; 62% in the media perfusion 
system and 55% in the presence of an insert. As the static system nears maximum infection, 
the differences between the three conditions grow smaller. At a 3:1 infection ratio, the 
infection after 72 hours was on average 100% in the static system, 93% in the media 
Chapter 3 Development of a Media Perfusion System Model for Leishmaniasis 
104 | P a g e  
 
perfusion system without insert and 83% in the media perfusion system with an insert. When 
a 6:1 infection ratio was used all three conditions show similar infection percentages. The 
optimal initial infection ratio for mouse peritoneal macrophages in the media perfusion 
system was a 3:1 parasite to host cell ratio.  
Comparing the data, using a one-way ANOVA, all matching data sets showed significant 
differences from each other except the data sets from the 6:1 ratio comparisons. 
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Figure 3.6-6. Box and whisker diagram showing the percentage of mouse peritoneal 
macrophages infected after 72 hours co-incubation with different ratios of L. major 
promastigotes either in static or flow conditions, with or without an insert. **** = p<0.0001 
** = p<0.01 Error bars = maximum and minimum values N =9. 
 
3.6.7 Comparison of L. major Infection in THP1 Cells at 
Different Media Perfusion Velocities 
A comparison of L. major infections in THP1 cells at an initial infection ratio of 15:1 across all 
the different conditions, except experiments where parasites were included in the media for 
the 72-hour incubation, is seen in figure 3.6-7. The higher the velocity of the media across 
the surface of the cells the lower the percentage infection. The percentage infection in the 
static condition was on average 93%. When a bulk flow of 50 µL/min was applied, the 
percentage infection was on average 81%. The mean percentage infection of the cells under 
higher bulk transfer rates, 360 µL/min and 1000µL/min are similar to the percentage 
infection when the bulk transfer rate was 50 µL/min. When the flow velocity across the cell 
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surface was increased by presence of an insert the average level of infection falls to 67%. 
When comparing the two conditions that are under the same volume of bulk flow, 
360µL/min, but with or without an insert the average infection drops from 81% down to 67%. 
This shows the increased velocity of media across the surface of the cells must cause this 
reduction of infection. 
When the data was compared, using a one-way ANOVA, all data sets show significant 
differences from the static condition. In addition to this the percentage infection levels are 
significantly different between the conditions of a bulk media transfer of 50µL/min and 
360µl/min when using an insert, p<0.05.  
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Figure 3.6-7. Box and whisker diagram showing a comparison of the percentage infection of 
THP-1 cells after 72 hours infected with an initial 15:1 infection ratio with L. major 
promastigotes either in all conditions tested using either a static system or a media perfusion 
system. * = p<0.05 *** = p<0.001 **** = p<0.0001 Error bars = maximum and minimum 
values N =9 
 
3.6.8 Discussion 
It is important to produce a high infection of between 80-90% in each condition in order to 
have a large population of infected macrophages available for treatment with compounds in 
efficacy experiments. If a system has too many external parasites, often found when using a 
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high infection ratio, then re-infection by promastigotes may bias the data. If a system has 
too few parasites then there will not be a large enough population of infected cells in order 
for drugs to have a measurable effect on. It is important to produce similar levels of infection 
between the two systems, to avoid dose inoculum effects, which is where a difference in 
infection levels and amastigote number could alter the EC50 and EC90 values in a drug assay. 
A drug that is able to reduce the percentage infection level from 100% down to 50% may 
appear the same as a different drug that has reduced the percentage infection from 50% 
down to 25%, as they both have halved the percentage of infected host cells. However, the 
first 50% reduction will have cleared a different parasite load whilst appearing the same in 
terms of overall reduction in percentage infection.  
It is clear from the experiments that for future assays the initial infection ratios used in the 
static and flow systems will need to be different, in order to provide the same level of 
percentage infection after 72 hours. The model that uses a 24-hour pre-incubation of the 
cells with parasites, before transfer to the media perfusion system, matches the schematic 
of the static experiment; both have a 24-hour pre-incubation before the addition of drug. 
This means that the cells, treated with the same infection ratio, have similar percentage 
infection levels after 24-hours, before they are transferred to the media perfusion system. 
Therefore, the difference between the two systems must be either due to a difference in 
parasite division within the host cell or a difference in invasion of host cell by any parasites 
remaining in the culture after the transfer to the media perfusion system or to a new well in 
the static culture. 
The data shows the progression of the infection was hindered by the application of flow, and 
that the faster the media velocity across the surface of the cells, the lower the percentage 
infection resulting from the same initial infection ratio. This could possibly be because the 
movement of the flow would limit the chances of successful parasite phagocytosis by the 
host cell, by causing the parasites to be rapidly moving and keeping them away from the cell 
surface293 & 294. A reduction in the time the parasites spend in contact with the cells could 
stop successful phagocytosis.  
Another reason could be that the cells are more viable in the media perfusion systems and 
hence are more quickly able to adapt and resist infection or able to naturally kill the parasite. 
Media perfusion systems have been used to show up-regulation or maintenance of gene 
regulation in HEPG2 cells295. If this was similar in macrophages then there is potential for the 
cells to either be primed by the media perfusion having a much faster response when the 
parasites are detected.  
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A further possibility is that the parasites struggle to survive in the dynamic flow conditions. 
The parasites that have remained on the glass slide during the transfer to the media 
perfusion system could be wasting energy swimming against the flow of the media, to reach 
the cells. If the parasites have less energy, they could be less able to divide. 
Another conclusion from this set of experiments was that the choice of cell used in 
experiments needs consideration. Data shows that the mouse peritoneal macrophages are 
more easily infected, and lower initial ratios of parasite to host cell can be used when 
compared to the THP1 cells. An infection ratio of 1:1 using THP1 cells gives an average of 
36.67% infection compared to an infection rate of 84.67% when using peritoneal 
macrophages. For this reason, it was decided that in future experiments peritoneal 
macrophages would be the cell used. 
3.7 Investigation of L. major Amastigote Division in the 
QV900 Media Perfusion System 
3.7.1 Rationale 
The reduced percentage infection seen in the media perfusion system could be related to 
the rate of parasite division within the system. To determine whether this was the case, a 5-
ethynyl-2´-deoxyuridine (Edu) incorporation assay was conducted. The principle of the Edu 
assay is that only cells that are actively dividing will incorporate the Edu, a nucleoside analog 
of thymidine. The Edu contains an alkyne that an Alexa Fluor® dye will bind to for fluorescent 
detection. If the parasites are dividing slower in the media perfusion system then there will 
be a lower percentage of Edu incorporation amongst the amastigote population. 
3.7.2 Incorporation of Edu in L. major Amastigotes in the 
QV900 Media Perfusion System 
The percentage of L. major amastigotes in mouse peritoneal macrophages, incorporating Edu 
was much lower in the QV900 media perfusion system, figure 3.7-1. On average the 
percentage of amastigotes that have incorporated Edu into their DNA, and hence are dividing 
parasites, was 26%. When the infected cells are maintained at the bottom of the QV900 
chamber, they are under a media velocity rate of 1.74 nm/sec. The average percentage 
incorporating Edu into their DNA, at this flow velocity was 12%. This was less than half of the 
percentage that are dividing in the static system. When the infected cells are maintained on 
top of an insert in the QV900 chamber, they are under a media velocity rate of 0.15 µm/sec. 
The average percentage incorporating Edu into their DNA, at this flow velocity was 11%. 
Comparing the data using a one-way ANOVA shows there to be significant differences 
between the static system and the two flow velocities in the QV900 media perfusion system, 
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p<0.05. The average burden of the mouse peritoneal macrophages was the same across all 
three conditions, figure 3.7-1, only the number of dividing parasites changes. The reduction 
of Edu incorporation shows that there are less dividing parasites in the media perfusion 
system compared to the static system, this could lead to the differences in percentage 
infection seen. 
S
ta
t i
c
L
o
w
 F
lo
w
H
ig
h
 F
lo
w
0
1 0
2 0
3 0
4 0
E d u  in c o rp o ra t io n  o f L .m a jo r p a ra s ite s
P
e
r
c
e
n
ta
g
e
 o
f 
p
a
r
a
s
it
e
s
 i
n
c
o
r
p
o
r
a
ti
n
g
 E
d
u
*
*
S
ta
t i
c
L
o
w
 F
lo
w
H
ig
h
 F
lo
w
0
1
2
3
T o ta l b u rd e n  o f  in fe c te d  m o u s e  p e r ito n e a l m a c ro p h a g e s
P
a
r
a
s
it
e
s
 p
e
r
 c
e
ll
 
Figure 3.7-1. Bar graph showing the percentage of L. major amastigotes that have 
incorporated the Edu marker into their DNA (Left), across three different conditions. A bar 
graph showing the parasite burden of mouse peritoneal macrophages, across three 
conditions. * = p<0.05 Error bars show SD N =3 
 
3.7.3 Incorporation of Edu into Mouse Peritoneal Macrophages 
in the QV900 Media Perfusion System 
Interestingly, another difference was seen when the Edu assay was conducted. The mouse 
peritoneal macrophages should not incorporate any Edu into their DNA, as they should be 
fully differentiated non-dividing cells. In the course of this thesis, it has been observed that 
cells maintained in the media perfusion system are more differentiated than the same cells 
maintained in a static system. Previously only visual observations had been made, but the 
Edu assay provided a quantifiable result. The percentage of cells that incorporated Edu was 
higher in the cells maintained under static conditions, figure 3.7-2.  On average the 
percentage of mouse peritoneal macrophages that have incorporated Edu into their DNA, 
and hence are dividing, was 7%. When the infected cells are maintained at the bottom of the 
QV900. The average percentage of cells incorporating Edu into their DNA, at this flow velocity 
was 0.7%. When the infected cells are maintained on top of an insert in the QV900 chamber. 
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The average percentage incorporating Edu into their DNA was 1%. The results from this 
experiment show, that the mouse peritoneal macrophages maintained under media 
perfusion conditions are incorporating less Edu, and as a whole population are more 
differentiated than the same cells maintained in a static system. 
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Figure 3.7-2. Bar graph showing the percentage of mouse peritoneal macrophages that 
have incorporated the Edu marker into their DNA (Left), across three different conditions. * 
= p<0.05 Error bars = SD N =3 
 
3.8 Conclusion 
The application of media perfusion to a static in vitro system has been shown to increase cell 
viability, longevity and metabolism in the literature288&289. In this section it has been shown 
that media perfusion in the Kirkstall QV500 system increases the cell viability, using a 
measure of mitochondrial metabolism as cell health. Whilst this may also be the case in the 
QV900 system the differences in flow velocity and time constrains caused by the 
contamination of the QV500 system have meant that this has not been measured with the 
QV900 system. 
The modelling of the QV900 system allowed for the direct comparison of the QV500 and 
QV900 media perfusion systems. It allowed for the calculation of the exact flow velocities 
and shear stress effect that the cells are under, whether they are either at the bottom of the 
well or raised on top of a 3D printed insert. The modelling shows that the chosen flow rate 
of 360µL/min is equal to a flow velocity of 0.14 µm/s when the cells are on top of the insert, 
which fits within the range of interstitial fluid flow rates within the skin, which was between 
2 and 0.1 µm/s. 
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Experiments on the initiation and progression of an infection with Leishmania parasites have 
shown that media perfusion inhibits the progression of the infection. Overall infection rates 
after 72 hours are significantly lower in the media perfusion system than in the static system. 
The results show the higher the flow velocity the lower the infection caused, using the same 
initial infection ratio. An Edu incorporation assay demonstrated that fewer parasites are 
actively dividing under media perfusion conditions. 
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Chapter 4 Evaluation of Anti-leishmanial Activity in a 
Media Perfusion System 
4.1 Introduction 
In this second results chapter, the media perfusion model developed in the previous section 
was used for the evaluation of anti-leishmanial drugs. Methods developed in the previous 
section were used to elucidate the anti-leishmanial activity of standard drugs and to show 
any differences between the media perfusion model and the standard static assays. 
The objectives were to: 
I.  To use the infected macrophage model to determine the activity of standard drugs 
in the flow system in comparison to the currently used static system. 
II. To understand potential differences found in the activities of the standard drugs 
through drug accumulation studies. 
III. Finally, to understand potential differences found in the activities of the standard 
drugs by measuring the cell’s activation status. 
 
4.2 Evaluation of Anti-leishmanial Activity using the 
Colorimetric Assay in the Kirkstall QV900 Media 
Perfusion system 
The anti-leishmanial drug activity of two standard drugs, amphotericin B and miltefosine was 
assessed in infected THP1 cells, under flow conditions using the QV900 media perfusion 
system. QV900 media perfusion system was set to a bulk media transfer rate of 360 µL/min, 
giving a media velocity rate of 1.75 ± 0.01 nm/s at the cell surface in this system. Static 
controls were used as a comparison to measure any difference from the standard procedure.  
Dose-response curves for amphotericin B and miltefosine, figure 4.2-1, were produced in 
both a static and media perfusion system and measured by two different methods. EC50 and 
EC90 values for amphotericin B, table 4.2-1, and miltefosine, table 4.2-2, were calculated 
using Graphpad Prism. A repeated measure one-way ANOVA showed no significant 
differences between any of the conditions, when the culture was dosed with amphotericin 
B. Using a two-way ANOVA, significant differences were detected at the middle 
concentration, between the two methods of counting and colorimetric when cells dosed with 
amphotericin B, and maintained under flow, where media velocity was 1.75 nm/sec, p<0.01. 
Significant differences are seen between the static and flow results measured by the 
colorimetric assay at the lowest concentration, p<0.05.  
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A one-way repeated measure ANOVA shows no significant difference between any of the 
conditions, when the culture was dosed with miltefosine. A two-way ANOVA showed no 
significant differences between the static and media perfusion system. 
Table 4.2-1 Table of EC50 and EC90 values of amphotericin B treatment against L. major 
infected THP1 cells, measured by both microscopic counting and the colorimetric assay. 
amphotericin B EC50 (nM) EC90 (nM) 
 Colorimetric Counting Colorimetric Counting 
Static (0 m/s) 55.2 52.3 220.2 129.4 
Media Perfusion (1.75 nm/s) 94.6 49.8 268.9 143.9 
Table 4.2-2 Table of EC50 and EC90 values of miltefosine treatment against L. major infected 
THP1 cells, measured by both microscopic counting and the colorimetric assay. 
miltefosine EC50 (µM) EC90 (µM) 
 Colorimetric Counting Colorimetric Counting 
Static (0 m/s) 4.11 4.38 12.7 16.8 
Media Perfusion (1.75 nm/s) 7.08 5.28 90.9 18.4 
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Figure 4.2-1. Dose-response curves showing the reduction in infection of THP-1 cells 
produced by treatment using amphotericin B (left) and miltefosine (right) with a variable 
slope and maximum and minimum set to 0 and 100%. The reduction in infection was 
measured either by the colorimetric assay or by microscopic counting and scaled to a 
reduction in total infection seen in the untreated control. N = 9 Error bars show SD 
 
4.2.1 Comparison 
No significant differences were seen between the static and media perfusion systems, when 
compared as a data set. When the EC50 and EC90 values of either drug are compared, using a 
one-way ANOVA this also showed no significant difference. Despite this, it is clear for both 
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drugs tested that, whilst the EC50 values are very similar, the EC90 values show more variation. 
EC90 values are higher in the media perfusion system than their corresponding values in the 
static system using both detection methods for each drug tested. 
4.2.2 Discussion 
The modelling conducted on the QV900 system shows that the flow velocity of the media 
across the surface of the cells was 1.74 nm/s-1, which is actually below the range of values 
used for interstitial flow within the skin. This means the system was running at a sub-optimal 
speed and it was no surprise that only a small non-significant difference was seen when 
comparing static and flow. In order to correct the flow velocity, a 3D printed insert was 
included in the chamber of the QV900 system, for future experiments. Currently, an 
experiment takes four QV900 media perfusion systems to run, one for each drug 
concentration and a control. Each QV900 system provides six samples, three for colorimetric 
and three for counting. However, to include the insert would require the use of double the 
number of media perfusion systems, as another six samples would need to be provided for 
each concentration. If the colorimetric assay was still used, and this would be unmanageable. 
Therefore, only the counting method was used in further experiments as it shows a lower 
variation in the results, and was more comparable to values in literature. 
4.3 Evaluation of Anti-leishmanial activity – Three Levels of 
Media Velocity 
Three levels of flow were used, static or zero media velocity, low flow which was 1.74 nm/sec 
and high flow of 0.146 µm/sec, using the inserts. For consistency, both the previous flow 
velocities, low flow and static were repeated for comparison with the higher flow rate. 
Having two media velocities in the QV900 system will allow comparison of the magnitude of 
effect of the speed of flow. In order for the results to be directly comparable, the inserts 
were placed in 3 out of 6 wells of the same plate. This way the cells, in the QV900 system, 
were maintained under identical conditions. These experiments measured drug efficacies 
against L. major in mouse peritoneal macrophages. 
4.3.1 Amphotericin B 
Dose response curves for amphotericin B dosing of L. major infected mouse peritoneal 
macrophages are seen in figure 4.3-1. The data shows that the addition of media perfusion 
reduces the activity of amphotericin B at certain conditions. EC50 values are similar across all 
three media velocities, table 4.3-1. EC90 values increase in value as the speed of media 
velocity increases, table 4.3-1. This effect was only seen minimally, as the drug is highly 
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effective and concentration driven. Despite this, there was clearly an upward trend in the 
EC90 value between the three conditions. 
A one-way repeated measure ANOVA showed no significant difference between any of the 
conditions. A two-way ANOVA showed significant differences between the static system and 
the QV900 system with inserts in the chambers at the highest, p<0.001, and middle, p<0.01, 
concentrations tested. 
Table 4.3-1 Table of EC50 and EC90 values of amphotericin B treatment against L. major 
infected mouse peritoneal macrophages. 
amphotericin B EC50 (95% CI) (nM)  EC90 (95% CI) (nM) 
Static (0 m/s) 53.7 (51.2 to 56.5) 128.3 (100.3 to 154.1)  
Media Perfusion (1.75 nm/s) 58.6 (52.0 to 66.9) 172.6 (114.4 to 244.1) 
Insert (146 nm/s) 67.3 (60.8 to 74.8) 237.2 (185.1 to 305.0) 
 
 
Figure 4.3-1. Dose-response curves showing the reduction in infection of mouse peritoneal 
macrophages produced by treatment using amphotericin B with a variable slope and 
maximum and minimum set to 0 and 100% respectively. The reduction in infection was 
measured by microscopic counting and scaled to a reduction in total infection seen in the 
untreated control. N = 9 Error bars show SD 
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4.3.2 Miltefosine 
Whilst the dose-response curves for miltefosine, figure 4.3-2, all start in the same place a 
clear separation of the curves was seen as the concentration increases. The data shows that 
the addition of media perfusion reduces the activity of miltefosine. EC50 values, table 4.3-2, 
generated show the higher the media velocity the higher the EC50 value. EC90 values 
generated show a similar pattern, table 4.3-2. The effect of media perfusion on the cell 
culture system was seen more easily using miltefosine, when compared to amphotericin B. 
This could be because the drug is less efficacious than amphotericin B and it has a time 
dependent mode of action, meaning a larger effect could be seen if the concentration was 
lower in the media perfusion system.  
A one-way repeated measure ANOVA shows no significant difference between any of the 
conditions. A two-way ANOVA showed a significant difference between the static system and 
the QV900 system both with and without an insert at the highest concentrations tested, 
p<0.0001. Significant differences can also be seen between the different media velocities in 
the media perfusion system at the highest drug concentration, p<0.01. Significant 
differences can be seen between the static system and the QV900 system with an insert at 
the middle concentration, p<0.01. Again, significant differences can be seen between the 
two media velocities of the QV900 system at the middle concentration, p<0.01. 
Table 4.3-2 Table of EC50 and EC90 values of miltefosine treatment against L. major infected 
mouse peritoneal macrophages. 
miltefosine EC50 (95% CI) (µM) EC90 (95% CI) (µM) 
Static (0 m/s) 13.0 (11.1 to 15.2) 59.6 (42.9 to 91.7) 
Media Perfusion (1.75 nm/s) 20.5 (18.5 to 23.1) 161.0 119.0 to 231.9 
Insert (146 nm/s) 29.5 (26.3 to 34.2) 177.0 121.4 to 276.3 
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Figure 4.3-2. Dose-response curves showing the reduction in infection of mouse peritoneal 
macrophages produced by treatment using miltefosine with a variable slope and maximum 
and minimum set to 0 and 100% respectively. The reduction in infection was measured by 
microscopic counting and scaled to a reduction in total infection seen in the untreated 
control. N = 9 Error bars show SD 
 
4.3.3 Sodium stibogluconate 
Dose-response curves for sodium stibogluconate, figure 4.3-3, showed a unique profile. The 
order of the efficacy of the drug across the three media velocity conditions are reversed 
when increasing the concentration from low to high. The experiments using sodium 
stibogluconate show again significant differences between the three conditions. The data 
shows that the addition of media perfusion reduces the activity of sodium stibogluconate at 
certain higher drug concentrations. The EC50 values for the three conditions are similar, table 
4.3-3. Whilst at higher concentrations, the activity appears to be weaker in the media 
perfusion systems. This reduction in activity also appears to correlate with velocity of media 
perfusion across the surface of the cells. However, it also shows at low drug concentration 
the activity was increased by the media perfusion. The other previously tested drugs, the 
higher the velocity of the media flow at the cell surface the lower the activity. The trend seen 
in this set of experiments fits with what was seen in the previous drugs studied. 
A one-way repeated measure ANOVA showed no significant difference between any of the 
conditions. A two-way ANOVA shows significant differences between the static system and 
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the QV900 system with inserts in the chambers at all concentrations. At the highest and 
lowest concentrations a significant difference was seen, p<0.01. At the middle concentration, 
the significant difference seen was p<0.05. 
Table 4.3-3 Table of EC50 and EC90 values of sodium stibogluconate treatment against L. major 
infected mouse peritoneal macrophages. 
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Figure 4.3-3. Dose-response curves showing the reduction in infection of mouse peritoneal 
macrophages produced by treatment using sodium stibogluconate with a variable slope and 
maximum and minimum set to 0 and 100% respectively. The reduction in infection was 
measured by microscopic counting and scaled to a reduction in total infection seen in the 
untreated control. N = 9 Error bars show SD 
 
sodium stibogluconate EC10 (95% CI) (µg 
of Sbv/ml) 
EC50 (95% CI) (µg 
of Sbv/ml) 
EC90 (95% CI) (µg 
of Sbv/ml) 
Static (0 m/s) 136.0 (114.9 to 
N/A) 
223.0(N/A to 
237.1)  
368.0 (N/A to 
465.3)   
Media Perfusion (1.75 
nm/s) 
98.0 (81.6 to 
115.6) 
212.0 (214.4 to 
242.3) 
532.0 (435.9 to 
635.2) 
Insert (146 nm/s) 63.0 (49.5 to 
79.3) 
228.0 (192.5 to 
232.5) 
709.0 (571.7 to 
892.4) 
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4.3.4 Paromomycin 
Partial dose-response curves for paramomycin are shown in figure 4.3-4. In the L. major 
infected macrophage assays, paromomycin had low efficacy. EC50 values generated, table 
4.3-4, show the trend seen in the previous drugs studied in the QV900 media perfusion 
system, but the two media perfusion conditions are similar in concentration. The general 
trend seen in previous drug studies of higher efficacies in the static system compared to the 
media perfusions system was replicated again. 
A repeated measure one-way ANOVA shows no significant difference between any of the 
conditions. A two-way ANOVA shows significant differences between the static system and 
the QV900 system without inserts at the highest and middle concentrations tested, 
p<0.0001. There was also a significant difference seen between the static system and the 
QV900 system with inserts at the highest, p<0.0001, and middle concentrations tested, 
p<0.01. There was no significant difference seen between the two different media velocities 
of media flow at any concentration tested. 
Table 4.3-4 Table of EC50 and EC90 values of paromomycin treatment against L. major infected 
mouse peritoneal macrophages. 
paromomycin EC50 (95% CI) (µM) EC90 (µM) 
Static (0 m/s) 84.9 (64.5 to 110.8) N/A 
Media Perfusion (1.75 nm/s) 198.0 (161.6 to 254.2) N/A 
Insert (146 nm/s) 188.0 (157.6 to 229.9) N/A 
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Figure 4.3-4. Dose-response curves showing the reduction in infection of mouse peritoneal 
macrophages produced by treatment using paromomycin with a variable slope and 
maximum and minimum set to 0 and 100% respectively. The reduction in infection was 
measured by microscopic counting and scaled to a reduction in total infection seen in the 
untreated control. N = 9 Error bars show SD 
 
4.3.5 Discussion 
The trend seen across all drugs used was that the higher the media velocity at the cell surface 
the lower the efficacy of the drug in that system. A Wilcoxon matched-pairs signed rank test 
was conducted comparing the EC50 and EC90 values produced by each individual assay, 
analysing the trend seen across all four drugs used. Using this, a significant difference was 
seen when comparing the EC50 values, between the static and media perfusion system 
without an insert, p<0.05. Much of the effect that flow has on the activities of the drugs was 
only seen at higher concentrations. When this statistical test was used to compare EC90 
values, significant differences were seen between the static system and both the media 
velocities in the QV900 media perfusion system. The static condition shows significant 
differences, p<0.001, from the media perfusion system without inserts. The static condition 
also shows significant differences, p<0.001, from the media perfusion system with inserts.  
Chapter 4 Evaluation of Anti-leishmanial Activity in a Media Perfusion System 
120 | P a g e  
 
The values of EC50 for all drugs used in the static system fit within previously studies and 
values reported within the literature72, 325 & 330. The main difference between the different 
conditions across all four drugs was an increased EC90 values in conditions that have a higher 
flow velocity at the cell surface. The EC90 values are also important for the treatment of 
parasites, as this signals a log reduction in parasite and this level of treatment is required to 
successfully kill enough parasites to inhibit a resurgence of the population.  This trend was 
seen in all four drugs tested to differing degrees, depending on the efficacy and mode of 
action of the compound used. 
A special effect produced by the media perfusion system was seen when using sodium 
stibogluconate to treat the Leishmania infection. The media perfusion increased the activity 
of the drug at low concentrations, whilst decreasing its activity at higher concentrations. A 
possible reason behind this is that media perfusion increases the metabolism of the host cell 
and therefore the metabolism of the drug. In order for sodium stibogluconate to be active 
against Leishmania parasites, metabolism is required for the pentavalent to be converted to 
its more active trivalent form362. Therefore, the higher the metabolism the more active agent 
is produced, and the stronger the reduction in parasite burden should be. This appears to be 
the case at low concentrations, although this effect was lost at higher concentrations. The 
reason for this was that when only a small amount of drug was present, a small increase in 
the production of the active metabolite can largely increase the effect. However, when a 
large amount of drug was present, enough to be in excess, then a small increase in the 
secondary metabolite due to the increase in metabolism, would make little difference as the 
concentration of this secondary metabolite would already be maximal and the additional 
effect would be a less significant addition. Additionally, with a large concentration of drug it 
is possible that the enzyme turnover has reached saturation. 
The main effect caused by the addition of media perfusion was the reduction in activity of 
the standard drugs tested.  The trend was that the higher the velocity of the media the higher 
the reduction in activity of the drug. Potential theories of why this effect was observed would 
require further investigation, but some suggestions can be outlined. As previously discussed 
the cells maintained under flow conditions show a higher cell metabolism and have better 
viability than their static counterparts. This effect could mean that the cell could produce 
more ATP for use in efflux pumps, removing the drug from the cell. Faster drug removal 
would allow the parasite to survive better346. 
Chapter 4 Evaluation of Anti-leishmanial Activity in a Media Perfusion System 
121 | P a g e  
 
Another factor that could be important is the media perfusion could also cause a reduction 
in drug molecule uptake. The flow velocity could interfere with the drug molecules binding 
to external receptors and this could lead to a lower level of accumulation of the drug within 
the cell. This lower accumulation could present as a lower activity, as less drug is available 
within the cell. Another possibility is that the zones of recirculating media found in the QV900 
media perfusion system could lead to localised reductions in drug availability. 
This effect could be extremely important when considering the purpose of this model. The 
purpose of these experiments was to elucidate the effect that media perfusion would have 
on a complete in vitro model, when both media perfusion and 3D co-culture of cells had been 
incorporated. The model would help to bridge the gap between static in vitro assays and in 
vivo experimentation. Fluid movement around the cells in in vivo in would affect compounds 
tested in animals. If we do not understand the effect that this fluid movement has, it could 
cost a lot of money, as drugs that appeared to work in static in vitro systems may lose some 
of their activity in vivo and could be unnecessarily discarded after being tested at a sub-
optimal range. The findings from this chapter show a higher dose than expected may be 
required in vivo. In addition to this, in vivo experiments may be able to withstand a higher 
dose before cytotoxicity is seen347. Another thing that needs to be taken into consideration 
is that many disease states cause an increase in local fluid flow velocities348. By increasing 
the fluid velocity this could again effect the concentration of drug that is required to 
successfully treat the disease. 
4.4 Drug Accumulation Studies in the QV900 System 
4.4.1 Rationale 
One way to find out if the difference in activity levels of the drugs tested in the media 
perfusion system, was caused by a reduced accumulation of drug molecules, was to carry 
out a drug accumulation assay. A protein assay was run on the samples to determine protein 
concentrations and allow for standardisation of the results by an estimate of cell number. 
After a 24-hour incubation with the drugs, the drugs were extracted from the L. major 
infected mouse peritoneal cells and analysed using HPLC-MSMS mass spectrometry using 
electrospray ionisation. The results were then compared to a standard curve of drug 
concentrations included as a reference. The results are a measure of how much drug had 
accumulated intracellularly 
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4.4.2 Comparison of Drug Accumulation in the Static or Media 
Perfusion System 
Different amounts of drug had accumulated in the cells that were maintained in three 
different velocities of media perfusion, figure 4.4-1. The accumulation of both drugs was 
significantly higher in the static system relative to the media perfusion system, after 24 
hours, table 4.4-1 and 4.4-2. Within the media perfusion system, cells maintained on top of 
the insert also showed a lower concentration of intracellular drug compared with the cells 
that were incubated at the bottom of the QV900 chamber. 
Accumulation of amphotericin B increased over time, figure 4.4-1, at first the concentrations 
in the cells were similar but eventually it can be seen that the highest concentration of 
amphotericin B within the cell maintained in the static system. The next highest 
concentrations were found in the low flow conditions. Finally, the lowest concentrations 
were found in the high flow conditions. Using a one-way repeated measure ANOVA test 
significant differences in the concentration of amphotericin B accumulated can be seen 
between the low flow and high flow conditions, p<0.05. Using a two-way ANOVA significant 
differences can be seen after 8 hours between static and low flow conditions, p<0.01, and 
between low flow and high flow conditions, p<0.05. At the 12-hour time point a significant 
difference was seen between the static system and the drug accumulation under high flow 
conditions, p<0.01. After 24 hours significant differences can be seen between the static and 
low flow condition, p<0.001, and between the static and high flow conditions, p<0.0001. 
The intracellular concentrations of miltefosine increased very slightly over time, as 
demonstrated in figure 4.4-1. Initially the cells had the same concentration of miltefosine 
within them at all three media velocities. By the end of the time course, the same pattern 
seen with amphotericin B was seen with miltefosine. There was no significant differences 
seen between the concentrations of miltefosine accumulated using a one-way ANOVA test. 
Using a two-way ANOVA significant differences can be seen after 8 hours between static and 
high flow conditions, p<0.05, and between low flow and high flow conditions, p<0.001. At 
the 12-hour time point, no significant difference was seen. After 24 hours significant 
differences can be seen between the static and low flow condition, p<0.01, and between the 
static and high flow conditions, p<0.001. 
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Table 4.4-1 Table showing intracellular drug accumulation concentrations of amphotericin B 
(with standard deviations) in the three different velocities of media perfusion. 
 
Table 4.4-2 Table showing intracellular drug accumulation concentrations of miltefosine (with 
standard deviations) in the three different velocities of media perfusion 
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Figure 4.4-1. Accumulation of amphotericin B (left) and miltefosine (right) over time in 
peritoneal macrophages maintained either in static conditions or in the QV900 media 
perfusion system. Low flow was a media velocity of 1.75 ± 0.01 nm/s and high flow was 
media velocity of 0.146 ± 0.001 µm/s. Graphpad prism was used to display the data and 
connecting lines are drawn between points. N = 9 Error bars show SD 
Time 
(h) 
Static (ng per µg 
of protein) 
0 m/s 
Low flow (ng per µg of 
protein) 
1.75 ± 0.01 nm/s 
High flow (ng per µg of 
protein) 
0.146 ± 0.001 µm/s 
4 0.68 ± 0.15 0.8 ± 0.25 0.62 ± 0.20 
8 1.1 ± 0.31 1.66 ± 0.60 1.19 ± 0.51 
12 1.56 ± 0.33 1.28 ± 0.23 0.96 ± 0.18 
24 2.56 ± 1.21 1.83 ± 0.66 1.56 ± 0.49 
Time 
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of protein) 
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protein) 
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protein) 
0.146 ± 0.001 µm/s 
4 0.19 ± 0.02 0.20 ± 0.03 0.19 ± 0.02 
8 0.26 ± 0.03 0.24 ± 0.03 0.20 ± 0.04 
12 0.26 ± 0.05 0.23 ± 0.05 0.22 ± 0.04 
24 0.35 ± 0.04 0.27 ± 0.02 0.24 ± 0.04 
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4.4.3 Discussion 
One caveat of these experiments was that the drug concentration used was higher than the 
highest concentration used in previous assays throughout this thesis. The concentration used 
was also high enough to kill over 90% of the Leishmania parasites present within the cells. 
This was because otherwise the results fall below the lower limit of detection of the HPLC-
MSMS system. Initially development of this method involved a range of relevant 
concentrations used over the same period; however, the results were below the lower limit 
of detection. The literature on the specific method used was checked and it was found that 
the concentrations used were too low for detection. It was decided that the use of higher 
concentrations would still be able to demonstrate any differences between the three 
conditions. There was no point in using a range of higher concentrations as they would all 
have the same effect on the infection and could lead to cytotoxic effects, hence a time course 
was chosen to study rates of absorption and accumulation.  
Both data sets show that, the cells maintained under flow conditions have accumulated less 
drug than the static alternative. Considering the media perfusion systems have 36 mL of drug 
containing media in total, compared to the static system’s 1 mL of drugged media, this was 
a surprising result, as there are more molecules of drug in the media perfusion systems. The 
data also shows the higher the flow velocity of the media, at the surface of the cells, the less 
drug was found accumulated within the cells.  
A higher cell metabolism, found in cells maintained under media perfusion conditions, could 
cause the cell to be more active and have a higher rate of drug molecules breakdown361. The 
faster turnover would lead to less accumulation as the rate at which the cells metabolise the 
drug in flow could cause a local decrease in concentration of the drug within the cell. The 
reduction in drug accumulation could also be due to a reduction in the rate of drug uptake. 
If the media perfusion effected the binding of the drug molecules to their receptors, either 
by reducing the time spent in contact with the receptor, or by affecting the probability of 
molecules coming in contact with the surface receptors. Another idea was that the media 
perfusion causes localised re-circulation within the media perfusion system, which could lead 
to the cells being surrounded by media containing a lower concentration of drug. These two 
things would reduce the probability of drug uptake and hence reduce the drug accumulation 
within the cell. 
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4.5 Nitrite Ion Release Following Cell Stimulation in the 
QV900 System 
4.5.1 Rationale 
Nitric oxide (NO) from activated macrophages has been shown to be one of the mechanisms 
by which macrophages kill Leishmania parasites349. Nitric oxide has an important role in 
cytotoxicity and has been shown to be toxic for a variety of pathogens, including Leishmania. 
One method for the indirect determination of NO is the Griess assay. The Griess assay 
involves the spectrophotometric measurement of its stable decomposition products NO−3 
and NO−2350. 
In this experiment, mouse PEMs were incubated under the three different flow conditions 
for 24 hours, and then stimulated with lipopolysaccharide (LPS), known to elicit a NO 
response. The response was then measured using the Griess assay. The reason that the assay 
was conducted this way was that, if the cells were stimulated with LPS whilst inside the media 
perfusion system, the NO released would be diluted by the volume of media within the 
system. This dilution would most likely mean that the NO release would be below the limit 
of detection for the Griess assay. 
4.5.2 Comparison of Nitrite Ion Release in Cells Conditioned 
either in the QV900 Media Perfusion or Static System 
The cells maintained under static conditions show a higher release of nitrite ion, hence nitric 
oxide release when challenged with LPS, figure 4.5-1. Cultures maintained in the QV900 
media perfusion system show a similar concentration of nitrite ion release regardless of the 
speed of media velocity. On average, the concentration of nitrite ion in the media 
surrounding the cells maintained in static conditions was 1.882 ± 0.006 µM.  In comparison 
to this the concentration of nitrite ion in the media surrounding the cells maintained in media 
perfusion system was 1.815 ± 0.034 and 1.813 ± 0.026 µM, with and without a 3D printed 
insert. A one-way ANOVA showed statistically significant differences between the static 
condition and both of the two media velocities in the QV900 media perfusion system, 
p<0.001. 
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Figure 4.5-1. A box and whisker diagram showing the concentration of nitrite ion in sample 
after incubation under the three different media flow velocities. *** = p<0.001 N = 3 
 
4.5.3 Discussion 
The results show that cells maintained under static conditions produced more NO when 
activated with LPS, compared to the cells maintained in the media perfusion system. The 
values of nitrite ion detected in the media surrounding the cell that had been maintained 
under static conditions match values found in the literature351 & 352. The more NO released 
the better a cell will be able to kill an invading parasite. One hypothesis behind this 
experiment is that cells maintained under media perfusion conditions may be more able to 
kill the Leishmania parasites due to their increased viability. This appears not to be the case 
as they have been shown to produce a lower concentration of NO, when challenged with 
LPS. This result does reflect what was seen when the parasites are treated with drugs. When 
using the media perfusion system the efficacy of drugs was lower, there are less parasites 
killed by the cells maintained under flow conditions than under static conditions when using 
the same drug concentration. The reduced concentration of nitric oxide produced by cells in 
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the media perfusion system could be a contributing factor in the reduced ability to kill the 
parasites. 
4.6 Conclusion 
The effect that media perfusion had on the treatment of cells infected with Leishmania 
parasites was non-significant in the experiments measured by two different methods. Whilst 
the colorimetric assay was shown to work, and matched to microscopic counting, it still has 
a large variation in its results. The experiments were conducted on cells maintained under 
very low flow velocity and shear stress. This meant that the differences seen between the 
static and flow systems were minimal, and the colorimetric assay struggled to detect the 
differences. Visually it appeared to show that the media perfusion makes treatment of 
leishmaniasis less effective when compared to the static system.  
With the introduction of the 3D printed insert, the effect of an interstitial fluid flow rate and 
the comparisons of two different flow rates was possible in the QV900 system. The results 
show that in the media perfusion systems the effectiveness of the drug treatment was 
statistically lower, in comparison to a static model. A reduction in the uptake of drug 
molecules, or an increase in metabolism leading to a higher efflux of drug, both lead to a 
reduced effectiveness of the drug treatment. The results also show that the higher the 
velocity of the media across the cell surface, the less effective the drug treatment was against 
a Leishmania infection. 
To investigate whether the differences in infection rates and drug treatments are to do with 
the rate of uptake into the cell, drug accumulation studies were carried out. The results from 
this show that less drug was accumulated by the cells maintained under the flow conditions. 
The data shows that the faster the flow velocity the lower the concentration of drug within 
the cells. A measure of nitric oxide release also showed that there was a reduced 
concentration of nitric oxide in cells maintained in the media perfusion system. This would 
mean that the cells were less able to kill the parasites and reduce the infection. 
Work in this area of testing drug efficacies in an in vitro model, that has a media perfusion 
aspect to it, is rare. The examples of these models in literature concentrate on establishing 
the model and measuring how the cell functions are maintained. A recent study (unpublished 
data) showed the application of media perfusion used the drug diclofenac and showed 
different EC50 values in static and media perfusion culture. The media perfusion system 
increased the sensitivity of the cells to the drug. In doing so, it brought the results from the 
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in vitro models closer to the results from in vivo studies and correctly identifies diclofenac as 
a cytotoxic drug. 
In conclusion, the application of media perfusion has wide-ranging effects on both the 
infection by Leishmania parasites and the treatment of infected macrophages. It is important 
to realise that in biological situations almost all cells are under some form of fluid flow, 
causing both movement of nutrient and a mechanistic shear stress effect. These factors are 
not taken into account in most in vitro assays and hence they can often give misleading 
results. The use of a media perfusion system is a key part in the creation of a more predictive 
and more biologically relevant in vitro model. 
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Chapter 5 Development of a 3D Cell Culture Model for 
Leishmaniasis 
5.1 Introduction 
The aim of this thesis was to investigate different ways in which the current in vitro model 
systems could be more predictive of in vivo results. Current approaches are based upon 2D 
cell assays and in vivo mouse models, both of which do not, in several ways, accurately reflect 
the infection in humans. In this third results chapter, the use of a 3D cell culture model for in 
vitro assays was investigated. 
2D cell culture systems have been used for in vitro assays to measure the infection rates and 
drug efficacies against Leishmania parasites since 1974327. In 2D cell culture systems, cells 
are plated out into the bottom of the well and left to settle and attach to the flat surface of 
the bottom of the well. When the cells form attachments to the flat surface of the well, they 
spread out becoming wider and flatter. The cells rearrange their cyto-architecture and 
internal structure to reflect the new environment. In contrast, cells found within the body 
will be found in a 3D conformation or will have assembled to form 3D architecture. It has 
been shown that maintaining the cells in 3D provide a more predictive model, as cells are 
more representative of the in vivo situation187&243, as discussed in more detail in the 
introduction. 
Maintaining the cells in 3D allows the cells to take a more physiologically relevant shape and 
volume. The change from 3D to 2D, alters the surface area to volume ratio and completely 
changes the availability of the cell surface, both for cell-cell interactions and receptor 
presentation. When the cell is maintained in 2D, much of the cell surface area is in contact 
with the culture plastic or glass and not available for interactions with other cells or signals 
from the environment. 3D maintenance of cells allows cells to maintain a natural shape and 
conformation and allows the cells to have a larger area where signals can be received or sent. 
In this project, two solid scaffolds were chosen for use in 3D cell culture of macrophages, 
their infection with Leishmania parasites and the evaluation of drugs against amastigotes 
within infected macrophages. A solid scaffold, rather than a hydrogel or free floating 3D 
structure such as a spheroid, was chosen for two reasons. Firstly, the free swimming nature 
of the Leishmania promastigotes was taken into consideration. The parasites might have had 
a problem moving through the hydrogel and the spheroid may not allow access to the cells 
in the centre of the spheroid giving an uneven infection. A solid scaffold with a well-organised 
pore system would allow the parasites to move through the scaffold and reach cells that are 
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within the scaffold. Another reason for this choice of scaffold was the extent of literature on 
solid scaffolds and specifically the use of the scaffold for the creation of skin models206 & 319. 
The two scaffolds chosen for this work were the 3D CelluSponge from Invitrocue, referred to 
in future as the Invitrocue scaffold. The second is a polystyrene spun scaffold from Alvetex®, 
referred to in future as the Alvetex scaffold. Both are discussed in more detail in the materials 
and methods section.  
The work covered in this section is novel and previously unreported. Notable work in the 
area of Leishmania involving 3D models for the infection mainly focused on ex vivo models.  
A Leishmania and HIV co-culture model used tissue explants from human tonsils to study the 
modulation of the HIV replication cycle by Leishmania parasites297. The paper uses the 
naturally occurring 3D structure of the tissue to provide a better microenvironment for the 
replication of the natural interactions between the parasite and the virus and detect the 
signals, as they could be happening within the body. Another paper298 demonstrates the 
ability of Leishmania parasites to migrate through an extracellular matrix like substance 
made using a 3D environment mainly composed of collagen I. In this paper, the 
promastigotes demonstrate a new type of migration dynamics compared to the free-
swimming forms found in 2D cultures. Their behaviour was altered by the 3D environment; 
the promastigotes showed a different pattern of migration and the collagen matrix increased 
the time taken for the parasites to infect the cells. This was despite the fact that parasites 
moved faster into the collagen matrix when cells were present. Another area of Leishmania 
research where a 3D environment is actively being used is for the development of labelled 
fluorescent or bioluminescent parasites. In another paper299, splenic explants were removed 
from infected mice and the parasite loads were measured, by measuring the fluorescence of 
the parasites before culture of the explants led to release of parasites. 
Examples of 3D systems being used in other infectious disease research areas are more 
common. Viral infections have been studied with the use of 3D cell culture systems. A paper 
by Straub et al300 showed that noroviruses could infect and replicate in a 3D organoid model 
of human small intestinal epithelium. Cells were grown on porous collagen-coated beads and 
differentiated into 3D architectures that resembled both the morphologic and physiologic 
function of in vivo tissues. A fully differentiated 3D cell culture model could support the 
natural growth of human noroviruses, whereas previous attempts using differentiated 
monolayer cultures had failed. Another example is the culture of Hepatitis C virus in 3D Huh7 
cells that were morphologically and transcriptionally distinct from more standard Huh7 2D 
monolayers301. These 3D cultures are highly permissive for HCV infection, thus providing an 
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opportunity to study HCV entry and the effects of HCV infection on host cell function in a 
more physiologically relevant cell culture system. More recently, the effects of Zika virus 
infection in human neural stem cells growing as neurospheres and brain organoids were 
studied302. 3D cell culture systems have been used extensively with bacteria. One example is 
a tuberculosis model of granuloma303. The paper describes the development of a biomimetic 
in vitro model of human tuberculosis granuloma using human primary leukocytes, in which 
the tuberculosis exhibited characteristics of dormant mycobacteria. The cells were 
maintained in 3D confirmation in an extracellular matrix mimic. In a study of Pseudomonas 
aeruginosa, 3D reconstituted lung models are regularly used304&305. Salmonella typhimurium 
was used with 3D small intestine306 and colon models307. For parasites, the technique is far 
less common and the literature reflects this. A paper on Cryptosporidium parvum308, shows 
the development of a three-dimensional human intestinal model for long-term infection. 
Asexual and sexual stages and the formation of new oocysts were observed during the course 
of infection in a 3D silk scaffold. A paper on Plasmodium309 incorporated primary human 
hepatocytes into engineered polyethylene glycol based macroporous human ectopic 
artificial livers; they demonstrated that porous livers support liver stage human malaria (P. 
falciparum) infection in vitro.  
A key example of a model that is relevant for the disease area that this thesis covers is a 
reconstituted skin model used to test the efficacy of miltefosine against Acanthamoeba310. 
As skin is the host organ infected by Leishmania parasites in cutaneous leishmaniasis, this 
model was of particular interest. A key difference however is that Leishmania parasites infect 
macrophages within the skin, whereas the Acanthamoeba model310 was largely based 
around keratinocytes. The model allowed the study of the infection caused by 
Acanthamoeba and to show that subsequent dosing with miltefosine was successful. 
 
The objectives of the work discussed in this chapter are: 
I. To establish methods to determine viability of host cells and of parasite in 3D 
models. 
II. To establish an infection in mouse peritoneal macrophages maintained in the 3D 
culture. 
III. To determine the infection potential within the system compared to a 2D 
alternative.  
IV. To use the infected macrophage model to determine the activity of standard drugs 
in 3D models compared to the currently used model system. 
Chapter 5 Development of a 3D Cell Culture Model for Leishmaniasis 
132 | P a g e  
 
5.2 Viability Studies on Invitrocue Scaffold 
Comparisons of 2D and 3D cell culture models in literature311 have indicated differences in 
cellular morphology and metabolism, commonly attributed to the closer representation of 
in vivo conditions of the 3D cell culture environment. To study the influence of 2D or 3D cell 
culture on cell viability, an Alamar blue assay was used on one million mouse peritoneal 
macrophages.  
The results, figure 5.2-1, show that initially the 3D system seems to confer lower cell viability 
compared to the 2D system. However, this may be due to the ease of cell adherence to a flat 
surface compared to a 3D scaffold. Cells in 3D may not have completely recovered from the 
initial plating. The next phase from about 72 hours to about 300 hours shows the cells having 
similar viabilities in 2D and 3D. Finally, by 300 to 400 hours the cell viability in the 3D was 
higher. When the data was compared using a t-test, no significant difference was seen. When 
comparing the data using a two-way ANOVA there was significant difference seen at the 24 
hour time point, p<0.05. No significant difference was seen at any other time point. The 
conclusions we can draw from this is that the cells have similar viability and hence metabolic 
processes in either 2D or 3D. However, the 3D systems show a better maintenance of viable 
cells over the long term. This result was similar to Bonnier et al312 who conclude that there 
was little difference between 2D and 3D conditions after 24 hours. Another paper313 showed 
over a longer period of time, 14 days, that there was only minimal differences in cell viability 
when maintained in 3D rather than 2D. 
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Figure 5.2-1. Graph showing the ratio of viability of mouse peritoneal macrophages 
maintained in the Invitrocue sponge (N=9) compared to the viability of mouse peritoneal 
macrophages maintained in 2D (N=9) A ratio of 1 means that they are equally viable. Error 
bars show SD 
 
5.3 Imaging the Scaffolds 
Cells were imaged in 3D to prove they had adopted a 3D configuration and to analyse the 
formation of any 3D tissue-like structures they formed within the scaffold. Cells can form 
many different larger structures in 3D as demonstrated by Kenny et al (2007)314 and Ingram 
et al (1997)245 and it is important to see what the microenvironment does to the different 
cell types used in experiments. Cells were stained with DAPI (Blue), a nuclear stain and 
phalloidin (Green), which stains actin fibres giving a general outline of the cell. Images were 
taken using a confocal microscope, as described in the methods section, both single plane 
and z-stacks. 
5.3.1 Culture of THP-1 Cells in 3D 
THP-1 cells were seeded at a density of 1 million cells per scaffold, shown in figure 5.3-1. The 
THP-1 cells settled in the Alvetex scaffold and whilst they can be seen to be in 3D and 
throughout the scaffold, they seem to not have formed any kind of secondary structure. 
The THP-1 cells settled in the pores of the Invitrocue scaffold, figure 5.3-1, and formed a 
secondary structure. Using the Kenny et al (2007)313 descriptions of the different forms that 
cells take as a secondary structure in 3D cell culture (figure 5.3-2), the cells in the Invitrocue 
scaffold most resemble a grape like structure. The phalloidin staining in figure 5.3-1 was not 
as strong and consistent as the cells seen in other images (figure 5.3-1 and 5.3-3), this was 
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because the phalloidin has more difficulty penetrating the Invitrocue sponge scaffold and 
reaching the cells. Incubation times with the phalloidin were increased to adjust for the extra 
time taken to diffuse throughout the sponge scaffold, and this improved staining of the fixed 
cells. 
 
Figure 5.3-1. Confocal image of THP-1 cells grown in an Alvetex scaffold (Left) and Invitrocue 
scaffold (Right). Cells stained with DAPI (Blue) and phalloidin (Green). 
 
Figure 5.3-2. Figure from Kenny et al (2007)313 showing different morphologies found in 3D 
cell culture 
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5.3.2 Culture of Mouse Peritoneal Macrophages in 3D 
Peritoneal macrophages settle on the Alvetex scaffold, figure 5.3-3, and whilst they can be 
seen to be in 3D and throughout the scaffold, they have not formed any kind of secondary 
structure. The peritoneal macrophages appear to act in a similar manner to the THP-1 cells. 
When the peritoneal macrophages settle in the pores of the Invitrocue scaffold, figure 5.3-3 
they form the same grape like secondary structure seen when using the THP-1 cells. The size 
for a grape like bundle varies greatly but is summarised in table 5.3-1. 
 
Figure 5.3-3. Confocal image of mouse peritoneal macrophages grown in an Alvetex scaffold 
(Left) or Invitrocue scaffold (Right). Cells stained with DAPI (Blue) and phalloidin (Green). 
 
Table 5.3-1 Maximum and minimum dimensions of observed 3D structures created by mouse 
peritoneal macrophages in the Invitrocue scaffold. N = 24 
Category Maximum Minimum Mean 
Height (No. of Cells) 17 3 8 
Width (No. of Cells) 20 2 7 
Depth (No. of Cells) 3 1 2 
Volume µm3 1,326,438 11,239 271,142 
Total number of cells 100 13 39 
 
Considering the peritoneal macrophages form the same structures in the two different 
scaffolds as the THP-1 cells but are easier to infect, it was decided to carry out further 
development of a drug assay with only mouse peritoneal macrophages. 
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5.3.3 Culture of Fibroblasts in 3D 
Cutaneous leishmaniasis infections are found in the dermis, which is largely made up of 
fibroblasts. A further test of the scaffolds ability to sustain cells in 3D was carried out using 
cells that are still dividing. Fibroblasts grow in flat sheets and their natural conformation 
shows a different pattern of structuring, compared the macrophages. 
In comparison to the fully differentiated macrophages, the actively dividing fibroblasts were 
left for 3 days to grow within the scaffold. It can be seen in figure 5.3-4, that the fibroblasts 
have proliferated and have nearly colonised the Alvetex scaffold. The cells have taken a flat 
elongated confirmation and have spread out to form full layers across the surface and slightly 
below it. Figure 5.3-5, demonstrates the position of the fibroblast within the scaffold. The 
majority of the fibroblasts sit on top of the scaffold to form a confluent layer but some do 
penetrate further into the scaffold. 
 
Figure 5.3-4. Confocal image of 3T3 fibroblasts grown in an Alvetex scaffold (Left) and 
Invitrocue scaffold (Right). Cells stained with DAPI (Blue) and phalloidin (Green). 
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Figure 5.3-5. Microscopic images of 3T3 fibroblasts grown in an Alvetex scaffold. Cells 
stained with Hematoxylin and Eosin stains. A = Fibroblasts that have penetrated through the 
scaffold. B = Layer of fibroblasts that has formed at the surface of the scaffold. 
The fibroblasts cultured in the Invitrocue scaffold take on the previously seen grape like 
structures. It can be seen in figure 5.3-4, that the fibroblasts have not proliferated but have 
formed the same grape like bundles similar to those seen with macrophages. The cells in this 
scaffold have not taken the usual flat elongated conformation seen for fibroblasts in most 
culture systems. The cells have not spread out to form layers as seen in the body, and seen 
when plated on the Alvetex scaffold. The fibroblasts have also not proliferated as seen in the 
Alvetex scaffold suggesting they might not be as suited to this scaffold. 
5.3.4 Fluorescent L. major Parasites for use in 3D 
A group at the Universidad de León, León, Spain engineered a transgenic L. major strain, 
figure 5.3-6, expressing the mCherry red-fluorescent protein for real-time monitoring of the 
parasitic load161. L. major LV39c5 (RHO/SU/59/P) strain was used for generating mCherry 
transgenic promastigotes, transfecting it with the 711-bp mCherry coding region. This 
A 
B 
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parasite has a maximum emission peak at 610 nm with a 587 nm excitation wavelength, 
giving it a red fluorescent signal, allowing the signal to be detected as a separate signal from 
the blue DAPI and green phalloidin.  
 
Figure 5.3-6. Confocal image of L. major mCherry parasites infecting peritoneal 
macrophages in the Invitrocue scaffold (Left) and free in the media (Right). An infected cell 
containing a L. major mCherry amastigote is shown by A. An external L. major mCherry 
parasite is shown by B. This strain was kindly gifted to us courtesy of Prof Rosa Reguera, 
University of Leon. 
 
5.3.5 Fluorescent L. amazonensis Parasites for use in 3D 
The World Health Organization (WHO) reference strain L. amazonensis (IFLA/BR/1967/PH8) 
was used to create a red fluorescent parasite, figure 5.3-7. The L. amazonensis parasites were 
transfected with the constructs pIR1SAT-LUC(a) DsRed2(b) (B5947) to create a red 
fluorescent protein expressing strain of Leishmania316. This strain was kindly provided to us 
by Eric Prina, Institute Pasteur Paris. 
 
A 
B 
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Figure 5.3-7. Confocal image of L. amazonensis DSRed2 parasites infecting peritoneal 
macrophages (Left) and free in the media (Right). An infected cell containing an L. 
amazonensis DSRed2 amastigote is shown by arrow A. An external L. amazonensis DSRed2 
parasite is shown by arrow B. 
 
5.4 Counting Methodology Development 
One problem that 3D cell culture causes, is the need to adapt current evaluation methods 
that have historically been developed for 2D cell culture. In the case of Leishmania, the main 
method of evaluation is microscopic counting of the number of infected cells. Once they have 
been fixed and stained. This cannot be used with 3D cell culture for several reasons, primarily 
the fact that the scaffold is opaque and cells cannot be directly visualised within it. Another 
issue was that the microscopes used for counting fixed and stained cells are oil immersion 
microscopes that could easily damage the scaffold. The most important reason is as the cells 
are in a 3D conformation, the whole of the cell will need to be imaged, as parasites could be 
located anywhere within the cell. To get around this, a confocal microscope and the z-stack 
capability will need to be utilised. This also means that fluorescent dyes will need to be used 
so that any image that is captured will be clear, and infected cells will be easy to identify. 
Once the samples have been fixed and stained, z-stacks are taken and stored for later 
analysis. 
5.4.1 Determination of the Level of Infection using Volocity 
The images and z-stacks taken on the confocal microscope were loaded into Volocity, an 
image analysis software package from PerkinElmer, as mentioned in the methods section.  
A 
B 
A 
B 
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The number of cells in each image was calculated using the automated measurements 
section of the Volocity program. The find objects command of Volocity was used in the DAPI 
(blue) channel to select all cell nuclei. Settings were adjusted by offsetting the threshold, if 
the threshold was too close to the initial peak of the signal and the minimum object size was 
set to 500 µm3. This produces a list of objects detailing volume and other parameters, each 
object was a possible nucleus that the program has counted. The list of objects was manually 
checked for volumes that were above 1000 µm3, if a volume above 1000 µm3 was found then 
the selected object was manually checked to make sure it represents only one nucleus. If the 
highlighted section was made of more than one nucleus then how many extra cells need to 
be added to the count once at the end of the list was recorded. Then all the objects on the 
list were highlighted and the image checked to see if any cell nuclei has been missed by the 
automated count. If there were nuclei that have been missed, they were added to the total 
count of number of cells present in the image. 
Once the number of cells in an image was determined, the image tab was selected and 
visualisation set to XYZ mode. Then the z-stack was manually advanced counting the number 
of infected cells. Intensities of the red parasite channel were maintained but on occasion, 
the phalloidin (green) channel can be reduced to make it easier to see if the red signal was 
inside or outside the cell. The percentage infection was calculated by comparing the number 
of infected cells to the total number of cells in the image. 
One limitation of this system was the time and concentration it takes to semi-automatically 
count the cells in each image. Another problem is that the Volocity method has more 
subjectivity than the Invitrocue method of counting. It has the advantage over the Invitrocue 
computational analysis that the decision-making behind whether a cell is infected is more 
experienced, and can make decisions on situations where the computational method would 
be unable to decide. Cells near the edges of the image are not ignored as if they are infected 
then it is obvious that they should count. The human aspect of this method makes up for 
some of the shortcomings of the computer analysis. This method also allows for the analysis 
of single plane images, which the computer analysis cannot do. It can also detect anomalies 
such as z-stack drift, which can cause the computer problems. 
5.4.2 Determination of the Level of Infection - Computer 
Analysis from Invitrocue 
The number of parasites per cell was counted using the ImarisCell module of Imaris 8.2.0 
(Bitplane AG). Imaris cell detection consists of three parts, namely nucleus detection, cell 
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body detection and vesicles detection, which in this case will detect the parasites. In our 
analysis, the red channel labelling the parasite was inputted as the vesicle channel so the 
number of parasites per cell can be determined directly from the measurements called 
number of vesicles per cell.  
Nucleus detection was performed on the DAPI channel. Local background subtraction with a 
region width of 2.8 μm was applied. Nucleus was detected using an estimated diameter of 7 
μm and an intensity threshold of 40.  
Cell body was detected using the green channel, which detects the signal from phalloidin 
that has labelled the actin. Local background subtraction with a region width of 12 μm was 
performed before applying an intensity threshold of 29. The cell splitting was done by 
enforcing the rule of one nucleus per cell. Extremely small nuclei and cells that resulted from 
wrong segmentation were removed by setting minimum size thresholds. 
For parasite (vesicles) detection, background subtraction was performed and an estimated 
diameter of 3 μm and an intensity threshold of 6.7 were used in the detection. 
The intensity threshold for all these three were set based on visual inspection of a few 
stained samples to get most desired segmentation. One of the limitations of this approach is 
that there might be variations in images obtained from samples stained and imaged on 
different days. To overcome this limitation, we tried to make sure that all samples were 
stained similarly so that same segmentation scheme can be applied to all samples. Other 
limitations of this system are that the algorithm used does not detect cells that are touching 
the edges of the image and it cannot process single plane images. Where the major 
difference is seen between the two different counting methods was the quantification of 
total cell number. This was partly due to cells not being detected as they are too close to the 
edge but also because of nuclei that are in close proximity of to each other being mistaken 
as a single object by the analysis.  
Advantages of this method of counting are the speed of detection and how rapidly images 
can be analysed and results produced. The algorithm has been through many cycles of 
improvement and can count both the percentage infection and the burden of parasites 
within the cells at the same time, producing high quality data on the infection status.  
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5.5 Determination of Level of Infection in 3D Cultures  
5.5.1 Rationale 
The differences between 2D and 3D cell culture models in cellular morphology, metabolism 
and the microenvironment lead to differences in infection potential. In 3D, the cells present 
more surface area for the parasite to attach to; this could increase the ease of parasite entry 
into the cell. To study the difference in infection rates between 2D and 3D, experiments were 
conducted using the two strains of fluorescent parasite.  
5.5.2 Evaluation of Infection Rates in 3D 
As the infection ratio was increased, the percentage infection after 72 hours also increases 
in all three conditions, figure 5.5-1. The mean value at an initial infection ratio of 0.5 L. major 
parasites to each cell in the 2D system was 72.3±2.2% infection after 72 hours. In the 3D 
systems, the mean infection percentage was 8.0±3.1% in the Alvetex scaffold and 
67.2±17.6% in the Invitrocue scaffold. The values are similar between the 2D and the 
Invitrocue scaffold. However, the Alvetex scaffold shows a much lower level of infection after 
72 hours. This pattern continues when the initial infection ratio of L. major was increased. 
When the data was compared using a one-way ANOVA, a significant difference was seen 
between the 2D and Alvetex scaffold, p<0.001. A significant difference was also seen 
between the Alvetex and the Invitrocue scaffold but to a lesser degree, p<0.01. 
The mean value at an initial infection ratio of 0.5 L. amazonensis parasites per cell in the 2D 
system was 54.8±1.0% infection after 72 hours, figure 5.5-1. In the 3D systems, the mean 
infection percentage was 5.4±3.4% in the Alvetex scaffold and 51.4±5.7% in the Invitrocue 
scaffold. Again, the values are similar between the 2D and the Invitrocue scaffold; however, 
the Alvetex scaffold shows a much lower level of infection after 72 hours. When the data was 
compared using a one-way ANOVA significant difference was seen between the 2D and 
Alvetex scaffold, p<0.01. In addition, significant difference was seen between the Alvetex 
and the Invitrocue scaffold, p<0.01. 
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Figure 5.5-1. Box and whisker charts showing the infection rates of L. major (left) and L. 
amazonensis (right) in both 2D (N=6) and 3D cell (N=6) culture. 3D cell culture was 
conducted in both the Invitrocue and Alvetex scaffolds. Red = 2D, Blue = 3D Invitrocue and 
Green = 3D Alvetex. Error bars show maximum and minimum values. 
 
5.5.3 Discussion 
As initial infection ratio, of either parasite, was increased the overall percentage infection 
after 72 hours increased. This was true of all three conditions. It can be seen that there was 
a higher variation of the final infection rate after 72 hours in the 3D scaffolds compared to 
the 2D system. The boxes in figure 5.5-1 are much larger for the 3D scaffolds. The variation 
in the Invitrocue scaffold gives rise to values that fall either side of the values produced by 
the 2D assay and they show similar average infection rates. In contrast, the Alvetex scaffold 
shows significantly less infection than the other two conditions. A reason for this could be 
the smaller pore size336 in the Alvetex scaffold. The smaller pores mean the scaffold blocks 
more of the cell surface and this may make it difficult for the parasite to enter the cell. If the 
cells are blocking the pores then the parasites will have trouble reaching cells deeper in the 
scaffold. 
Leishmania infection in the Alvetex scaffold was very variable and difficult to achieve. For 
this reason, experiments from this point onwards will be conducted using only the Invitrocue 
scaffold. 
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5.6 3D Infection Dynamics 
5.6.1 Rationale 
Once the optimum infection ratio was chosen, the progression of the infection could be 
studied. In three dimensions, the cells have a different confirmation and cytoarchitecture, 
these differences could affect the division rate of the parasite. Infections were conducted 
using the two strains of fluorescent parasite on both 2D and 3D cell culture and the 
progression of the infection was measured. 
5.6.2 Evaluation of Infection Progression 
The change in percentage infection of either parasite over time, when maintained in either 
2D or 3D, is shown in figure 5.6-1. The mean value after 24 hours for L. major parasites in the 
2D system was 70.3±1.5% compared to the 3D systems that shows a mean infection 
percentage was 71.7±3.2% in the Invitrocue scaffold. This increased to 91.3±1.5% and 
89.0±5.2%, for the 2D and 3D respectively, after 48 hours of incubation. After 72 hours, the 
percentage infection rates were 89.8±2.5 percent for 2D and 83.8±2.8 percent for 3D. Values 
are similar between the 2D and the Invitrocue scaffold at each time point. When the data 
was compared using a student’s t-test no significant difference was seen between the 2D 
and the Invitrocue scaffold. 
The infection pattern was seen again, when the infection was caused by the L. amazonensis 
parasite, figure 5.6-1. The mean value after 24 hours in the 2D system was 64.3±1.2% 
compared to the 3D system, which shows a mean infection percentage of 63.7±0.6% in the 
Invitrocue scaffold. This increased to 83.7±4.5% and 82.7±0.5% for the 2D and 3D 
respectively, after 48 hours of incubation. After 72 hours, the percentage infection rates 
were 87.5±3.1 percent for 2D and 87.3±4.3 percent for 3D. Values are very similar between 
the 2D and the Invitrocue scaffold at each time point. When the data was compared using a 
student’s t-test no significant difference was seen between the 2D and the Invitrocue 
scaffold. 
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Figure 5.6-1. Box and whisker charts showing the infection rates of L. major (left) and L. 
amazonensis (right) in both 2D (N=6) and 3D (N=6) cell culture. 3D cell culture was 
conducted in the Invitrocue scaffolds. Red = 2D and Blue = 3D Invitrocue Error bars show 
maximum and minimum values. 
 
5.6.3 Discussion 
As expected, considering the similar infection after 72 hours in the previous experiment, the 
progression of infection was similar in both the 2D and the 3D Invitrocue scaffold. They also 
showed similar overall infection rates after 72 hours (figure 5.5-1). 
5.7 Determination of Drug Efficacies in 3D 
5.7.1 Rationale 
The effect of culturing cells in 3D on drug efficacies was determined. Changes to the cells 
confirmation allows a higher percentage of the surface area of the cell to be accessible to 
drug molecules. A larger surface area accessible could also affect the availability of 
transporters and may affect permeability. A more biologically relevant cyto-structure 
compared to cells in 2D could affect how the drugs are trafficked and processed within the 
cell. To study the differences between drug efficacies in 2D and 3D cell culture systems, AmB 
and MIL were evaluated against the L. major and L. amazonensis fluorescent strains.  
Drug efficacies were determined measuring reduction in both percentage infection and the 
number of parasites within each cell; this measurement of burden could be very different 
between macrophages cultured in 3D compared to 2D. Cells cultured in 3D have very 
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different appearances compared to those in 2D, which have spread out and flattened. This 
change in cell shape may not affect the overall number of infected cells but could have an 
effect on how many parasites have accumulated within each cell. 
Images taken in the course of the experiments were analysed computationally, both by 
Invitrocue and using the Volocity software, to produce values for both percentage infection 
and the number of parasites per cell for the 3D data. 2D counts were done manually using a 
microscope to determine both the percentage infection the average number of amastigotes 
per cells after 100 cells were counted. 
5.7.2  Determination of Drug Efficacies against L. major 
5.7.2.1 amphotericin B 
A clear reduction in percentage infection caused by dosing with amphotericin B 
concentrations between 200 nM and 12.5 nM was seen in both 2D and 3D, figure 5.7-1. EC50 
and EC90 values can be seen in table 5.7.1.  When the 2D and the 3D data, that has been 
manually counted, was compared using a one-way ANOVA there was a statistical difference, 
p<0.05. 
Parasite burden is reduced with AmB and Mil treatment, figure 5.7-1. The reduction in 
average burden with L. major shows that initially there are more parasites per cell at the 
lowest concentration of amphotericin B in 2D than in 3D. When the concentration of 
amphotericin B was increased past 50 nM, the two cell culture systems show very similar 
parasite burdens.  
No significant difference was seen in parasite burden between the two data sets when 
comparing with a one-way ANOVA. When a two-way ANOVA was used no significant 
difference was seen at any concentration. 
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Figure 5.7-1.  (Left) Dose-response curves for 2D (N=6) and 3D (N=6) cell culture showing 
the reduction in percentage infection of peritoneal macrophages by L. major produced by 
treatment using amphotericin B. The reduction in infection was scaled to a reduction in 
total infection seen in the untreated controls in either condition. (Right) Reduction in L. 
major parasite burden of peritoneal macrophages for 2D (N=6) and 3D (N=6) cell culture, 
produced by dosing with amphotericin B. Error bars show standard deviation 
 
Table 5.7-1 Table summarising the results of dosing with amphotericin B on the reduction in 
percentage infection, seen in peritoneal macrophages infected with L. major amastigotes, in 
either 2D or 3D cell culture. 
 
5.7.2.2 miltefosine 
A reduction in infection caused by treatment with miltefosine was seen in both 2D and 3D, 
figure 5.7-2. EC50 and EC90 values are shown in table 5.7-2. When the data was compared 
using a one-way ANOVA there was no a statistical difference seen. 
The graph showing the parasite burden of peritoneal macrophages that have been dosed 
with miltefosine shows, the average number of parasites per cell decreases as the 
concentration of miltefosine increases. The reduction in average burden with L. major shows 
that initially there are more parasites per cell at the lowest concentration of miltefosine in 
2D than in 3D. When the concentration of miltefosine was increased past 50 nM, the two cell 
culture systems show very similar parasite burdens. This was the same pattern seen in the 
amphotericin B treated cultures; the reason for this may be partly due to the limitations of 
 
3D Volocity Counting 3D Computer Counting 2D 
EC50 (95% CI) 
(nM) 
52.3 (46.6 to 58.7) 76.2 (37.7 to 203.5) 34.9 (31.4 to 38.6)  
EC90 (95% CI) 
(nM) 
216.6 (165.5 to 288.2) 1070.0 (237.3 to N/A) 161.5 (132.4 to 201.2)  
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the computation counting methods ability to differentiate parasites from each other in highly 
infected cells, where the fluorescent signal may overlap. Treatment of infected cells with 
miltefosine does not always show a concentration dependent reduction in a linear fashion. 
For the L. major infected macrophages the average burden per cell appears to rise between 
the lowest and the middle concentration. This was despite the percentage infection 
decreasing, meaning cells that have not been cleared by miltefosine treatment have more 
parasites in them. No significant difference was seen between the conditions when 
comparing with a one-way ANOVA. When a two-way ANOVA was used there are significant 
differences at the lowest amphotericin B concentration between the burden of L. major in 
2D and 3D, p<0.05. 
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Figure 5.7-2. (Left) Dose-response curves for 2D (N=6) and 3D (N=6) cell culture showing 
the reduction in percentage infection of peritoneal macrophages by L. major produced by 
treatment using miltefosine. The reduction in infection was scaled to a reduction in total 
infection seen in the untreated controls in either condition. (Right) Reduction in L. major 
parasite burden of peritoneal macrophages for 2D (N=6) and 3D (N=6) cell culture, 
produced by dosing with miltefosine. Error bars show SD 
 
Table 5.7-2 Table summarising the results of dosing with amphotericin B on the reduction of 
percentage infection, seen in peritoneal macrophages infected with L. major amastigotes, in 
either 2D or 3D cell culture. 
 
3D Volocity Counting 3D Computer Counting 2D 
EC50 (95% CI) 
(µM) 
5.85 (5.52 to 6.21) 
  
6.90 (4.09 to 12.22) 5.02 (4.88 to 
5.16)  
EC90 (95% CI) 
(µM) 
20.4 (17.6 to 23.7) 
  
32.0 (N/A to 189.0) 13.2 (12.0 to 
14.5)  
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5.7.3 Determination of Drug Efficacies against L. amazonensis 
5.7.3.1 amphotericin B 
Amphotericin B treatment gave a reduction in percentage infection in both 2D and 3D, figure 
5.7-3. EC50 and EC90 values are shown in table 5.7-3. When the data was compared, using a 
one-way ANOVA there was no statistically relevant difference seen. 
When comparing the burden of L. amazonensis in amphotericin B treated cultures the 
burden was always lower in cells maintained in 2D than it was in cells kept in 3D. All 
treatments of infected cells with amphotericin B show a concentration dependent reduction 
in parasite burden. No significant difference was seen in parasite burden between the two 
data sets when comparing with a one-way ANOVA. When a two-way ANOVA was used there 
are significant differences at the lowest amphotericin B concentration between the burden 
of L. amazonensis in 2D and 3D, p<0.05. 
-8 .0 -7 .5 -7 .0 -6 .5 -6 .0
-2 0
0
2 0
4 0
6 0
8 0
1 0 0
E v a lu a tio n  o f th e  a n ti- le is h m a n ia l a c tiv ity  o f  a m p h o te r ic in  B
L o g  C o n c e n tra tio n
%
 R
e
d
u
c
t
io
n
 o
f
 I
n
f
e
c
t
io
n
3 D  V o lo c ity  C o u n tin g
3 D  C o m p u te r C o u n tin g
2 D
 
Figure 5.7-3. (Left) Dose-response curves for 2D (N=6) and 3D (N=6) cell culture showing 
the reduction in percentage infection of peritoneal macrophages with L. amazonensis 
produced by treatment using amphotericin B with a variable slope and maximum and 
minimum set to 0 and 100% respectively. The reduction in infection was scaled to a 
reduction in total infection seen in the untreated controls in either condition. (Right) 
Reduction in L. amazonensis parasite burden of peritoneal macrophages for 2D (N=6) and 
3D (N=6) cell culture, produced by dosing with amphotericin B. Error bars show standard 
deviation 
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Table 5.7-3 Table summarising the results of dosing with amphotericin B on the reduction of 
percentage infection, seen in peritoneal macrophages infected with L. amazonensis 
amastigotes, in either 2D or 3D cell culture. 
 
3D Volocity Counting 3D Computer Counting 2D 
EC50(95% CI) 
(nM) 
46.65 (41.48 to 52.95)
   
63.47 (36.06 to 117.0) 68.00 (65.33 to 
70.81)  
EC90 (95% 
Ci) (nM) 
126.8 (N/A to 189.3)
  
441.7 (134.9 to 4002.0) 245.4 (223.1 to 
270.2)  
 
5.7.3.2 Miltefosine 
A reduction in infection caused by dosing with miltefosine was seen in both 2D and 3D, figure 
5.7-4. EC50 and EC90 values are shown in table 5.7-4. EC90 values generated are extrapolated 
and may not be a true indicator of the data collected.  When the data was compared, using 
a one-way ANOVA there was no statistical difference seen. 
When comparing the burden of L. amazonensis in miltefosine treated cultures the burden 
was always higher in cells maintained in 2D than it was in cells maintained in 3D. The average 
burden of the L. amazonensis infected macrophages show a very slight decrease in value 
compared to the decrease seen in the L. major infected macrophages. This matches the 
percentage infection data, as miltefosine treatment at the concentrations used in the 
experiment only manage to reduce the percentage infection by about 50%.   
No significant difference was seen between the conditions when comparing with a one-way 
ANOVA. When a two-way ANOVA no significant differences observed at any concentration 
of miltefosine. 
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Figure 5.7-4. (Left) Dose-response curves for 2D (N=6) and 3D (N=6) cell culture showing 
the reduction in percentage infection of peritoneal macrophages with L. amazonensis 
produced by dosing with miltefosine with a variable slope and maximum and minimum set 
to 0 and 100% respectively. The reduction in infection was scaled to a reduction in total 
infection seen in the untreated controls in either condition. (Right) Reduction in L. 
amazonensis parasite burden of peritoneal macrophages for 2D (N=6) and 3D (N=6) cell 
culture, produced by dosing with miltefosine. Error bars show standard deviation 
 
Table 5.7-4 Table summarising the results of dosing with amphotericin B on the reduction of 
percentage infection, seen in peritoneal macrophages infected with L. amazonensis 
amastigotes, in either 2D or 3D cell culture. 
 
5.7.4 Comparison of the Two Counting Methods used  
When the results from the two different counting methods, Volocity and Invitrocue’s 
computational counting method, for assessment of Leishmania infection in 3D cell culture 
system were compared, no significant difference was seen in any experiment when the data 
was analysed using a one-way ANOVA. The two methods show a good similarity in the values 
they produce (table 5.7-5) and hence in all cases produce similar curves. The main difference 
seen between the two methods is found at the extremities of the curves affecting the EC90 
values. A possible reason behind this was the Invitrocue computational method returned 
results with slightly less infection seen in the positive controls. This meant that when 
percentage infection rates were calculated the values were scaled up giving higher values for 
lower infection rates. This has led to a reduction in the Hill slope for some of the curves. 
 
3D Volocity Counting 3D Computer Counting 2D 
EC50 (95% CI) (µM) 19.8 (16.2 to 25.9)
  
21.4 (17.4 to 28.7) 47.6 (37.2 to 66.8)  
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Despite the difference in analysis methods, the results show a striking similarity and either 
method could be used for future analysis. 
Table 5.7-5 Table summarising the values produced by fitting a curve to the data when 
analysed in Graphpad Prism by either Volocity or Invitrocue automated counting methods 
 
5.7.5 Discussion 
There was only one case of statistically significant differences between the 2D and 3D cell 
culture systems, seen when amphotericin B was used to treat a L. major infection, and the 
data for 3D was manually counted. Whilst the rest of the results lack statistical significance, 
patterns in the data emerge. When the peritoneal macrophages were infected with L. major 
then treatment with either amphotericin B or miltefosine appears to be weaker, but not 
significantly, in the 3D cell culture system than in the 2D cell culture system. The EC50 value 
for amphotericin B when used against L. major in 2D was lower than in 3D. The values for 
miltefosine show the same pattern. EC50 values produced by both the 2D and 3D assays 
match the range of values seen in the literature50 & 161. 
Interestingly, peritoneal macrophages that are infected with L. amazonensis responded 
differently. Treatment with either amphotericin B or miltefosine appears to be more potent 
in the 3D cell culture system than in the 2D cell culture system. EC50 values generated by 
treatment of the infected macrophages with amphotericin B show the 2D system to have an 
EC50 value higher than the 3D system, when measured using the Volocity counting method 
or the Invitrocue computational counting method. Miltefosine shows the same pattern of 
higher EC50 values in the 2D system than in the 3D system. EC50 values produced by both the 
2D and 3D assays match the range of values seen in the literature316 & 325. The data shows 
that the small effect that using a 3D cell culture system has, in this experiment over a 2D cell 
culture system, is reliant on the strain of Leishmania parasite used. 
Patterns of reduction in average parasite burden between 2D and 3D are similar but there 
are some differences in the values that each system generates. As previously mentioned the 
Species EC50 of drug: Volocity Counting (µM) Invitrocue Counting 
(µM) 
L. major 
mCherry 
Amphotericin  0.052 0.076 
Miltefosine  5.85 6.90 
L. amazonensis 
DSRed2 
Amphotericin  0.047 0.063 
Miltefosine  19.8 21.4 
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burden of the 3D system was computationally counted by Invitrocue and the algorithm for 
this may have problems discerning the true number of parasites per cell in a highly infected 
cell. The fluorescent signal from the parasites may overlap, and the images captured at the 
LSHTM were not of very high quality due to the equipment used. The time and memory 
constraints if extra quality were to be added were a problem in the capture of each image as 
part of a z-stack. 
This difference in drug sensitivities between stains seen in these experiments have been 
previously reported in the literature50, 161, 316 & 325. Even in the 2D cell culture systems, the two 
different strains show different efficacies to the drugs tested. Infected peritoneal 
macrophages treated with amphotericin B show EC50 values of 34.9 nM and 68.0 nM, when 
infected with L. major or L. amazonensis respectively. Infected peritoneal macrophages 
treated with miltefosine show EC50 values of 5.0 µM and 47.6 µM, when infected with L. 
major or L. amazonensis respectively. It was clear that the two standard drugs tested show 
a higher efficacy against the L. major parasite than the L. amazonensis parasite. 
When comparing the average parasite burden data, it was clear that amphotericin B was 
more effective at reducing the parasite burden and clearing the parasite from the cells. It 
was the only drug that was able to reduce the burden below an average of 0.5 parasites per 
cell, which was seen for amphotericin in both strains and both 2D and 3D conditions. Whilst 
the miltefosine was able to reduce the percentage infection328, cells that remain infected 
show high parasite burden in comparison of those cells still infected when treated with 
amphotericin B. This high parasite burden may be able to re-establish a higher infection rate 
if treatment is not continued. This is because miltefosine shows a time and concentration 
dependent mechanism of killing, and in order to show the same reduction in burden the 
treatment time would need to be extended. 
The results shown in this experiment are largely seen when other compounds are compared 
between 2D and 3D models. Bielecka et al329, tested various anti tuberculosis drugs in a 2D 
and 3D system showing 3D has no effect on the use some compounds to treat infection, 
when compared to 2D cell culture. They also show a number of compounds that are effected 
by the switch from a 2D to a 3D cell culture system. Whether a compound changes its efficacy 
when used in 3D compared to 2D is dependent on the compound used. 
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5.8 Conclusion 
The main difference in the use of 3D cell culture is the physical shape that the cells are able 
to take. This was demonstrated by the different cell types tested in the two scaffolds. 
Another point made in the development of the 3D culture systems, was that the morphology 
and secondary structures that the cells can take are different depending on the type of 3D 
cell culture or scaffold used. Here, the two types of solid support scaffold used show drastic 
differences in the behaviour of the cells and the shapes that form within them. Another 
important distinction was that different types of scaffold are more suited for different cell 
types. Macrophages are fully differentiated cells that are infected more naturally in the 
Invitrocue sponge. In the Invitrocue sponge, they have formed large grape like structures 
allowing the parasites a loci of cells to infect or re-infect. The large pore size is perfect for 
the cells to accumulate grouping together forming a secondary structure with only the cells 
in the periphery forming contacts to the sponge. The cells can be maintained in each pore 
without the cells multiplying forcing the cells to move out of the pore to find more space. 
Alternatively, the macrophages are more difficult to infect in the Alvetex scaffold, the cells 
are more spread out and can be seen to stick fully to the scaffold and its smaller pore system. 
Hence, for the establishment of infection and treatment of infection, the Invitrocue sponge 
was the obvious choice. 
The switch from 2D to 3D cell culture showed no difference in the viability of the cells over 
short periods of time. The period of time where there was no obvious difference between 
the viability in the two systems covers the standard time taken for a 3 day drugging 
experiment. Whilst opinions vary on whether 2D and 3D cell culture differ in cell viability, at 
least when using the Invitrocue sponge it can been seen that there was no significant 
difference over the period that all experiments were run. After this period, the 3D cell culture 
seems to maintain the cells for longer than the 2D cell culture, another observation reported 
in the literature317-319. 
The infection of the macrophages by Leishmania parasites, either in 2D or 3D cell culture 
systems, show no difference in the total percentage infection after 72 hours or in the 
development of that infection. This was not surprising, as the 3D cell culture system has large 
pores, which allow the Leishmania parasites easy access to the macrophages. Additionally, 
the secondary grape like structure that the cells form was on average only a few cells thick, 
meaning almost every cell is freely accessible to the parasites direct from the media. The way 
that the parasites encounter the macrophages is similar in the 2D and 3D cell culture systems 
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used here. Another study337 using the Invitrocue scaffold with Hepatitis C virus showed that 
the virus accumulated more in the cell maintained in 3D. This however, may be due to the 
cell type used, hepatocytes in 3D has been shown to maintain their function better238, 301 & 
311, and this may lead to a higher accumulation of virus. 
With no differences in viability or infection potential between the 2D and 3D cell culture 
systems, the starting point of the experiments for determining drug efficacies are the same 
in both 2D and 3D. The slight differences seen in either 2D or 3D cell culture systems appear 
to be dependent on the species of parasite used. L. major parasites are less susceptible to 
treatment with drugs when cultured in 3D, when compared to a 2D cell culture system. 
Whereas, L. amazonensis parasites appear to be more susceptible to treatment when 
cultured in 3D. However, there was no statistically significant differences between the two 
different culture systems when comparing percentage infection. When comparing reduction 
of parasite burden, there are some significant differences at certain concentrations of drug. 
This could be due to the differences between the counting methods and when compared as 
a whole trend of parasite reduction, no significant difference in the trend was seen. 
In other studies in this area, a variety of differences in sensitivity to drug exposure between 
cells grown in 2D and 3D are seen. One study279 showed, A431.H9 cells grown in 2D and 3D 
show differences in viability when treated with the same concentrations of 5-fluorouracil 
and tirapazamine. In the case of 5-fluorouracil, 2D cultures showed a reduced viability 
compared 3D spheroids. Additionally, cells treated with tirapazamine showed a higher 
viability in 2D compared to 3D. This research highlights the fact that cells in 3D do not 
necessarily exhibit a higher drug resistance, but that it is a combination of the specific drug 
and the cellular environment that influence the cells reaction. Another paper338 showed that 
fibroblast in 3D exhibited a higher resistance to doxorubicin compared to 2D controls and 
cells grown in 3D and then treated with tamoxifen are less susceptible to the cytotoxic effects 
of the drug than cells grown in 2D. 
In conclusion, the transition from 2D cell culture to 3D cell culture has large effects on the 
morphology and the dynamics of cell to cell contact, depending on the type of 3D system 
used. The choice of 3D scaffold can alter the pattern of infection by Leishmania parasites. 
Therefore, selection of scaffold to suit the purposes of the model is very important. 
There was little to no effect on the infection of macrophages maintained in the Invitrocue 
scaffold by Leishmania parasites. Additionally, the treatment of infected macrophages in 
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mouse peritoneal macrophages, in the Invitrocue scaffold appears to be largely unaffected 
by being maintained in a 3D cell culture system. It is important to realise that in biological 
situations cells will be far more similar to the cells maintained in the 3D cell culture systems 
than cells maintained in 2D. This section shows that the differences between 2D and 3D cell 
culture are not enough to show a statistically relevant difference when comparing the results 
of the experiments. Differences between 2D and 3D cell culture systems may have effects in 
other areas but in the context of the experiments conducted, no significant differences are 
seen. The use of a 3D cell culture system may take on a more important role when combined 
with other aspects in the creation of a more predictive and more biologically relevant in vitro 
model. 
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Chapter 6 Evaluation of Cell Choice for an In Vitro 
Model 
6.1 Introduction 
The aim of this thesis is to investigate different ways in which the current In vitro model 
systems could be more predictive of in vivo results. Current in vitro approaches use a variety 
of different cell types. From cell lines to primary cells, the choice of cell for use in an assay 
can depend on availability and personal preferences. In this results chapter, the use of 
induced pluripotent stem cells are compared to mouse and human bone marrow derived 
macrophages and to THP1 cells for their suitability in in vitro assays. 
In 2006, Takahashi and Yamanaka320 showed that the forced expression of four transcription 
factors (Oct4, Sox2, Klf4, and c-Myc) was sufficient to convert fibroblast cells into embryonic 
stem cell-like cells, which were called induced pluripotent stem cells (iPSC). A process called 
reprogramming, where timed expression of master regulator factors changed differentiated 
cells into iPSCs. Since then, a variety of starting cell types, different combinations of main 
transcription factors and techniques used to deliver the transcription factors into cells have 
been used successfully. 
Pluripotent stem cells allow the production of primary human cells of any lineage in a way 
that can be constantly replenished, just as with cell lines. iPSC derived macrophages are 
genetically highly related to their original donor cells, sharing phenotypic and functional 
similarities with primary human macrophages. Being closer to the cells found within the 
human body, these cells could be more predictive in cellular assays191. The use of iPSCs has 
the added advantage that the cells can be donor specific and have been shown to react in 
the same way as the macrophages taken from the patient. However, the potential of iPSC 
derived macrophages in host-pathogen interaction has not been fully investigated.  
In the past, a large range of cell types and sources have been used to study infection by 
Leishmania parasites and determination of anti-leishmanial drug activity. Cell lines such as 
the Sticker dog sarcoma fibroblasts cell line155, transformed rodent macrophage cell lines156 
and human monocytic cell line, derived from an acute monocytic leukaemia patient (THP-1), 
have been widely used due to their immortalised status. Cell lines have advantages such as 
unlimited division potential and are easy to maintain in culture. Cell lines however, are 
usually immortalised because of a mutation in the controls of the cell cycle; this can affect 
the response of the cell and its functions. Immortalized cell lines can be created by fusing a 
primary cell with a cancer cell line. This can lead to the resulting cell line having some of the 
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properties of the cancer, such as the intended immortalisation but also other phenotypes190. 
The mutation means that the cell line, whilst easy to obtain and use, may not be the same as 
the cell that they are representing within an in vitro system. 
Primary isolated cells are cells taken directly from the body, such as mouse peritoneal or 
bone marrow macrophages and human monocyte-derived macrophages. These cells are 
normally used straight away, as they only maintain the functionality and similarity to cells 
within the body for a short period229. The main problem with primary cells is that they are 
difficult to obtain. Human primary cells are mainly generated from surgery and require the 
patient’s permission for research. Mouse cells are more easily obtainable but a Home Office 
license and training are required for use of animals in experimentation, as well as a 
specialised unit for the animals. A finite number of cells are obtained from each animal, and 
this means that multiple animals are needed to generate the number of cells required.  
iPSC derived macrophages are both able to proliferate and are primary cells showing 
similarity to the native cell. They are more difficult to obtain than cell lines and more 
expensive to maintain. When compared to primary cells, their expansion potential is a great 
advantage but they can occasionally mutate into a cancer phenotype due to their 
unrestricted growth cycle321, caused by the additions of stem cell transcription factors.  
There is currently no literature, to the best of my knowledge, on the use of iPSC derived 
macrophages and Leishmania parasites. However, iPSC derived macrophages have been 
used for other infectious diseases. Such as Chlamydia trachomatis322 and Salmonella 
enterica323. A recent paper showed that iPSC derived macrophages support the full infectious 
life cycle of C. trachomatis mimicking the infection of human blood-derived macrophages in 
vivo322. Transcriptomic and proteomic profiling of the macrophage response to chlamydial 
infection highlighted the role of the type I interferon and interleukin 10-mediated responses, 
as in the body. The researchers used human iPSCs in combination with CRISPR/Cas9 gene 
editing technology, to knock out genes making the macrophages more susceptible and 
showing the importance of the gene in resistance to the pathogen, which would be difficult 
to do on primary cells. They showed the iPSC to be suitable for gene editing with CRISPR/Cas9 
and C. trachomatis infections, allowing the study of pathogen host interactions322. Another 
group explored the potential of human iPSC derived macrophages to study S. enterica 
interactions323. They showed iPSC derived macrophages express a panel of established 
macrophage specific markers, produce cytokines, and polarise into classical and alternative 
activation states in response to IFN-γ and IL-4 stimulation, respectively. iPSC derived 
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macrophages also efficiently phagocytosed inactivated bacterial particles as well as live 
Salmonella typhi and S. typhimurium and were able to kill these pathogens. It was concluded 
that iPSC derived macrophages can support productive Salmonella infection and propose this 
as a flexible system to study host/pathogen interactions323. 
Other groups have used iPSC derived macrophages to study viruses. In one study, 
researchers generated iPSCs and edited their genome to give a phenotype of resistance to 
HIV-1 infection. These modified iPSCs were then differentiated into macrophages and 
demonstrated their resistance to a HIV-1 challenge. It was concluded that this strategy might 
provide an approach toward a functional cure of HIV-1 infection324. 
The objectives of the work discussed in this Chapter are to: 
I. Establish an infection in iPSC derived macrophages with Leishmania 
parasites and compare with that in other cells that are commonly used in in 
vitro assays.  
II. Determine the activity of standard drugs in iPSC derived macrophages and 
compare with results in other cell lines.  
III. Determine the suitability of iPSC derived macrophages as a host cell in in 
vitro assays to investigate the anti-leishmanial activity of compounds. 
6.2 Cell Comparison 
As mentioned in the previous chapter, the conformation of a cell is important to its function 
and response to Leishmania parasites. Whilst all the cells used in this chapter are cultured in 
2D and are all macrophages, they are not all equal. In this section, the different cells were 
compared, table 6.2-1, showing they come in a variety of sizes and whether this has any 
effect on the infection with Leishmania parasites. 
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 Table 6.2-1 Table comparing the properties of the four cell types used in this chapter. 
 
6.2.1 Cell Size 
The average size of each cell type was measured using two different methods. Firstly, the 
protein content of the cells was determined using a BCA protein assay, figure 6.2-1, the 
theory being that the larger the cell, the more protein it will contain. The second method of 
size determination was to culture each cell type in 3D, then capture images of the cells using 
the confocal microscope, then analyse the images with the Volocity software to determine 
cell volume, shown in figure 6.2-1.  
 
 THP-1 cells Mouse bone 
marrow 
macrophages 
Human bone 
marrow 
macrophages 
iPSC 
Abbreviation THP1 MBMM HBMM iPSC 
Species Human Mouse Human Human 
Cell type Monocyte Mononuclear Mononuclear Monocyte 
Category Cell line Primary cell Primary cell iPSC 
Source Acute 
monocytic 
leukaemia 
Mouse femur 
and tibia 
Bone Originally Skin 
Supplier ATCC LSHTM ATCC Wellcome 
Trust Sanger 
Institute  
Differentiation 
signal 
phorbol 12-
myristate 13-
acetate 
Human m-CSF Human m-CSF Human m-CSf 
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Figure 6.2-1.  Protein concentrations of single cells (Left) (N=9) and cell volume (Right) (N=9) 
for each cell type. Statistical significance in a one-way ANOVA * = p<0.05 ** = p<0.01 *** = 
p<0.001 **** = p<0.0001. Error bars show SD. 
 
The four cell types can be seen to have the same size order in both measures of cell size, 
shown in figure 6.2-1. THP-1 cells are the largest, followed by iPSCs while the mouse and 
human bone marrow macrophages are the smallest and are similar to each other. There are 
statistical differences among the cells when the data was compared using a one-way ANOVA. 
The protein concentration of THP-1 cells show a statistical difference when compared to 
mouse bone marrow macrophages, p<0.0001, human bone marrow macrophages, p<0.0001, 
and iPSCs, p<0.05. iPSC protein concentrations show statistical differences when compared 
with the protein concentrations in mouse bone marrow macrophages and human bone 
marrow macrophages, p<0.001. When comparing the volume of the cells statistical 
difference was seen only between THP-1 cells and the other three cell types. The volume of 
THP-1 cells shows a statistical difference when compared to mouse bone marrow 
macrophages, p<0.0001, human bone marrow macrophages, p<0.001, and iPSCs, p<0.01.  
6.2.2 Parasite Burden 
To give a representation of how the cell size affects the parasite burden, L. major JISH 
samples from the establishing infection potential section, Chapter 6 Section 3, were re-
analysed.  The number of parasites in a population of infected cells were counted to give an 
average parasite burden. 
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Figure 6.2-2. Two measurements of parasite burden, parasite burden across different cell 
types when using the same initial infection ratio (Left) (N=3) and parasite burden when 72 
hour percentage infection rate was kept within ± 5% (Right) (N=3) in each cell type. 
Statistical significance in a one-way ANOVA * = p<0.05 ** = p<0.01 *** = p<0.001 **** = 
p<0.0001. Error bars show SD. 
 
When comparing the parasite burden per cell (figure 6.2-2), the same pattern emerges 
whether burdens are compared across cell types with the same initial infection ratio or cell 
with the same final infection rate. The pattern shows that parasite burden was highest in 
iPSC derived macrophages. The next highest burden was in HBMM closely followed by 
MBMM. Finally, THP1 cells show the lowest parasite burden. 
Using a one-way ANOVA, comparing the burden data for the data set generated using 
samples which all had the same initial infection ratio, statistical significant differences are 
seen between all cell types, p<0.0001, except between THP1 cells and MBMM which have a 
significance value of p<0.01. Using a one-way ANOVA, to compare the burden data for the 
data set generated using samples which all had the same final infection rate, statistical 
significant differences are seen between iPSC derived macrophages and all other cell types, 
p<0.0001. Significant differences are also seen between THP1 cells and both MBMM and 
HBMM, p<0.001. No difference was seen between HBMM and MBMM.  
The pattern observed in the burden of the cells was that the easier the cell type was to infect 
the higher the burden is in both sample sets. Cell size has no effect on the parasite burden, 
this is clear as THP1 cells are the largest cell and show the lowest burden. 
6.3 Establishing the Infection Potential 
The first step in exploring how the different cell types respond to Leishmania infection was 
to establish an infection within the system. A variety of initial infection ratios have been 
studied using four different parasite strains to try to establish a high infection rate that is 
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equivalent across all cell types, for each parasite. An optimal infection rate would be 
between 80-95%, as this is high enough for reductions to be easily seen, but not so high that 
the cells are over infected. It is important that the overall levels of infection match, as they 
will need to be the same to avoid dose inoculum effects when treating with drugs. 
6.3.1 Infection Rates 
As the initial infection ratio was increased, an increase in percentage infection after 72 hours 
was seen (figure 6.3-1) for all four parasites strains. The percentage infection after 72 hours 
showed variation between both strains and cell types. In the L. major JISH graph the infection 
rates, when an initial infection ratio of 0.5 parasites per cell was used, are 11.3, 46.0, 66.4 
and 75.1% for the four cells types, THP1, MBMM, HBMM and iPSC derived macrophages 
respectively. iPSC derived macrophages pass over the 80% mark at a 1:1 ratio and reach 
100% infection at an initial infection ratio of 2:1. The HBMM exceed the 80% infection rate 
at the 3:1 ratio and reach their peak infection at 7:1. The MBMM exceed the 80% infection 
rate at the 3:1 ratio and reach their peak infection at 5:1. The THP1 cells pass over the 80% 
infection rate at the 5:1 ratio. 
In the L. major mCherry graph (figure 6.3-1), the infection rates, when an initial infection 
ratio of 0.5 parasites per cell was used, are 12.1, 38.2, 67.7 and 70.8% for the four cells types, 
THP1, MBMM, iPSC derived macrophages and HBMM respectively. iPSC derived 
macrophages pass over the 80% mark at a 2:1 ratio and reach 100% infection at an initial 
infection ratio of 3:1. The HBMM pass over the 80% infection rate at the 2:1 ratio and reach 
their peak infection at 7:1. The MBMM pass over the 80% infection rate at the 5:1 ratio and 
reach their peak infection at 10:1. The THP1 cells pass over the 80% infection rate at the 5:1 
ratio and reach their peak infection at 10:1. 
In the L. amazonensis graph (figure 6.3-1) the infection rates, when an initial infection ratio 
of 0.5 parasites per cell was used, are 12.0, 32.7, 42.2 and 50.3% for the four cells types, 
THP1, MBMM, HBMM and iPSC derived macrophages respectively. iPSC derived 
macrophages pass over the 80% mark at a 3:1 ratio and reach 100% infection at an initial 
infection ratio of 7:1. The HBMM pass over the 80% infection rate at the 5:1 ratio and never 
reach their peak infection, in the tested range. The MBMM pass over the 80% infection rate 
at the 7:1 ratio and never reach their peak infection, in the tested range. The THP1 cells pass 
over the 80% infection rate at the 10:1 ratio. 
In the L. mexicana graph (figure 6.3-1) the infection rates, when an initial infection ratio of 
0.5 parasites per cell was used, are 28.8, 44.6, 52.8 and 78.8% for the four cells types, THP1, 
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HBMM, iPSC derived macrophages and MBMM respectively. iPSC derived macrophages pass 
over the 80% mark at a 2:1 ratio and reach 100% infection at an initial infection ratio of 5:1. 
The HBMM pass over the 80% infection rate at the 5:1 ratio and reach their peak infection 
at 7:1. The MBMM pass over the 80% infection rate at the 1:1 ratio and reach their peak 
infection at 2:1. The THP1 cells pass over the 80% infection rate at the 7:1 ratio and reach 
their peak infection at 10:1. 
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Figure 6.3-1. Percentage infections of L. major JISH (Top Left), L. major mCherry (Top Right), 
L. amazonensis (Bottom Left) and L. mexicana (Bottom Right) after 72 hours measured in 
each of the four cell types. N = 9. Line shows 80% infection. Error bars show maximum and 
minimum values. 
 
6.3.2 Strain Variation 
Differences in the percentage infection after 72 hours were seen between the four different 
parasite strains, figure 6.3-1. In THP1 cells, L. mexicana gave the highest percentage infection 
after 72 hours when initial infection ratios of parasite:cell between 0.5:1 to 2:1 were used. 
At these concentrations the percentage of cells infected with L. mexicana was statistically 
significantly higher than all other parasites used, p<0.0001. Between initial infection ratios 
of 3:1 and 10:1 in THP1 cells L. mexicana had a similar percentage infection after 72 hours as 
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L. major JISH and L. major mCherry. L. amazonensis was consistently giving the lowest 
percentage infection after 72 hours, figure 6.3-1, and was statistically lower than all other 
parasite strains between initial infection ratios of 2:1 up to 10:1, p<0.0001.  
In mouse bone marrow macrophages, L. mexicana gave the highest percentage infection 
after 72 hours at all initial infection ratios. L. mexicana gave statistically significantly higher 
percentage infection than all other parasites used, p<0.0001, until the 3:1 ratio, where L. 
major JISH becomes statistically the same. At an initial infection ratio of 7:1 the L. major 
mCherry becomes statistically the same as the L. mexicana. At an initial infection ratio of 
10:1 percentage infection with L. mexicana showed a smaller statistical significance when 
compared with L. amazonensis, p<0.01. L. amazonensis was consistently giving the lowest 
percentage infection after 72 hours, and was statistically lower than all other parasite strains, 
except L. major mCherry, at initial ratios of 5:1 and 10:1.  
In human bone marrow macrophages, L. major JISH and L. major mCherry gave the highest 
percentage infections after 72 hours at all initial infection ratios, figure 6.3-1. The two strains 
gave a statistically significantly higher percentage infection than other parasites used, until 
the 7:1 ratio. After this, all parasites gave near 100% infection rates after 72 hours. L. 
mexicana and L. amazonensis showed similarity in the percentage infection between an 
initial infection ratios of 0.5:1 to 2:1. After this L. amazonensis, again, becomes the strain 
that causes the lowest percentage infection. 
In iPSC derived macrophages, L. major JISH gave the highest percentage infections after 72 
hours, at all initial infection ratios, figure 6.3-1. The two L. major strains gave a statistically 
significantly higher percentage infection, p<0.0001, than other parasites used until the 3:1 
ratio, when the infection rate reaches 100%. At 5:1, all parasite strains gave infection rates 
near 100% after 72 hours. L. major mCherry gave the next strongest infection rates, at the 
lower initial infection ratios, followed by L. mexicana. L. amazonensis again showed the 
lowest percentage infection of all strains at any initial infection ratio. 
To give an overall perspective, L. amazonensis consistently gave the lowest percentage 
infection at most initial infection ratios. L. mexicana gave the highest infection in both THP1 
cells and mouse bone marrow macrophages. L. major JISH gave the strongest infection in 
iPSC derived macrophages and L. major mCherry gave the strongest infection in human bone 
marrow macrophages. In general, L. major JISH, L. major mCherry and L. mexicana all gave 
over 80% infection rates at the same initial infection ratio across the different cell types.  
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6.3.3 Discussion 
THP1 cells consistently showed the lowest percentage infection when infected at any ratio 
of parasites to cells. They are the cell type that was most resistant to infection by Leishmania 
parasites. The iPSC derived macrophages showed the highest percentage infection for most 
of the infection ratios, across the four parasites used. Mouse and human bone marrow 
macrophages showed similar infection when using L. major JISH and L. amazonensis, but 
when using L. mexicana mouse bone marrow macrophages showed a higher infection than 
human bone marrow macrophages. The opposite was seen when using L. major mCherry, 
with human bone marrow macrophages showing a higher infection than mouse bone 
marrow macrophages. 
All cell types used were successfully able to phagocytose Leishmania parasites, and infection 
was sustained up to 72 hours. Each cell has the required receptors for Leishmania entry to 
the cells; however, the number of receptors may differ between cell types.  Another 
difference between the cell types could be the survival process for the Leishmania. A study339 
has shown that the iPSC derived macrophages and THP1 cells are both able to phagocytose 
inert particles at similar rates. Further to this, a study340 on the differential gene expression 
in macrophages upon polarization looked at the gene expression of all four cell types used 
here. They concluded that the iPSC derived macrophages were most similar to the human 
bone marrow macrophages. The results of the experiments in this chapter show the same, 
with infection rates similar between the iPSC derived macrophages and the human bone 
marrow macrophages. The paper’s340 findings, for the classical M1 type activation, shows 
that the mouse bone marrow macrophages show the most difference when compared to the 
other cell types. This result, of mouse bone marrow macrophages showing the most 
difference, was not replicated in the experiments in this chapter, as the data produced shows 
THP1 cells to have the largest difference in response to Leishmania parasites. 
In a previous study341, L. infantum was used to infect macrophages derived from human 
peripheral blood, macrophages differentiated from human cell line U-937, mouse bone 
marrow derived macrophages, mouse peritoneal macrophages and canine monocyte-
macrophage cell line DH82. The study showed mouse peritoneal macrophages and DH82 
macrophages were less permissive to Leishmania infection. The other three showed similar 
infection rates. Although these are not the same cells as those used in our study, the results 
in this thesis agree by showing similar percentage infection between mouse and human bone 
marrow macrophages, whilst the cell line show the lowest infection. 
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The goal of this set of experiments was to elucidate the initial infection ratio that would give 
an overall infection percentage after 72 hours of between 80-90%. This is important as it 
means that future experiments can be standardised, giving similar percentage infections in 
all wells after 72 hours, using any parasite strain or cell type. Using the information in table 
6.3-1, dose inoculum effects can be avoided and treatment with drugs can be compared 
fairly.  
Table 6.3-1 Table showing the optimal initial infection ratio for each parasite strain for each 
of the four different cell types used in this results chapter. 
 
6.4 Determining the Efficacy of Standard Drugs 
6.4.1 amphotericin B 
A dose-response was seen when amphotericin B was used to treat the infected macrophages 
(figure 6.4-1). EC50 and EC90 values for the amphotericin B treatment, of each cell type 
infected with each parasite are shown in table 6.4-1. 
Table 6.4-1 EC50 and EC90 results for amphotericin B against different parasites in different cell 
types. 
Parasite/Cell Value IPSC (nM) MBMM (nM) THP1 (nM) HBMM (nM) 
L. major JISH EC50 35.9 33.5 46.4 33.6 
EC90 105.2 62.9 69.8 54.4 
L. major 
mCherry 
EC50 70.7 44.1 69.0 38.2 
EC90 182.0 85.0 102.8 78.5 
L. amazonensis EC50 79.8 60.9 63.4 51.1 
EC90 229.2 251.6 163.5 188.8 
L. mexicana EC50 59.8 55.4 76.5 67.8 
EC90 102.4 109.2 140.1 131.5 
 
A two-way ANOVA, testing the influence of cell type on the treatment of L. major JISH 
parasite infection, showed  a statistical difference between iPSC derived macrophages and 
Species THP1 mBMM hBMM iPSC 
L. major JISH 5:1 3:1 3:1 1:1 
L. major mCherry 5:1 5:1 2:1 2:1 
L. amazonensis 10:1 7:1 7:1 3:1 
L. mexicana 7:1 1:1 5:1 2:1 
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THP1 cells at the highest drug concentration used, p<0.05. At the second highest 
concentration statistical difference was seen in the percentage reduction between iPSC 
derived macrophages and all other cell types, p<0.0001. At the second lowest concentration 
statistical difference was seen in the percentage reduction between all cell types, p<0.0001. 
At the lowest concentration statistical difference was seen in the percentage reduction 
between iPSC derived macrophages and all other cell types, p<0.001. 
When a two-way ANOVA, testing the influence of cell type on the treatment of L. major 
mCherry parasite infection, was used a statistical difference was seen between iPSC derived 
macrophages and all other cell types at the highest concentration used, p<0.0001. At the 
second highest concentration, statistical difference was seen in the percentage reduction 
between all cell types, p<0.0001, except when comparing MBMM and HBMM. At the second 
lowest concentration, statistical difference was seen in the percentage reduction between 
all cell types, p<0.0001. At the lowest concentration, no statistical difference was seen. 
When a two-way ANOVA was used, testing the influence of cell type on the treatment of L. 
amazonensis parasite infection, no statistical difference was seen at the highest 
concentration used. At the second highest concentration, statistical difference was seen in 
the percentage reduction between all cell types p<0.01, except between iPSC derived 
macrophages and MBMM and between THP1 cells and HBMM. At the second lowest 
concentration, statistical difference was seen in the percentage reduction between all cell 
types, p<0.001. At the lowest concentration, statistical difference was seen in the percentage 
reduction between MBMM and all other cell types, p<0.05.   
When a two-way ANOVA, testing the influence of cell type on the treatment of L. mexicana 
parasite infection, was used no significant difference was seen between any of the cell types 
used at the highest concentration. At the second highest concentration, statistical difference 
was seen in the percentage reduction between all cell types, p<0.01, except when comparing 
iPSC derived macrophages and MBMM. At the second lowest concentration, statistical 
difference was seen in the percentage reduction between all cell types, p<0.01. At the lowest 
concentration, no significant difference was seen in the percentage reduction when 
comparing all cell types, except between HBMM and THP1 cells, p<0.01. 
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Figure 6.4-1. Reduction of percentage infections of L. major JISH (Top Left), L. major 
mCherry (Top Right), L. amazonensis (Bottom Left) and L. mexicana (Bottom Right) after 72 
hours caused by treatment with amphotericin B measured in each of the four cell types. N = 
9 Error bars show Standard deviation (SD) 
 
6.4.2 Miltefosine 
A dose-response was seen when miltefosine was used to treat the infected macrophages, 
figure 6.4-2. EC50 and EC90 values for the miltefosine treatment of each cell type infected with 
each parasite are seen in table 6.4-2. 
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Table 6.4-2 EC50 and EC90 results for miltefosine against all parasites in all cell types used. 
 
A reduction in percentage infection was seen when increasing the concentration of 
miltefosine used to dose, across all cell types and all Leishmania species used, although it 
was noticeably weaker against L. amazonensis. When a two-way ANOVA was used, testing 
the influence of cell type on the treatment of L. major JISH parasite infection, statistical 
difference was seen between all cell types used, p<0.0001, at the highest concentration, 
except between iPSC derived macrophages and HBMM and between THP1 cells and MBMM. 
At the second highest concentration, statistical difference was seen in the percentage 
reduction between MBMM and all other cell types, p<0.05. At the second lowest 
concentration, statistical difference was seen in the percentage reduction between all cell 
types, p<0.0001, except between MBMM and HBMM. At the lowest concentration, statistical 
difference was seen in the percentage reduction between iPSC derived macrophages and 
both MBMM and THP1 cells, p<0.01. Significant differences are also seen between THP1 cells 
and HBMM, p<0.01. 
When a two-way ANOVA was used, testing the influence of cell type on the treatment of L. 
major mCherry parasite infection using miltefosine, statistical difference was seen between 
HBMM and all other cell types at the highest concentration used, p<0.0001. A significant 
difference was also seen when comparing MBMM and THP1 cells at the highest 
concentration of miltefosine. At the second highest concentration, statistical difference was 
seen in the percentage reduction when comparing all cell types, p<0.0001, except when 
comparing MBMM and iPSC derived macrophages. At the second lowest concentration, 
statistical difference was seen in the percentage reduction between all cell types, p<0.0001, 
except when comparing MBMM to either HBMM or THP1 cells. At the lowest concentration, 
Parasite/Cell Value IPSC (µM) MBMM 
(µM) 
THP1 (µM) HBMM (µM) 
L. major JISH EC50 5.8 6.4 7.7 7.4 
EC90 37.0  19.2 17.4 34.2 
L. major 
mCherry 
EC50 15.3 14.9 9.6 4.9 
EC90 105.2 170.3 67.7 16.1 
L. amazonensis EC50 76.6 25.3 28.2 14.3 
EC90 229.2 251.6 163.5 188.8 
L. mexicana EC50 5.3 5.0 4.8 6.0 
EC90 17.2 16.1 15.8 25.1 
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statistical difference was seen when comparing HBMM to the other cell types, p<0.05, same 
comment as above, group 
When a two-way ANOVA, testing the influence of cell type on miltefosine treatment of L. 
amazonensis parasite infection, statistical difference was seen at the highest concentration 
used between all cell types, p<0.0001, except between MBMM and THP1 cells. At the second 
highest concentration, statistical difference was seen between all cell types p<0.05, except 
between HBMM and MBMM. At the second lowest concentration, statistical difference was 
seen in the percentage reduction between iPSC derived macrophages and both HBMM and 
MBMM, p<0.001. Significant differences are also seen between THP1 cells and HBMM, 
p<0.001, at the second lowest concentration. At the lowest concentration, no statistical 
difference was seen in the percentage reduction any of the cell types. 
When a two-way ANOVA was used, to test the influence of cell type on the treatment of L. 
mexicana parasite infection with MIL, no significant difference was seen between any of the 
cell types used at any concentration except the second highest. At the second highest 
concentration, statistical difference was seen in the percentage reduction between HBMM 
and all other cells types, p<0.0001. 
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Figure 6.4-2. Reduction of percentage infections of L. major JISH (Top Left), L. major 
mCherry (Top Right), L. amazonensis (Bottom Left) and L. mexicana (Bottom Right) after 72 
hours caused by treatment with miltefosine measured in each of four cell types. N = 9 Error 
bars show SD. 
 
6.4.3 Sodium Stibogluconate 
A dose-response was seen when sodium stibogluconate was used to treat the infected 
macrophages, figure 6.4-3. EC50 and EC90 values for the sodium stibogluconate treatment of 
each cell type infected with each parasite are seen in table 6.4-3. 
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Table 6.4-3 EC50 and EC90 results for sodium stibogluconate against all parasites in all cell types 
used. 
Parasite/Cell Value IPSC (µg of 
SBV/ml) 
MBMM (µg 
of SBV/ml) 
THP1 (µg of 
SBV/ml) 
HBMM (µg 
of SBV/ml) 
L. major JISH EC50 355 2770 186 348 
EC90 N/A N/A N/A N/A 
L. major 
mCherry 
EC50 220 730 253 434 
EC90 N/A N/A N/A N/A 
L. amazonensis EC50 306 503 459 255 
EC90 N/A N/A N/A N/A 
L. mexicana EC50 347 435 1840 299 
EC90 N/A N/A N/A N/A 
 
When a two-way ANOVA was used, to test the influence of cell type on the treatment of L. 
major JISH parasite infection with sodium stibogluconate, statistical difference was seen 
between all cell types at the highest concentration used, p<0.0001. At the second highest 
concentration, statistical difference was seen in the percentage reduction between iPSC 
derived macrophages and all other cell types, p<0.0001, except between iPSC derived 
macrophages and HBMM, which only gave a p value less than 0.05. At the second lowest 
concentration, statistical difference was seen in the percentage reduction between all cell 
types, p<0.0001, except between THP1 cells and HBMM. At the lowest concentration, no 
statistical difference was seen in the percentage reduction between any of the cell types, 
except between MBMM and THP1 cells, p<0.01. 
When a two-way ANOVA was used, to test the influence of cell type on the sodium 
stibogluconate treatment of L. major mCherry parasite infection, statistical difference was 
seen between all cell types at the highest concentration used, p<0.0001. At the second 
highest concentration, statistical difference was seen in the percentage reduction between 
all cell types, p<0.0001, except when comparing THP1 cells and iPSC derived macrophages. 
At the second lowest concentration, statistical difference was seen in the percentage 
reduction between MBMM and all cell types, p<0.0001. At the lowest concentration, 
statistical difference was seen between iPSC derived macrophages and MBMM and THP1 
cells, p<0.05. 
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When a two-way ANOVA was used to test the influence of cell type on the treatment of L. 
amazonensis parasite infection with sodium stibogluconate, statistical difference was seen 
at the highest concentration used, between the different cell types used, p<0.0001. At the 
second highest concentration, statistical difference was seen in the percentage reduction 
between all cell types p<0.01. At the second lowest concentration, statistical difference was 
seen in the percentage reduction between all cell types, p<0.0001, except when comparing 
MBMM and THP1 cells. At the lowest concentration, statistical difference was seen in the 
percentage reduction between HBMM and THP1 cells, p<0.05. 
When a two-way ANOVA was used, to test the influence of cell type on the dosing of L. major 
JISH parasite infection with sodium stibogluconate, significant differences are seen between 
all of the cell types, p<0.0001, at the highest concentration, except when comparing iPSC 
derived macrophages and MBMM, p<0.05. At the second highest concentration, statistical 
difference was seen in the percentage reduction between all cell types, p<0.01, except when 
comparing iPSC derived macrophages and MBMM. At the second highest concentration, 
statistical difference was seen in the percentage reduction between all cell types, p<0.01, 
except between iPSC derived macrophages and HBMM. At the second lowest concentration, 
statistical difference was seen in the percentage reduction between all cell types, p<0.01, 
except between iPSC derived macrophages and both HBMM and MBMM. At the lowest 
concentration, no significant difference was seen in the percentage reduction when 
comparing all cell types. 
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Figure 6.4-3. Reduction of percentage infections of L. major JISH (Top Left), L. major 
mCherry (Top Right), L. amazonensis (Bottom Left) and L. mexicana (Bottom Right) after 72 
hours caused by treatment with sodium stibogluconate measured in each of four cell types. 
N = 9 Error bars show SD 
 
6.5 Discussion 
When using AmB the EC50 values generated were similar to each other, across all cell types. 
There was no set, or repeated order, that was conserved amongst infection using the 
different species of parasite.  
EC50 values for MIL show similarity when L. major JISH or L. mexicana cause the infection. 
When L. major mCherry was used, responses are more variable. However, when L. 
amazonensis was used, the MIL was seen to be ineffective in treating the infection. There 
was no repeated pattern seen in the data, no one cell type that responds better to the 
treatment with MIL no matter the species used. When EC90 values were compared, THP1 
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cells show the lowest EC90 values and iPSC derived macrophages showed the highest EC90 
values. 
EC50 values for SSG treatment of infected macrophages show relative similarity between cell 
types with a couple outliers. MBMM gave a very high value for the EC50 values when SSG was 
used to treat L. major JISH or L. major mCherry infections. Another high EC50 value was seen 
when THP1 cells were infected with L. mexicana parasites. 
A study342 on three cell types; THP1 cells, human peripheral blood mononuclear cell derived 
macrophages and mouse peritoneal macrophages infected with L. donovani, tested 
numerous drug compounds. They showed that the efficacy of the drug molecules changed 
depending on the cell type used. This was shown in the data presented here, also shown in 
the paper was that there was no pattern of ranking between the cell types. In the paper, 
miltefosine was used as a control and the paper showed that it was most potent in mouse 
peritoneal macrophages, and least potent in THP1 cells. This pattern is replicated when using 
L. major JISH but not for any other parasite species. 
Another paper344 discusses the use of THP1 cells as a model for macrophages, comparing 
them to circulating monocytes. They found that using THP1 cells had many limitations. THP1 
cells have a lower response to lipopolysaccharide due to a low expression of CD14 in 
comparison to circulating monocytes. This in turn leads to low IL-8 production and a lower 
response to bacteria. This shows that although the THP1 cell line may be useful it does not 
always respond as expected of human macrophages. Indeed, in the experiments in this thesis 
it is shown to require a higher number of parasites to achieve infection, when compared to 
other cell types.  
A much larger variation was seen when comparing the EC50 and EC90 values between 
Leishmania species in the same cell type. Overall, when comparing the efficacies of all three 
drugs, to all of the parasites, in each cell type, there is no obvious pattern. When the drugs 
are considered separately then patterns are more obvious. When using amphotericin B, L. 
major JISH shows the lowest EC50 values across all cell types. The highest EC50 value are 
produced when amphotericin is used against either L. amazonensis or L. mexicana. When 
miltefosine was used, L. amazonensis always showed the highest EC50 value. The next highest 
EC50 values was usually seen when using miltefosine to dose L. major mCherry infected 
macrophages. There was no species pattern seen when using sodium stibogluconate. 
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What can be seen in this section is that iPSC derived macrophages respond just as well to 
drug treatment as other cell types commonly used in in vitro assays325. The curves generated 
do not look out of place next to the curves generated by the other cell types, the same 
patterns in reduction of infection is seen in all cell types, when using the same parasite 
species. The EC50 values produced match values seen in the literature50, 316 & 325 and produced 
in other labs using the same cell types. When comparing the iPSC derived macrophages to 
the range of values seen in the literature, when the standard drugs were used, the iPSC fit 
within the range of accepted values. 
The amount of literature on iPSCs, and more specifically iPSC derived macrophages, is 
relatively small at the moment. Those papers that do use iPSC derived macrophages are 
usually papers that are establishing them as a model for a disease, specifically showing that 
they can be infected and respond as expected. The papers rarely compare the iPSC model to 
other models using different cell types, and never do this in a quantified experiment. The 
work in this thesis is novel for many reasons; not only does it show iPSC derived macrophages 
as a model for Leishmania, it quantitatively compares them to other cell types used in this 
area. However, the literature comparing the infection and treatment of Leishmania in 
different cell types is also difficult to find. A low number of papers use numerous cell types, 
and an even lower number use a panel of cell types for comparison. With different 
laboratories actively using different cell types and different species, then data produced by 
one lab is very difficult to validate.  
6.6 Conclusion 
Whilst each cell type was a different size, and required slightly different conditions to grow 
and differentiate, this did not have an effect on how easily the cells were infected or how 
heavy the parasite burden was.  
It has been shown that iPSC derived macrophages are capable of successfully supporting an 
infection with Leishmania parasites of a variety of species. The studies show that the iPSC 
derived macrophages are often the easiest cell to infect. 
It has also been shown that infected iPSC derived macrophages respond as expected to 
treatment with standard drugs. The response shown provides EC50 and EC90 values that are 
similar to those obtained using other cell types. 
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As iPSC derived macrophages were easily infected with Leishmania parasites, and the 
infection was reduced with treatment using standard drugs, they represent a useful cell type 
that could be used in in vitro models. 
  
Chapter 7: Conclusion 
179 | P a g e  
 
Chapter 7: Conclusion 
7.1 Conclusion 
The aim of the project was to assist the discovery and development of drugs against 
Leishmania by developing in vitro tissue culture infection models, which are more predictive 
of the in vivo infection. 
The objectives of the project were to: 
I. Establish and compare 2D static and 2D flow cell culture models, in terms of the 
influence of flow on host cell infection and on drug activity. 
II. Develop a 3D tissue culture model of infection. 
III. Use iPSC derived macrophages to determine whether they offer a valid alternative 
to currently used cell types. 
 
To date, there is no literature on in vitro models for Leishmania infection in the skin, or on 
drug screening in in vitro models incorporating media perfusion, 3D cell culture or iPSC 
derived stem cells. An in vitro model with such added complexity could be extremely useful, 
and the aim of this work was to develop and characterise more complex models for drug 
discovery. A complex in vitro model (compared to the standard 2D cell line based one) could 
be more predictive, by providing a more advanced/complete infection for drug screening, 
and this is expected to enhance in vitro-in vivo correlations.   
In Chapter 3, the objective was to establish a 2D media perfusion cell culture model and 
establish methods to study Leishmania infection. I compared the Kirkstall Ltd Quasi Vivo 500 
and the Quasi Vivo 900 media perfusion systems, eventually choosing the QV900 media 
perfusion system. In silico modelling was conducted on the QV900 to compare the two media 
perfusion systems and to justify the chosen flow rate. Interstitial flow rates between 0.1–2 
μms−1 have been reported in the literature233-235, the QV900 modelling showed that our 
chosen flow rate was 0.15 μms−1 when a 3D printed insert was placed in the chamber of the 
media perfusion system. A colorimetric method was adapted for use with L. major JISH 
parasites and the media perfusion system. Infection studies showed that the media perfusion 
system inhibited the progression of infection. When infection studies were conducted in the 
media perfusion system, the percentage infection counted after 72 hours was lower than the 
percentage infection seen in static controls. The data showed the higher the velocity of the 
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media at the cells’ surface the lower the percentage infection was after 72 hours. To 
investigate this the proliferation of the Leishmania parasites in the host cell was measured, 
showing the parasites in the media perfusion system were dividing at a slower rate. This 
lower rate of proliferation could result in a lower infection after 72 hours, seen within the 
media perfusion system. 
In Chapter 4, I compared 2D static and 2D flow cell culture models, in terms of the influence 
of flow on drug activity, using the models and methods developed in the previous chapter. I 
showed that the activities of four standard anti-leishmanial drugs were reduced when cells 
were treated in the media perfusion systems. To investigate why, I conducted drug 
accumulation studies, which showed a reduced accumulation of drugs in cells in the media 
perfusion system. In addition, studies on the production of nitric oxide showed a lower 
production of nitric oxide in the media perfusion system compared to the static controls. 
In vitro cell culture models that incorporate media perfusion are far less common than 3D 
models. In fact, most models using media perfusion to maintain the cells within the 3D 
culture. The media perfusion provides a continuous flow of media, reducing the need for 
daily media changes and providing constant nutrients matching the higher demands of the 
3D culture. Media perfusion has been most often incorporated into organoid models, such 
as the kidney and liver, enabling cells such as hepatocytes to maintain their function in vitro. 
Another field where media perfusion is extensively used is bone cell culture and bone 
regeneration. For direct comparison with the work undertaken in this thesis, a few papers 
are of special note. In one paper358, the authors measured the viability of HepG2 hepatocytes 
and GBM cancer cells at different media flow velocities, and found the lowest flow velocity 
to be optimal. In this thesis, I took a different approach, and used the most biologically 
relevant flow velocity rather than the velocity which enabled the highest cell viability. The 
complex interplay between increased nutrients and increased shear stress generated by 
media flow can create a window of optimum flow rates that will differ among media 
perfusion systems. Another paper236 shows similar results but compares it to the static 
conditions showing a better viability in the media perfused culture.  A field in which drug 
transport via media perfusion is important is in models of human placental transfer. Initially, 
the media perfusion model, produced by Hutson et al363 (2011), did not fully predict the 
transport of drugs across the placental barrier. After adjusting for differences in maternal 
and fetal protein binding and blood pH, the perfusion results were able to accurately predict 
in vivo transfer under steady state conditions. The field of microfluidics is new and still 
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expanding, while organ models with media perfusion are becoming more common, drug 
testing in these models, especially for infectious diseases, are rare. When microfluidic 
devices are used for infectious disease, it is far more common for them to be used as 
diagnostic tools. The results from the comparisons of the media perfusion system to static 
culture, showed vast differences between the two systems. This is in agreement with what 
is found in the literature359, which suggests that the application of media flow contributes far 
more than 3D cell culture to the outcome of a model. In the paper359, they showed that with 
both oral and dermal ﬁbroblasts physiological levels of ﬂuid ﬂow induced widespread 
changes in gene expression compared to static cultures, including up-regulation of genes. 
In Chapter 5, I established a 3D cell culture model on two different scaffolds, then proceeded 
to try and infect the 3D models. I then developed methods to determine the percentage 
infection in mouse peritoneal macrophages maintained in the 3D culture. A Volocity based 
counting method was compared to a computer based analysis method, developed by the 3D 
scaffold provider, Invitrocue. I then used the infected macrophage model to determine the 
activity of standard drugs in 3D models and compared it to the currently used model system. 
I showed that the activity of standard drugs was similar between the 3D model developed 
and the 2D control. 
 
Complex 3D co-culture skin models have been used to successfully determine skin irritation 
and cytotoxicity202 with high rates of accuracy when compared to the in vivo203 studies. The 
models have been so successful that they have replaced animal models in some areas of 
cosmetics and toxicity testing353. Many commercial examples of in vitro skin models are 
commercially available and many research groups have developed their own model for use 
in a specific disease state356. In terms of the work in this thesis, the 3D model we use is 
rudimentary in comparison, using only macrophages to study the main relevant Leishmania 
interaction with the host. Having said that, the model we have developed for infection and 
determination of drug efficacy is a first in the field for Leishmania. Skin based models for 
infectious diseases are far less common, with most of them being used to study the 
interaction between the invading pathogen and host skin355&356, and treatment of such an 
infection is usually only a future plan once the model has been fully characterised. An 
example where treatment has been examined, as described in a paper by Andrei et al357 
(2005) where compounds were tested against a variety of viruses that had colonised an in 
vitro skin model. The authors showed that the compounds reduced virus titre, with 
Chapter 7: Conclusion 
182 | P a g e  
 
comparative efficacies to those seen in 2D culture. Our results reflect this; we showed drug 
efficacies were similar in 2D and 3D cell cultures. 
In Chapter 6, I aimed to determine whether iPSC derived macrophages are a valid alternative 
to currently used cell types. I did this by establishing an infection in iPSC derived 
macrophages with Leishmania parasites, which was compared with other cells that are 
commonly used cells in in vitro assays. I showed that the iPSC derived macrophages were 
capable of maintaining a Leishmania infection. Percentage infection was higher in iPSC 
derived macrophages for several different Leishmania species/strains. I then determined the 
activity of standard drugs in iPSC derived macrophages to compare with results in other cell 
lines. iPSC derived macrophages showed the expected response to standard drugs, and 
showed similar EC50 values to those that have been reported in literature for other cell types. 
I concluded that iPSC derived macrophages are a suitable model cell type for use in the study 
of Leishmania. 
The development of iPSCs is a recent development, and their full potential is still being fully 
explored. Most papers discuss the possibility of using the iPSCs to derive cells that could then 
be used in infections, and some go as far as showing that the cells will sustain an infection 
just as well as previous models. The focus then switches to the interaction between the 
pathogen and the cells, or to the cellular response to the infection. Groups working in this 
area are categorising the responses seen in the model, to understand the biology before 
moving forward with treatment. The work conducted in this thesis is the only work 
conducted on Leishmania infections and treatment in iPSC derived macrophages. To date, 
there is no literature available comparing the efficacies of drug compounds in iPSC derived 
macrophages to a range of different cell types, using a range of Leishmania strains. 
The ultimate goal of biomedical research is to develop new and improved therapies, vaccines 
or diagnostics. Advances have been made in developing disease models, like the 
development of transgenic mice for in vivo studies. Advances in in vitro modelling have also 
been made in several fields, where the use of 3D cell culture, microfluidic devices and stem 
cell technologies have led to an improvement in the design of disease models. However, 
many of these models fail to fully reproduce the human condition. Another problem is that 
while some scientific fields have fully adopted these advances to bring complexity into the 
models used, such as toxicology, other fields have not responded to the changes created by 
recent advances. While in the field of infectious disease modelling, efforts have been made 
to improve the predictivity of models using recent advances, we are still a long way behind 
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other fields. Even when models incorporating more complexity have been produced, they 
are considered to be novel and are not adopted for use by other researchers in the field. The 
field of drug discovery using infectious disease models has not fully accepted that by 
improving their models, the outcome may also be improved. A more predictive disease 
model would not just give a better indication of whether a potential drug candidate will be 
successful; it will also allow compounds that may not fare well in simple in vitro cell culture 
to be discovered.  
A recent review345 on the opportunities and challenges in phenotypic drug discovery suggests 
that a resurgence of phenotypic drug screening may be occurring. They suggest that the 
reason for this is the existence of more advanced and complex disease models, which better 
reflects the disease in vivo. This opens up new opportunities to discover novel drug entities, 
as phenotypic screening in complex models could identify interactions that were previously 
uncaptured in simpler models, which can then become targets. 
The aim of this project was to develop a more predictive in vitro model (compared to the 
current 2D macrophage cell lines), which could be used as an extra step between in vitro and 
in vivo studies, giving another chance for low potency compounds to be discovered. The 
model could help reduce animal usage and save both time and money spent pursuing poor 
compounds. It could also provide a new platform for drug discovery, as new interactions are 
incorporated within the model and the biological system is better replicated. The work 
presented in this thesis as a whole is both novel in substance and viewpoint, no literature 
exists on an in vitro model that has been broken down to its component parts, and then 
tested to see the effect each component brings to the model. In the field of Leishmania, the 
work conducted on Leishmania infections in 3D, under flow conditions or in iPSC derived 
macrophages is all first of its kind.  
7.2 Future Work 
In the context of improving existing models and elucidating how each increase in complexity 
will affect the model as a whole, as shown in this thesis, one area has been overlooked. The 
addition of other cell types to a model could be very important. Co-culture models 
incorporate the complex interaction between different cell types that is found in vivo. 
Originally, this was part of the work in this thesis but the questions raised by experiments 
led us to appreciate that the time and resources needed were not possible within this PhD. 
Plans for using co-culture in the model for Leishmania involved the culture of macrophages 
in co-culture with fibroblasts and keratinocytes. This would effectively capture the 
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environment of the skin and allow a simulation of cutaneous leishmaniasis to be established. 
Leishmania parasites are capable of infecting any cell that can carry out phagocytosis, this 
includes fibroblasts. This infection of fibroblasts may affect the infection profile of the cell 
culture and may have long term ramifications. It has been suggested that fibroblast may act 
as a reservoir for Leishmania parasites, which can thus hide from the immune system20. 
Another reason this section of work was left until last was that it would be the starting point 
of bringing all the different parts of the thesis together, figure 7.2-1. Further plans were to 
assess whether a model where macrophages and fibroblasts were mixed together inside a 
3D scaffold and then layered with keratinocytes would correctly mimic skin. The layered 
model would then be maintained in the media perfusion system, first submerged to allow 
cell growth and differentiation, and then raised to an air liquid interface to allow 
keratinisation of the keratinocytes at the top of the model365. Another option would be to 
create the skin substitute 3D model with fibroblasts and keratinocytes, created using the 
media perfusion system and an air liquid interface, then have the macrophages circulating in 
the media perfusion system as monocytes and see if they would be attracted to the signals 
generated from the infected skin. Another option would be to incorporate the use of iPSC 
derived cells into the model. The iPSCs could be derived into macrophages, fibroblasts and 
keratinocytes for the model. Using cells that are all from a single source, and share the same 
DNA, might give the most relevant model. This model would have reduced variability, in 
comparison to models created from multiple cell lines. In addition, the iPSC derived models 
would be identical to each other each time they were produced, providing a reproducible 
model that would hopefully lead to more reproducible results.  
Infection studies using this model would be used to determine the best way to apply 
promastigotes; whether by injection with a needle or potentially using infected sand flies. To 
determine infection levels in these models new methods of detection would have to be 
utilised. The colorimetric assay used in this thesis could be used to detect the levels of 
infection, as conventional microscopy would be impossible, and confocal microscopy would 
require many more specific cell labels to identify each cell type. Another option would be the 
use of a reverse transcriptase quantitative polymerase chain reaction assay (RTqPCR) 169. This 
could be used to detect the RNA of the parasites and the macrophages to give an accurate 
reading of how many host cells and parasites were present within the sample. The reverse 
transcriptase part of the assay has the advantage over standard qPCR that only live cells are 
producing RNA and the RNA, from dead cells will be rapidly degraded.  
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Once an infection model has been established, the next step would be to test its application 
for the determination of drug efficacies. Again, the complexity of the model allows for the 
route of drug administration to be varied. The dose of compound could be applied to the 
model through a topical application of the compound, possible now due to the size and 
nature of the model and its ability to mimic skin functions. Another option could be through 
the media circulating in the media perfusion system, which would mimic a systemic route of 
administration. This systemic route has implications for the pharmacokinetic and 
pharmacodynamics modelling of the compound within the system. PK/PD modelling and 
simulation can be used to provide answers on efficacy and safety of new drugs faster and at 
a lower cost366. Using the media perfusion system, the compound could be applied either in 
a continuous manner or in a pulsed scenario, mimicking the fluctuating levels of drug found 
within the body. These drug level fluctuations could be tailored, in both concentration and 
duration, allowing the fluctuations of drug seen within the body to be replicated. An example 
where this method has already been utilised in seen in papers by Bakshi et al237 &364, which 
studied the different profiles of anti-malarial drugs when they were applied in a media 
perfusion system in either a bolus or continuous manner. This method requirement for 
efficacy showing the drugs match pharmacokinetics obtained in vivo. Data provided by this 
PK/PD study can be used to make changes to the computer modelling, allowing for better 
predictions in both the in silico and in vitro models. 
The most important next step for this project would be to validate the model in comparison 
to both existing in vitro and in vivo models. Whilst direct comparisons could be difficult, a 
selection of unknown compounds could be blindly tested in the different models to 
determine if the rank order of their efficacies was the same. This would help to prove the 
predictability and validity of the model, and mean that in future it could be used before in 
vivo studies in animals.  
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Figure 7.2-1. Schematic of possible future work 
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